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Abstract 
 
Tuberculosis affects millions of people worldwide every year. The current treatment for TB is 
divided into a regimen of both first- and second-line drugs, where first-line treatments are more 
tolerated and require shorter treatment lengths. With rising levels of resistance, alternative 
treatment regimes are urgently needed to fight this disease. 
Ethionamide, a second-line drug is administered as a prodrug which is activated in vivo by the 
enzyme EthA, which is in turn regulated by EthR. The disruption of the action of EthR could lead 
to novel therapeutics which could enhance the efficacy of ethionamide, and raise it to a first-line 
treatment. 
The work reported in this thesis examines the elaboration of three chemical scaffolds using 
fragment-based approaches to develop novel inhibitors capable of disrupting the EthR-DNA 
interaction. The first scaffold, 5-(furan-2-yl)isoxazole was investigated by fragment-merging 
approaches and produced compounds with the best of these having a KD of 7.4  M. The second 
scaffold, an aryl sulfone was elaborated using fragment-merging strategies. This led to several 
modifications of the fragment, leading to several variants with KDs around 20  M. With both of 
these series the affinity could not be improved below 10  M and due to the synthetic complexity 
a further scaffold was prioritised. 
The third scaffold was explored was a 4-(4-(trifluoromethyl)phenyl)piperazine using fragment-
growing from the NH of the piperazine to probe deeper into the EthR binding pocket. In 
addition to this, SAR around the 4-(trifluoromethyl)phenyl group was assessed to explore the 
interactions with EthR. These modifications led to compounds with nanomolar IC50s. A range of 
compounds were then screened by REMAssay to determine the boosting effect on ethionamide, 
and this identified compounds with up to 30 times boosting in the ethionamide MIC. 
The final chapter examines a concept where compounds were designed to exploit the dimeric 
nature of EthR by linking two chemical warheads with a flexible linker. These compounds are 
examined using mass spectrometry to investigate the stoichiometry of the interaction to 
provide insight into the binding of these extended compounds and exploring an alternative 
strategy to inhibit EthR. 
The work in this thesis demonstrated the successful use of fragment-based approaches for 
development of novel EthR inhibitors which showed significant ethionamide boosting effects.  
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1.0 Introduction 
1.1 Tuberculosis 
 
Despite worldwide efforts, tuberculosis (TB) remains a major public health concern and  a 
leading cause of death worldwide .1-3 Known since ancient times, 2,4-6 tuberculosis is caused by 
the bacterium Mycobacterium tuberculosis (M.tb.).5,7-10 Currently, the preferred preventative 
method for TB is performed using the Bacillus Calmette-Guerin vaccine (BCG). This was 
identified in the early 20th century by the French scientists Albert Calmette and Camille Guerin 
and first administered in 1921.2,6 This live, attenuated strain of Mycobacterium bovis 5,7,11  
provides some resistance to M.tb., although the effect can be variable.4,5,7 
Tuberculosis is acquired primarily by inhalation of bacilli, aspirated from an infected patient, 
which lodge in the upper respiratory tract 10,12,13 and here, they invade the macrophages.2,4,13 
While the lungs remain the most prominent locale, M.tb. can infect almost any organ or joint in 
the body, including the spine, brain, and heart,7,12,14 and can activate or reactivate months or 
years after the initial infection.4,5,9,13 
It is believed that around one-third of the world s population carry the bacterium,10,12,15,16 with 
over 90% of infected individuals asymptomatic carriers of latent infection.7,11-13 The remaining 
10% who develop active TB show a wide range of symptoms, ranging from fever, headache, 
malaise or cough to blindness, paraplegia, coma or death.11,12,14,15 The World Health Organisation 
(WHO) estimates that 1.8 million people died as a result of tuberculosis in 2015, although the 
number of annual fatalities is gradually decreasing.1 
Treatment for tuberculosis generally uses a combination of several drugs, which include the 
first-line drugs isoniazid 1, rifampicin 2, pyrazinamide 3, ethambutol 4 and streptomycin 5 
(Figure 1), in two phases of treatment.7-9,14,17 These treatment regimens typically run for six to 
twelve months, and are well tolerated.1,14 Unfortunately, due to low patient compliance and poor 
completion of the treatment courses, drug-resistant strains have developed, and these continue 
to be a major impediment to treatments.13,18-20 Where resistance is found against both rifampicin 
and isoniazid, the infection is classified as multiple-drug-resistant TB (MDR-TB).1,6 Management 
of this form of infection requires further treatment with second-line drugs, which include 
ethionamide 6, cycloserine 7, fluoroquinolones (e.g. levofloxacin 8), aminoglycosides (other 
than streptomycin) and polypeptides (e.g. capreomycin 9). These drugs are more expensive and 
less well tolerated than first-line drugs,17,21,22 and the treatment regimen runs from 20 months to 
   2 
as long as four years,1,9,20,23 which further contributes to low compliance and incomplete courses 
of treatment. Where resistance to a second-line drug is found in addition to isoniazid and 
rifampicin, the bacterium is considered to be extensively drug-resistant (XDR-TB),1 and can be 
extremely difficult to treat.9 
 
Figure 1: Structures of first and second line TB drugs; Isoniazid 1, rifampicin 2, pyrazinamide 3, 
ethambutol 4, streptomycin 5, ethionamide 6, cycloserine 7, levofloxacin 8, capreomycin 9. 
 
The emergence of resistant strains of M.tb. makes it essential to identify new targets for drug 
discovery to enhance or replace the current treatment regimens.8,9,13,24 
  
1 2 3 
4 5 
6 7 8 9 
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1.2 EthR 
 
1.2.1 Cell Wall and Mycolic Acid Biosynthesis 
The mycobacterial cell wall in M.tb. is composed of five layers (Figure 2). The first is a lipid 
bilayer to contain the cytosol, which is covered on the extracellular side by a layer of 
peptidoglycan.24,25 This is a common feature of many cell types made of a series of alternating 
sugars, crosslinked by a short peptide sequence.10,24,25 Although normally consisting of  
N-acetylglucosamine and N-acetylmuramic acid, in mycobacteria (except M. leprae) the  
N-acetylmuramic acid is replaced by N-glycolylmuramic acid.10,24,26 These sugars are further 
crosslinked by a pentapeptide unit.10,26 Building from the N-glycolylmuramic acid, the 
pentapeptide sequence consists of L-alanine, D-glutamic acid, meso-diaminopimelic acid (meso-
DAP), D-alanine, D-alanine. The crosslinking occurs from the meso-DAP to an adjacent meso-
DAP or D-alanine of an adjacent pentapeptide.10,26 
 
Figure 2: Structure of the mycobacterial cell wall in M.tb. A: lipid bilayer. The lipid bilayer 
contains the cytosol by forming a hydrophobic barrier; B: peptidoglycan. A network of 
crosslinked peptides capped with a layer of N-acetylglucosamine and N-acetylmuriamic acid;  
C: arabinogalactan. A series of arabinose and galactose sugars which provide an anchor for the 
mycolic acids; D: mycolic acids. Waxy esters which influence cell permeability and oxidative 
stress in mycobacteria; E: mycosides. Outer layer of the mycobacterial cell wall, consisting of 
peptidoglycolipids and phenolic glycolipid dimycocerates. 
 
A          B        C              D         E 
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Outside this peptidoglycan layer is another sugar layer, formed of arabinogalactan.10,25 
Mycobacteria produce an additional, waxy layer composed primarily of mycolic acids beyond 
this (Figure 2).25,27-31 These mycolic acids consist of a  -hydroxy fatty acids of 54-63 carbons 
attached to another chain of 22-24 carbons in length.22,27,28,30 The longer of these two chains 
typically has one of three substitution patterns  termed  -, keto- and methoxymycolates.27,28,30,31 
The keto- and methoxy- forms are both produced as cis and trans isomers, generating five basic 
mycolic acids (Figure 3), which are linked to the arabinogalactan layer.27 Approximately 70% of 
the mycolic acids present are of the  -type, with a further 10-15% each of the keto- and 
methoxy- forms.27 It is believed that these fatty acids are responsible for preventing damage to 
the bacterium, in addition to regulating permeability.25,31 
 
Figure 3  Structure of mycolic acids  from top   -mycolic acid 10, keto-(cis)-mycolic acid 11, 
keto-(trans)-mycolic acid 12, methoxy-(cis)-mycolic acid 13, methoxy-(trans)-mycolic acid 14. 
 
Beyond this layer resides the final layer of the cell wall, the mycosides (Figure 2).25 These 
consist of a series of peptidoglycolipids and phenolic glycolipid dimycocerates.25 
The mycolic acids are produced in two parts by two biosynthetic pathways; Fatty Acid Synthase 
I (FAS-I) and Fatty Acid Synthase II (FAS-II). The shorter chain  known as the  -branch) is 
produced by the FAS-I pathway. In contrast to the FAS-II pathway, FAS-I utilises CoA rather than 
the acyl carrier protein from mycobacterium (AcpM).31 
10 
11 
12 
13 
14 
   5 
 
Figure 4: FAS-II cycle in M.tb. FAS-II catalyses the extension of shorter fatty acids from FAS-I 
into the longer meromycolates necessary for mycolic acid production. EthR regulates the 
expression of EthA, which is responsible for activating ethionamide – an inhibitor of InhA, 
preventing the successful production of mycolic acids by FAS-II. 
 
The longer chain (meromycolate) is produced by the FAS-II pathway (Figure 4). Part of the 
meromycolate is produced by the FAS-I cycle and incorporated as the alkyl terminus of the 
growing meromycolate, as the FAS-II system (unlike FAS-I) is unable to perform de-novo fatty 
acid synthesis.31 The CoA ester produced is converted to C16-AcpM by a β-keto AcpM synthase 
(mtFabH) using malonyl-AcpM as the additional unit to enter the FAS-II cycle. This alkyl-AcpM 
compound is then elongated by two carbons via the β-ketoacyl AcpM synthase KasA/KasB 
complex. The ketoacyl intermediate is subsequently reduced by MabA (a β-keto AcpM 
reductase) with NADPH and dehydrated by β-hydroxyacyl AcpM dehydratase to the enoyl-AcpM 
compound. This compound is then reduced by InhA (enoyl AcpM reductase), consuming NADH 
to complete one round of the elongation cycle.27,28,31 After modification, the two chains (the 
meromycolate from FAS-II and the α-branch from FAS-I) are condensed by Pks13 (poly-ketide 
synthase) to form the finished mycolic acid.28 
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1.2.2 ETH and EthA Activity 
Ethionamide, like the structurally similar Isoniazid is administered as a prodrug, requiring 
modification into its active form.25,32-34 Despite their similarities, these drugs are activated by 
different enzymes in M.tb. Isoniazid is activated by KatG, a catalase/peroxidase, while 
ethionamide (ETH) is activated by EthA, a Bayer-Villager monooxidase.29,32,35-37 These different 
mechanisms of activation for both drugs function by inhibiting the same enzyme – InhA, a 
member of the FAS-II pathway.25,29,35 
Ethionamide activation involves a series of intermediates. The initial activating step is 
recognised to be the oxidation of the thioamide functionality (ETH-SO) 15,22 while the active 
product is thought to be the ETH-NAD adduct 16 (Figure 5).22,23,33 The exact sequence of 
intermediates is not known, but it is thought that ETH is oxidised to the amidopyridine 20 or the 
methanol form,29 possibly via a radical intermediate.3,22 
 
 
Figure 5: Structures of (L-R) ETH 6, ETH-SO 15 and ETH-NAD 16. ETH is initially oxidised to 
the S-oxide form, which is then converted to the ETH-NAD adduct, which inhibits InhA in the 
FAS-II pathway, preventing the synthesis of the mycolic acids, which are essential components 
of the mycobacterial cell wall. No intermediates between the S-oxide and the ETH-NAD adduct 
have been isolated. 
 
1.2.3 EthR 
EthA expression is regulated by the transcriptional repressor EthR which is a 216 amino acid 
protein of the TetR family.32-34,37-39 Composed entirely of helices, EthR has two domains, a helix-
turn-helix DNA-binding domain, and a ligand-binding domain (Figure 7).  In solution, this 
dimerizes, and is reported to form an octamer 35,37,38 upon binding to its 55 bp operator, situated 
in the intergenic region between the ethR and ethA genes (Figure 6).35,37,38 A recent paper by 
Chan et al. (2017) however, indicates that EthR binds to its operator as a hexamer instead.40 
6
 
15 16 
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Figure 6: Construction of the ethA-R intergenic region. The ethA and ethR genes are expressed 
in opposing directions with 75 base pair intergenic region containing the 55 base pair EthR 
operon between. 
 
EthR has been considered a validated target for some time.22 Bacteria overexpressing EthR were 
shown to be hypersensitive for ETH by both DeBarber et al.29 and Baulard et al.41 while 
examining the activation process for ETH.22,29,37,41 Meanwhile, EthA knockdown models have 
proven to be ETH resistant.36 Despite this, no direct evidence for a natural role for EthA has 
been forthcoming,34,36,37 although the present theory is that it plays a role in oxidation of 
meromycolates or the catabolism of mycolic acids to maintain appropriate levels in the cell 
wall.36 
 
Figure 7: Structure of the EthR dimer (PDB: 1T56). Helices are numbered from the N-C 
terminal. Helices α1-3 form the helix-turn-helix DNA-binding domain, while helices α4-9 form 
the drug-binding domain, with helices α8-9 forming the dimerization interface.35 
α6 
α1 
α2 
α3 
α4 
α5 
α7 
α8 
α9 
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The binding domain of EthR (Figure 7) is located between helices 4-9 in an ‘L’ shape, with the 
main pocket paralleling helices 4, 5, 7 and 8, while an additional binding region can be observed 
running parallel to helix α6 under the side chain of Trp138.32,33,37,42,43 Amino acids lining this 
pocket are largely hydrophobic, aromatic residues resulting in a long greasy surface available 
for ligands.35,37 This is reinforced by the presence of the “natural ligand”, hexadecyloctanoate 17, 
as reported by Frenois et al.32,43 and Willand et al.44 (Figure 8). 
 
 
 
Figure 8: EthR bound to hexadecyloctanoate 17 (purple), with key binding site residues 
(orange) (only the monomer is shown, PDB: 1U9N).43 
 
The binding site of EthR is accessible only by a small opening, situated at the opposing end of 
the protein to the DNA-binding domain that leads to a pocket of approximately 20 Å in 
length.35,37 Within the binding site, several amino acids of interest have been identified. The 
Trp138 provides a border between the regions of the binding site, forming the ‘L’ shape, while 
Asn176 and Asn179 provide a polar region within the centre of the pocket.16,22,33,39 In addition, 
two Phe residues have been shown adopt differing orientations (Phe184 and Phe114).16,22,39 
The distance between the binding domains of the dimer is altered upon binding of the 
ligand.32,43 Frenois, Baulard and Villeret have shown that upon binding of the natural ligand, the 
two binding domains increase in separation from 37 Å to 48-52 Å when compared with 
Trp138 
Asn176 
Asn179 
17 
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analogous TetR family transcriptional repressors (Figure 9A and Figure 9B), resulting in the 
loss of DNA binding capability (Figure 9C and Figure 9D).32,43 
 
Figure 9: (A) - DNA-bound structures of TetR family member QacR (PDB: 1JT0) 38.7 Å 
(Gly37Cα-Gly37’Cα); (B) – DNA-bound structure of TetR (PDB: 1QPI) 31.1 Å (Pro39Cα-
Pro39’Cα); (C) – DNA binding domain distance for EthR binding dioxane (PDB: 1T56) 49.5 Å 
(Thr60Cα-Thr60’Cα); (D) – DNA binding domain distance for EthR binding hexadecyloctanoate 
(PDB: 1U9N) 52.5 Å (Thr60Cα-Thr60’Cα); Figures A and B adapted from Schumacher et al. 
(2002),45 figures C and D adapted from Willand et al. (2009).44 
 
1.3 FBDD 
 
1.3.1 What is FBDD? 
Fragment-based Drug Discovery (FBDD), also known as Fragment-based Lead Discovery (FBLD) 
is an approach that has gained favour among drug design scientists in both academia and 
industry.46 Pioneered by companies such as Astex Pharmaceuticals and Abbott Pharmaceuticals 
A B 
C D 
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in the mid-1990s,47-53 this relies on a cascade of biophysical assays to quantify binding of small 
molecules (or fragments) to known targets.53,54 
This method employs screening of libraries of small molecules, typically less than 250 Da 
molecular weight, and ranging in size from around a few hundred to around 10,000 
molecules,47,51,55-57 to identify molecules which can efficiently bind to target proteins. Many 
companies are now incorporating fragment-based approaches into their drug discovery 
programs.50,58 
To date, there have been three fragment-derived drugs approved for use by the FDA, and there 
are a number currently in Phase I, II, and III clinical trials.51,53,54,59 The first drug approved which 
was derived from a fragment-based approach was Vemurafenib, developed by Plexxicon and 
Roche to treat advanced skin cancers.46,60 The initial fragment hit 7-azaindole 18, showed an IC50 
>200 µM against the PIM1 (used as a surrogate for B-Raf),61 and this fragment was developed 
into the final drug 23, which exhibited an IC50 of 0.031 µM against the target B-RafV600E  
(Figure 10).51,60-64 The FDA approved Vemurafenib in August 2011,60 taking just six years from 
the start of development.51 
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Figure 10: (A) - Development of Vemurafenib 23. The fragment 7-azaindole 18 was identified 
and elaborated by fragment growing strategies; (B) – X-ray crystal structure of elaborated 
fragment 19 bound to PIM1 (PDB: 3C4E); (C) – Overlaid X-ray crystal structures of compounds 
21 (pink; PDB: 3C4C) and 22 (blue; PDB: 4FK3) bound to BRAFV600E.62 
 
In April 2016, the second drug derived from a fragment-based approach was approved by the 
FDA, Venetoclax 28 (Scheme 1) and is used for the treatment of chronic lymphocytic leukemia 
46,51,53,65 and was developed by AbbVie and Genentech as a result of over 20 years of research on 
this target.51 With a molecular weight of 865 Da, this would suggest that this would be 
inappropriate for an orally administered drug according to Lipinski’s rules.66 Despite this, 
Venetoclax has been formulated as an oral drug,67 and shows excellent activity and selectivity 
against its target Bcl-2.51,54 
18 19 
20 
23 
21 
22 
A 
B C 
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Scheme 1: Development of Venetoclax 28. Two fragments (24, 25) were identified and linked 
to form compound 26, then elaborated to produce compound 27 (Navitoclax) and finally 
Venetoclax (28) with a Ki of <0.01 nM.51,54 
 
The latest fragment-derived drug to receive approval is ribociclib from Astex Pharmaceuticals 
in conjunction with Novartis. As a treatment for breast cancer, ribociclib is a Cyclin-Dependent 
Kinase 4 and 6 inhibitor, and is used with an aromatase inhibitor.68 
 
1.3.2 FBDD in comparison to HTS 
Traditionally, pharmaceutical companies have used high-throughput screening (HTS) as the 
basis of their drug discovery programmes. This consists of screening libraries that typically 
contain upwards of 105 compounds.53 
Estimates of the size of  drug-like  chemical space predict that there may be as many as 1063 
individual molecules with 30 or fewer heavy atoms.57,58,69-71 In 2013, Polishchuk, Madzhidov and 
Varnek predicted that compounds of      Da (approximately 36 heavy atoms   C, N, O, S, 
Halogens) and following the Lipinski rule of 5 could comprise as much as 1033 compounds.66,72 
When restricted to 17 heavy atoms (C, H or N), this space is reduced to around 1011 
molecules.51,72 While estimates of chemical space vary greatly, it is clear that molecules with a 
lower molecular weight encompass a smaller amount chemical space, thus allowing the same 
number of molecules to cover a much larger portion of that space.57,58,69,73 This allows fragment 
24 
25 26 
27 28 
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libraries to be smaller in size while still covering the same or a larger portion of chemical space 
than HTS libraries.74 
In addition, fragment-based approaches allow for selection of molecules that can have better 
physical properties than larger HTS-type molecules. Fragments tend to be more polar than 
molecules found in a HTS library, often giving a starting point with better pharmacological 
properties.51,58,75 The smaller size of fragment libraries (typically 1000-5000 compounds) mean 
fewer compounds are screened and subsequently less material such as protein is required. The 
nature of fragments also means that binding affinities are weaker than HTS hits (in the order of 
0.1 to 10 mM), however these interactions tend to be of higher quality than those gained from 
HTS.55,56,59,69,73,75 Lead-like molecules derived from high-throughput screening may not be 
flexible enough to achieve optimal binding orientations within the protein of interest, while 
fragments, by nature of their small size and limited functionality, can better arrange themselves 
for higher quality interactions (Figure 11).69 
 
Figure 11: Fragment hits v HTS hits. While each fragment hit constitutes a small binding 
energy, the interactions are generally better quality than those from HTS, which have higher 
affinity, but may not possess optimal functionality or flexibility. Figure taken from Scott et al. 
(2012).49 
 
1.3.3 Fragment Elaboration Strategies 
Once a fragment hit has been obtained, there are a number of methods that can be used to 
elaborate the compounds to high affinity inhibitors. These strategies have been classed as 
fragment merging, fragment linking and fragment growing. 49,51,73,75,76 
 
1.3.3.1 Fragment Merging 
Fragment merging is perhaps conceptually the simplest of methods, although in practice, this 
may not necessarily be true (Figure 12). In the event that library screening identifies molecules 
which are found to overlap as determined using X-ray crystallography, the fragments can be 
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merged into a single molecule in order to exploit the binding characteristics of both 
fragments.49,51,69 
 
Figure 12: Fragment merging. When multiple fragments bind in overlapping fashion, fragment 
merging takes the best structural components of each fragment and combines them into a single 
molecule. 
 
Hudson et al.77 examined a fragment-based approach to targeting cytochrome P450 121 
(CYP121) from M.tb. A fragment library of 668 fragments was screened against CYP121 using a 
fluorescence-based thermal shift assay which was used as a primary screen followed by ligand-
based nuclear magnetic resonance (NMR) and isothermal titration calorimetry (ITC). Sixty-six 
fragment hits were identified and four X-ray crystal structures were obtained. These four 
fragments could be divided into two classes; the haem binders (29 and 30), and the non-haem 
binding fragments (32 and 33) and the KDs of these fragments were found to range from  
400 µM – 3 mM.77 When the X-ray crystal structures of these fragments were overlaid together, 
a number of fragment merging strategies were possible. 
The first strategy involved the overlay of fragments 29 and 30, where there is clear overlap 
between the aniline ring of 29 and the aromatic ring of 30. The synthesis of the merged 
compound 31 gave an increase in affinity to 28 µM while maintaining ligand efficiency  
(LE = -ΔGbinding/#non-hydrogen atoms = -RTlnKD/#non-hydrogen atoms)78 (Figure 13). When the NH2 of the 
aromatic amine was removed, the affinity significantly decreased as this is the key metal 
binding group for the haem iron.77 
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Figure 13: Fragment merging strategy for CYP121. Fragments 29 and 30 were merged which 
led to the development of compound 31; A - Overlaid X-ray crystal structures of 29 (blue) and 
30 (green) (PDB: 4G44, 4G45); B - X-ray crystal structure of merged compound 31 (PDB: 
4G1X).77 
 
A second fragment merging strategy involved the merging of fragments 32 and 33 (Figure 14), 
however the merged structures (34, 35) were not observed to bind to CYP121.77 
  
A B 
29 30 
31 
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Figure 14: Fragment merging strategy for CYP121. Fragments 32 and 33 were merged to give 
compounds 34 and 35, however neither of these were observed to bind. X-ray crystal structures 
of 32 (blue, PDB: 4G46) and 33 (green, PDB: 4G47). 33 binds in two orientations.77 
 
Interestingly, in the X-ray crystal structure of fragment 33, this was observed to bind in two 
orientations, and merging of these led to the development of a series of compounds (36-40) 
with KDs from 500 µM - 4 mM (Figure 15).77 However, no significant improvement in affinity 
was observed. When the 1,2,3-triazole ring was changed to a pyrazole ring only a small increase 
in affinity was observed. Introduction of an amino group onto the pyrazole resulted in 
compound 41, where an increase in affinity to 40 µM was observed. Substituting the amine 
group with a phenol ring 42 again increased potency to a KD of 15 µM.77 Further work by 
Kavanagh et al.79 in optimisation of this fragment merged series resulted in compound 43 which 
had an affinity of 15 nM. The key to the increase in affinity of this compound was to build 
towards the haem iron using an aniline, which was discovered in the original fragment series. 
32 33 
34 
35 
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36 
37 38 39 
40 41 42 43 
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Figure 15: Structures of compounds 36-43 bound to CYP121; (A) - X-ray crystal structure of 36 
(PDB: 4G2G);77 (B) - X-ray crystal structure of 40 (PDB: 4G48);77 (C) - X-ray crystal structure of 
compound 41 (PDB: 4KTF);76 (D) - X-ray crystal structure of compound 42 (PDB: 4KTL);76  
(E) - X-ray crystal structure of compound 43 (PDB: 5IBE).79 
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1.3.3.2 Fragment Linking 
Fragment linking may be thought of as ‘chaining’ two fragments together. These may be 
fragments that bind in different sites or even different parts of the same pocket, or they may be 
different compounds that result in different but not overlapping positions on the target  
(Figure 16).49,51,69,73 An interesting effect may be observed when fragment linking approaches 
are used, and that is super-additivity.80,81 This relates to the amount of energy necessary to 
overcome the entropic loss on binding the ligand to the protein – the rigid body entropy. In a 
linked compound, there is only one rigid body entropy term to overcome, as opposed to two 
terms in the non-linked fragments, therefore raising the potential for a linked fragment to have 
a greater binding affinity than the sum of the two fragment affinities would suggest.49,61,82 The 
major difficulty that can arise in this strategy is trying to identify the optimum linker.51,54,61 
 
Figure 16: Fragment linking. Where two fragments bind in close but non-overlapping positions, 
these separate fragments can be connected to create one compound, which retains the binding 
of both fragments. This linked compound may show binding greater than the sum of the two 
fragments, since there will only be one rigid body entropic penalty to be overcome when 
binding to the target. 
 
Pelz et al.83 examined linking strategies for Mcl-1 inhibitors. Using a known ligand 44 to bind in 
the P2 site, seven fragments were identified which bound within the nearby P4 subpocket 
(Scheme 2). Of the seven fragment hits identified, compound 51 was reported as being the most 
potent, with a KD of 1.5 mM.83 
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Scheme 2: Structures of compound 44, and fragments 45-51. Taken from Pelz et al.83 
 
Compound 52 was synthesised whereby the acid functionality of 44 was replaced with an 
acylsulfonamide to retain important interactions with R263, however a drop in affinity was 
observed in comparison to the original compound 44 (Figure 17). 
The authors then proceeded to link the fragments to compound 52, resulting in compounds 53 
and 54, with Kis of 278 and 308 nM respectively. From here, the authors continued to optimise 
the compounds until they produced compound 55, with a Ki of 1 nM.83  
44 
45 46 47 
48 49 50 51 
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Figure 17: A - structure of compound 52; B - X-ray crystal structure of 52 bound to Mcl-1 
showing important interactions. Figure taken from Pelz et al. (2016).83; C - Structures of 
compounds 53-55 which were shown to bind to Mcl-1.83 
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1.3.3.3 Fragment Growing 
Fragment growing allows the greatest degree of freedom in design of new molecules. This 
requires the synthesis of larger molecules to probe the space near the fragment (Figure 18).51,69 
 
Figure 18: Fragment growing. When one fragment is bound in the binding pocket, potential 
nearby interactions may be probed by building new functionality onto the existing fragment. 
 
An example of the use of fragment growing was reported by Wyatt et al.84 in their development 
of the cyclin-dependant kinase (CDK) inhibitor AT7519 (Scheme 3). The initial fragment hit 
indazole 56, was grown from the 3-position, and guided by X-ray crystallography (Figure 19), 
additional H-bonding interactions were obtained which led to the development of compound 
57. This subsequently had the sulfonamide group removed (58) to simplify synthesis, and this 
did not lead to a loss in ligand efficiency from 57. The introduction of two fluorine atoms at the 
2 and 6 positions of the phenyl group and addition of an amide as a hydrogen-bond acceptor led 
to compound 59, with an improved ligand efficiency and a 100-fold improvement in activity 
over compound 52.84 
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Scheme 3: Development of CDK inhibitor 63 (AT7519).84 Indazole 56 was developed by 
fragment growing strategies into compound 63, which has an improvement in IC50 of almost 
4000 times over compound 56, while still maintaining a ligand efficiency >0.4.84 
56 57 58 
59 60 61 
62 63 
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Modification of the amide with a phenyl ring, 60, resulted in an improvement in activity  
(IC50 0.14 µM), at the expense of torsional strain of the phenyl ring. The introduction of a  
2,6-disubstitution (61) increased both activity and ligand efficiency.  Replacing the opposing  
4-fluorophenyl group with piperidine for improved hydrophilicity led to 62, after which the two 
fluorines in the 2 and 6 positions were swapped with chlorines (63) to better fill the binding 
pocket (Figure 20), with the end result being a compound of higher activity (IC50 = 0.047 µM) 
and ligand efficiency (0.42) when compared to compound 62.84 
A B 
C 
Figure 19: A – Overlay of X-ray crystal 
structures of 56 (green, PDB: 2VTA), 57 
(pink, PDB: 2VTI) and 58 (orange, PDB: 
2VTL) with CDK; B - Overlaid X-ray crystal 
structures of 59 (pink, PDB: 2VTN), 60 
(grey, PDB: 2VTO) and 61 (orange, PDB: 
2VTP); C – X-ray crystal structure of 59 
(PDB: 2VTN) with measurements. Nitrogen 
shown in dark blue, fluorine in light blue, 
oxygen in red and sulfur in yellow.84 
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Figure 20: X-ray crystal structure overlay of 62 (yellow, PDB: 2VTQ) and 63 (orange, PDB: 
2VU3) bound to CDK. Nitrogen shown in dark blue, oxygen in red, chlorine in green and fluorine 
in light blue.84 
 
1.3.4 Biophysical Screening Techniques 
Fragment-based drug discovery approaches rely on a suite of biophysical data to provide 
information on the binding nature of fragments to the protein target.50,51 These are usually used 
as a cascade of screening techniques (Figure 21) designed to enrich the fragment hits through 
successive rounds of biophysical screening.53 Each technique provides different information 
about the binding interaction under investigation,53 so multiple techniques should be used in 
parallel to confirm the binding to the protein and lead to an enrichment of the fragment 
hits.53,59,74 
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Figure 21: Fragment screening cascade. The primary screen identifies fragment hits from the 
fragment library, which are validated in the secondary screen. Validated fragments are then 
iteratively examined through a cycle of design, synthesis and biophysical analysis to improve 
the compound properties towards a lead candidate. 
 
1.3.4.1 Surface Plasmon Resonance 
Surface plasmon resonance (SPR) is a functional assay, where the binding of the protein of 
interest to its target is assessed in the presence of the ligand. SPR uses the change in refractive 
index to determine changes to the material under investigation,51,53,54,85 without the requirement 
for labelled materials or additional fluorescent substrates,85 with the exception of the 
immobilised component.50,51,59 
SPR relies on the total internal reflection of the IR light beam by the gold-coated surface of a 
chip.85 When the free component binds to its immobilised partner, the sample changes 
refractive index, causing a change in the total internal reflection angle, which can be recorded as 
a change in intensity of the reflected signal.51 SPR can be used to measure several parameters 
about the binding interaction, including IC50, binding stoichiometry, specificity, and kinetic 
parameters (e.g. KD, association and dissociation rate constants).53,85 
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1.3.4.2 Differential Scanning Fluorimetry 
Differential Scanning Fluorimetry (DSF or Thermal Shift) is a technique used as a first-line 
screening technique due to its high-throughput nature.51,52 The technique involves heating the 
samples of protein with or without ligand at a fixed rate in the presence of a fluorescent dye 
such as SYPRO® Orange, which fluoresces upon binding to hydrophobic surfaces51-53 as the 
protein unfolds. As this happens, more of the internal hydrophobic surface is exposed, and the 
change in fluorescence in recorded (Figure 22A). The first derivative of the fluorescence curve 
(Figure 22B) is obtained, from which the change in melting temperature   TM) between the 
control and ligands/fragments can be calculated.51 
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Figure 22: DSF plots for thermal denaturation of a protein in the presence of varying 
concentrations of ligand. (A) - RFU (response fluorescence units)/temperature; (B) - dRFU (1st 
derivative response fluorescence units)/temperature, where minima represent TM. a) DMSO 
control TM, b-d) sample TMs at increasing concentrations of compound added (b = 0.01 mM; c = 
0.1 mM; d = 1 mM). 
 
 
 
3,000
3,500
4,000
4,500
5,000
5,500
6,000
6,500
7,000
35 45 55 65 75 85
R
F
U
Temperature (°C)
-130
-80
-30
20
70
120
35 45 55 65 75 85d
R
F
U
Temperature (°C)
A 
B 
a 
b 
c d 
   29 
1.3.4.3 Ligand-observed NMR 
Ligand-observed NMR utilises the phenomenon of magnetisation transfer to investigate the 
binding of the ligand to the macromolecule.53,59 Three different experiments are commonly used, 
saturation transfer difference (STD), water-ligand observed by gradient spectroscopy 
(WaterLOGSY) and Carr-Purcell-Meiboom-Gill (CPMG) spin-lock relaxation edited experiments 
(Figure 23).69,75,86 
STD is performed by irradiating the methyl groups on the protein, and observing the transfer of 
magnetisation to the ligand signals.75,86 The technique is performed in two parts; an ON- and 
OFF-resonance, which are combined to generate a difference spectrum.69,75,86,87 Ligand peaks are 
only observed when nOe is transferred from the irradiated protein to bound ligands, therefore 
the presence of ligand peaks in the difference spectrum is indicative of ligand binding.69,86,87 
Since the intensity of the observed signal is dependent upon the rotational properties of the 
protein-ligand complex, larger (and therefore slower rotating complexes) will be able to 
transfer more magnetisation, generating stronger signals and greater sensitivity in the 
spectrum.78  
WaterLOGSY observes the change in nOe of the ligand after irradiation of the bulk water.69,75,86,87 
The ligands receive the transferred magnetisation from water while bound to the protein, 
causing a build-up of nOe of opposite sign to that of free ligand. Tris (which does not generally 
bind to proteins) can be used as an internal reference when present in the buffer to phase the 
spectrum to a negative signal, meaning signals from ligands in the bound state present as 
positive (or less negative) signals, while free ligands appear as negative signals.86,88 
CPMG relies on the difference in transverse relaxation time between the slow-moving proteins 
(giving rise to broad signals and fast relaxation) and fast moving ligands (resulting in sharp 
signals and slow relaxation). The experiment eliminates the protein and protein-ligand complex 
signals by delaying the acquisition for a few hundred milliseconds, allowing the slow tumbling 
molecules to relax before acquisition begins. Comparison of the signals to an equivalent sample 
without protein can be used to identify ligands binding to the target.69,86 
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Figure 23: Ligand-observed NMR. (A) – STD difference spectra. Ligands will produce a signal 
only in the presence of the protein if binding. Non-binding ligands will not be observed;  
(B) – WaterLOGSY spectra. In the presence of the protein, the ligand has a signal which is less 
negative than the spectrum without protein, indicating binding; (C) – CPMG spectra. The change 
in intensity of the ligand signal is indicative of binding. Figure adapted from Sledz, Abell and 
Ciulli (2012).86 
 
1.3.4.4 X-Ray Crystallography 
X-ray crystallography is considered the gold standard for the identification of fragments that 
bind to the protein of interest.52,53,59 Protein crystals are grown and can be soaked with solutions 
of the desired ligand, and the resulting protein-ligand complex structure determined by X-ray 
analysis.54,59,75,89 In some cases, where soaking does not produce suitable results,  
co-crystallisation can be used, whereby both protein and ligand are crystallised together before 
X-ray analysis.75,89 Key considerations in the use of X-ray crystallography for drug design include 
the ability to produce diffraction quality crystals, which are sufficiently stable for soaking and 
X-ray data generation, and generate sufficient diffraction.74 
  
A B C 
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1.3.4.5 Computational Docking 
Computational docking, although useful in some respects, can be difficult when working with 
fragments due to the small energies involved in binding, small size of the molecules and the 
design of programs which favour larger molecules.59,73,75 It has been reported that 
computational docking accurately predicts binding mode between 40 and 70% of the time.73,90 
Docking is performed by loading a protein model and ligand structure(s), and the program 
generates one or more binding poses for the ligand and searches for an energy minima with the 
protein, with constraints on the available binding site.91 Docking is useful for gaining insight into 
possible binding motifs and molecules, and can be used to assist in directing synthesis.49 
 
1.3.4.6 Isothermal Titration Calorimetry 
Isothermal Titration Calorimetry (ITC) can be used to measure the binding energy (as heat) 
released or absorbed upon binding of the ligand molecules to the protein of interest.49,52,53 The 
technique is performed by titrating one component of the system into the other, where this is 
typically the ligand being titrated into the protein.53,92 As each aliquot of ligand is injected into 
the mixing cell, the change in heat is recorded by comparison to a reference cell which 
maintains a constant energy input for a stable temperature.93,94 Upon completion, the heat 
profile is integrated and fitted to a sigmoidal curve model.94 
Isothermal titration calorimetry is typically used as a second-line screen due to the low 
throughput nature of the technique.53 The ITC experiments (Figure 24) can provide 
measurement of several important thermodynamic properties of the binding, most importantly 
the Gibbs free energy and association constant (KA), which is inversely proportional to the 
dissociation constant (KD) in addition to giving an indication as to the stoichiometry of the 
interaction (N value).53,54,92,93 
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Figure 24: ITC Trace. Top   Heat profile. This is the change in heat measured during the 
experiment plotted against the experiment time; Bottom - integrated heat profile (binding 
isotherm) measured against molar ratio of the two components, fitted to a single site binding 
model. 
 
1.4 Research Focus 
 
The focus of this thesis will be to examine the use of fragment-based drug discovery to target 
the mycobacterial transcriptional repressor EthR. Three fragment scaffolds (Figure 25) will be 
explored using a combination of fragment merging, growing and linking. Chapter 2 will 
investigate two scaffolds, the first is based on 1-(3-(furan-2-yl)-1,2,4-oxadiazol-5-yl)-N-
methylmethanamine 64 and examines fragment linking strategies. The second scaffold based on 
2-((4-chlorophenyl)sulfonyl)ethanethioamide 65 will be investigated using fragment merging 
strategies. 
Chapter 3 examines (5-trifluoromethyl)pyridin-2-yl)piperazine 66 through fragment growing, 
producing a series of compounds which show strong affinity for EthR. Results of a resazurin 
microtiter assay (REMAssay) are reported to demonstrate the effectiveness of these molecules 
in boosting the efficacy of ethionamide. 
Chapter 4 will examine the synthesis of linked molecules designed to stabilise the dimeric form 
of EthR in an inactive conformation. 
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Figure 25: Fragments 64-66. These fragments form the scaffolds examined in chapters 2 and 3, 
while chapter 4 examines linking strategies using compounds based on fragment 66 developed 
in chapter 4. 
64 65 66 
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2.0 Fragment merging and growing approaches for 
targeting EthR 
2.1 Oxadiazoles and sulfones in drug design 
 
This chapter will describe fragment growing and merging approaches to targeting EthR. The 
first strategy employs a 1,2,4-oxadiazole fragment as a starting point for elaboration. A second 
strategy will examine fragment merging and growing employing an aryl-sulfone fragment. 
Oxadiazoles have been used in a variety of applications in the medicinal and materials 
chemistry fields.95-97 These 5-membered heterocycles have been shown to be important 
scaffolds in drug design 98,99 due to their increased lipophilicity when compared with other 
isomers such as the 1,3,4-oxadiazole.96,97 The 1,2,4-oxadiazole scaffold (Figure 26) has gained 
interest as bioactive molecules for a variety of conditions ranging from anti-asthmatic and anti-
diabetic agents, to apoptosis promoters and immuno-suppressants due to their synthetic 
tractability, altered H-bonding capacity and high metabolic turnover. They have also shown 
promise in antimicrobials, with a particular focus on anti-tuberculosis medicines.95,97 
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Figure 26: Selected examples of 1,2,4-oxadiazole-containing bioactive molecules.95,97 
 
The use of fragment-merging strategies with sulfur-containing fragments was utilised by 
Goswami et al. where they described the use of the technique with a sulfonamide-containing 
compound to develop inhibitors of matriptase.100 A targeted library of benzamidine analogue 
fragments were screened and fragments 73 and 74 were observed to bind to matriptase with 
Kis of 79 µM and 81 µM respectively. As these compounds were binding in overlapping binding 
sites P  P  and P  P  , a fragment linking strategy was employed. Compound 75 (S-isomer) 
gave a Ki of 7.4 µM, while the R-isomer was shown to be less active than the original fragment 
hits, with a Ki of 99 µM (Figure 27).100 
67 
68 
69 70 
71 
72 
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Figure 27: (A) - Structures of compounds 73-76. Compounds 73 and 74 were identified by a 
fragment screen, and subsequently merged to form compound 75. Moving the imidamine group 
to the meta-position (compound 76), a sub-micromolar Ki was obtained against matriptase;100 
(B) - X-ray crystal structure of matriptase with compound 76 bound (orange, PDB: 4R0I). 
Inset – close-up of compound 76 in the binding pocket of matriptase.100 
B 
A 
73 74 
75 76 
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When the imidamine group on compound 75 was moved from the para- to the meta-position 
(compound 76) the Ki improved to 0.3 µM which was a result of a change in the binding mode. 
The replacement of the naphthalene ring with a sterically bulky 2,4,6-triisopropylbenzene ring 
yielded the strongest binding inhibitor with a Ki of 0.1 µM.100 This demonstrates a successful 
fragment merging strategy resulting in an over 700-fold improvement in Ki. 
The scaffolds investigated in this chapter rely upon fragment-merging strategies as the primary 
technique for elaborating the fragment hits, containing 5-membered heterocycles and sulfones 
as core functionalities. 
 
2.2 Fragment merging strategies to target EthR 
 
The fragment 64 was identified previously from a fragment screen against EthR, and a ΔTM of 
+6.9 °C [10 mM] was measured (Narin Hengrung, Dept. of Biochemistry). The X-ray crystal 
structure (Sachin Surade, Dept. of Biochemistry) showed that two molecules of 64 bind in 
opposing directions and in close proximity (Figure 28A, ‘1’ and ‘2’), with the NH of molecule 1 
situated 1.4 Å from the CH2 of molecule 2. This suggests the merging of these two binding 
positions through an amine or amide bond as a possible strategy for elaboration. 
     
Figure 28: (A) - X-ray crystal structure of fragment 64 (blue and green), bound twice to EthR. 
The NH of 1 (blue) is 1.4 Å  from the CH2 of 2 (green); (B) - Structure of fragment 64. 
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2.2.1 5-(Furan-2-yl)-isoxazole fragment-linking approach 
A fragment linking strategy, guided by X-ray crystallography was applied by linking fragments 
(5-(furan-2-yl)isoxazol-3-yl)methanamine (77) and 5-(furan-2-yl)isoxazole-3-carboxylic acid 
(78). This was achieved in an amide bond forming reaction, using COMU to obtain the 
compound 79 in 74% yield (Scheme 4). 
 
Scheme 4: Synthesis of compounds 79 and 81. Compound 79 was synthesised by coupling the 
amine 77 and acid 78 using COMU. Acid 78 was reduced to the alcohol 80 with LiAlH4, then 
coupled to the amine 77 via the alkyl chloride to form compound 81. 
 
In order to obtain the symmetrical molecule (81), the acid (78) was reduced using LiAlH4 to the 
alcohol (80). The acyl chloride was synthesised using oxalyl chloride and the amine (77) was 
coupled to yield the compound (81). 
Compounds 79 and 81 were examined by differential scanning fluorimetry (DSF), and  TMs  
[1 mM] of +9.3 and +3.0 °C were measured respectively. Compound 79 was examined by 
isothermal titration calorimetry (ITC), where a KD of 7.4 µM was measured. These results 
demonstrate a significant improvement in binding affinity over the starting fragment 64. 
  
77 78 79 
78 80 81 
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2.2.2 1,2,4-Oxadiazole fragment-linking approach 
In order to allow for potential modification of the terminal furan ring of fragment 64, a synthetic 
strategy was selected using a 1,2,4-oxadiazole heterocyclic ring to synthesise the molecules, 
allowing the compounds to be treated as modular in nature. Willand et al. showed that 1,2,4-
oxadiazoles were tolerated as scaffolds that can bind in the EthR-binding pocket.44 The 
synthesis of these heterocyclic rings can be achieved where the starting materials are prepared 
from commercially available carboxylic acids combined with amidoximes which are synthesised 
from the corresponding nitriles. Benzonitrile was utilised as the starting nitrile to provide a 
simplified aromatic functionality. 
Benzonitrile (82) was converted to benzamidoxime (83) through heating with hydroxylamine 
hydrochloride in the presence of diisopropylethylamine (DIPEA). The product was obtained in 
76% yield. This was reacted with Boc-glycine and HBTU in the presence of DIPEA to synthesise 
the Boc-protected compound. This was deprotected with HCl to yield compound 85 in 42% 
yield (Scheme 5). The benzamidoxime (83) was coupled with ethyloxalyl chloride at 0 °C in the 
presence of pyridine to yield the ester (87) in 25% yield, in order to synthesise the carboxylic 
acid for the linking strategy. The hydrolysis of this ester was attempted with sodium hydroxide, 
however the acid was not obtained due to decarboxylation which was observed by MS and NMR. 
An attempt to synthesise the amide directly from the ester 87 and amine 85 was also 
unsuccessful, as was synthesising the tert-butyl ester with deprotection by TFA. 
 
Scheme 5: Synthesis of compounds 83-87. The amidoxime 83 was synthesised from 
benzonitrile (82) with hydroxylamine hydrochloride. This was used to synthesise compound 85 
from Boc-glycine (84) followed by deprotection of the amine with HCl. The amidoxime (83) was 
also used to synthesise compound 87 from ethyloxayl chloride (86). 
 
82 83 84 85 
83 86 87 88 
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As the carboxylic acid 88 proved difficult to synthesise, an alternative strategy was employed 
where an amine linked compound (93) was proposed. This was synthesised using a one-pot 
strategy from glycine (89) and isobutyl chloroformate (90) at 0 °C with triethylamine (TEA) and 
activated 4 Å molecular sieves. This was followed by the addition of benzamidoxime and heating 
the reaction to reflux where compound 91 was isolated in 86% yield. The carbonate (91) was 
treated with sodium hydroxide to yield the alcohol (92) (Scheme 6). 
 
 
Scheme 6: Synthesis of compounds 91-93. 
 
Compounds 92 and 85 were used to synthesise the linked compound 93 by treatment of 92 
with oxalyl chloride followed by addition of the amine 85 and heating to 80 °C, to yield 93 in 
59% yield (Scheme 6). 
During the course of this work, Huguet et al. reported that the treatment of 1,2,4-oxadiazole-5-
carboxylate esters with base results in the decarboxylation of the starting material rather than 
the hydrolysis of the ester.101 In light of this, the oxadiazole strategy was changed to use a  
5-aryl-1,2,4-oxadiazole as the starting scaffold. As proof of concept, compound 97 was 
synthesised by reacting 95 with benzoyl chloride (94) in DCM with pyridine at room 
temperature, followed by heating in DMF to promote the ring closure to the oxadiazole  
89 90 83 
91 92 
93 
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(Scheme 7) and this yielded the ester 96 in 80% yield. The ester product was hydrolysed with 
lithium hydroxide to yield the corresponding acid 97 in 62% yield. 
 
Scheme 7: Synthesis of compounds 96 and 97. 
 
The ester (96) was screened by DSF  where a  TM of +2.0 °C [1 mM] was observed. Due to the 
difficulties in synthesising the desired 1,2,4-oxadiazole compounds, and solubility difficulties 
with this series of compounds this series was discontinued in favour of other fragments which 
were more synthetically tractable. 
 
2.3 Sulfone fragment merging strategies 
 
Fragment 65 (Scheme 8) was identified from the fragment screen as having a  TM of +4.5 °C, 
and a KD of 36 µM suggesting that this is a good starting point for fragment elaboration. X-ray 
crystallography (Sachin Surade, Department of Biochemistry) showed that fragment 65 bound 
twice within the EthR binding pocket. The first molecule (Scheme 8a) is located in the centre of 
the binding pocket, making interactions between the sulfonyl oxygens and the side-chain 
nitrogen of Asn179, while the thioamide nitrogen H-bonded with the side-chain carbonyl of 
Asn176. The second molecule of 65 (Scheme 8b) was shown to bind at the solvent exposed end 
of the EthR binding pocket, lying across the entrance making a H-bonding interaction with the 
hydroxyl of Tyr148. 
94 95 
96 97 
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Scheme 8: (A) - X-ray crystal structure of 65 showing H-bonding interactions. The oxygens of 
the sulfonyl of ‘a’ is able to interact with the N of Asn179 at distances of 2.9 and 3.2 Å (green 
dashed lines), while the nitrogen of the thioamide sits at 3.0 Å from the oxygen of Asn176 
(orange dashed line). One oxygen of the sulfonyl of ‘b’ rests at 3.0 Å from the hydroxyl of Tyr148 
(red dashed line); (B) - Structure of 65; (C) - Synthesis of compounds 99-102. 
A 
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b 
a 
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The synthesis of the thioether 99 was carried out where the thiol of 4-bromothiophenol (98) 
was alkylated with bromoacetamide in the presence of potassium carbonate in 83% yield 
(Scheme 8). The sulfur was oxidised using Oxone™, controlling the quantity of Oxone™ at 1.5 
(sulfoxide) and 4 (sulfone) equivalents to produce a hydrogen-bond donor near the Asn179 
side-chain nitrogen of EthR. When these compounds (99 and 100) were screened by DSF 
against EthR, they showed no indication that they stabilised EthR, while the sulfone compound 
101 produced a KD of 43 µM by ITC. The thioamide (compound 102) was synthesised from 
compound 101 using Lawesson’s reagent in 39% yield. This compound gave a KD of 17 µM as 
measured by ITC, an improvement by a factor of two over fragment 65 (Table 1). 
 
Table 1: DSF and ITC results for compounds 99-102. DSF solutions: 1, 2.5 or 5 mM fragment,  
20 mM EthR, 150 mM NaCl, 20 mM Tris-HCl (pH 8.0), 2.5x SYPRO® Orange, 100 µL final volume. 
ITC conditions: buffer 300 mM NaCl, 20 mM Tris-HCl (pH 8.0), glycerol (matched to EthR stock). 
Compounds (100 mM in DMSO) were diluted to 0.75 mM in buffer. EthR (75 µM) prepared in 
buffer with 10% DMSO. 
 #  
ΔTM 
(°C) 
KD 
(µM) 
99 
 
0.3 
[1 mM] 
- 
100 
 
-0.3 
[2.5 mM] 
- 
101 
 
-1.0 
[5 mM] 
43 
102 
 
0.5 
[1 mM] 
17 
 
 
An overlay of the X-ray crystal structures of fragments 103 and 65 (Figure 29) led to the 
development of merged compound 104 (Scheme 9). The synthesis employed a method similar 
to those described by Curti et al.102 where the sodium sulfinate intermediate was synthesised, 
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followed by oxidative addition of bromoacetamide in the presence of pyridine. The amide 107 
was converted to the thioamide using Lawesson’s reagent in 53% yield. This compound (104) 
was shown to bind to EthR when screened by DSF (ΔTM +4.2 °C [1 mM]), ITC (KD 21 µM), and 
SPR (IC50 20 µM) (Table 2).  
 
 
 
Scheme 9: (A) – Fragment merging strategy of fragments 65 and 103. Overlap (blue) of the 
phenyl ring of 65 with the pyridine ring of 103 led to compound 104; (B) – Synthesis of 
compounds 104 and 106. 
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Figure 29: (A) – Structure of compound 103; (B) - Overlay of X-ray crystal structures of 65 
(pink) and 103 (orange) bound to EthR (Sachin Surade) with compound 104 (green, Michal 
Blaszczyk). This overlay led to the merged fragment series containing the biphenylsulfonyl 
scaffold; (C) - X-ray crystal structure of 104 showing the H-bonding interactions between the 
compound and Asn179. The oxygens of the sulfonyl group are able to interact with the side-
chain NH2 of Asn179 at 3.4 and 2.9 Å (red dashed lines). The thioamide orientation changes in 
comparison to 65, where it no longer makes an interaction with Asn176. 
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Table 2: Biophysical screening results for compounds 106 and 104. DSF solutions: 1 or 5 mM 
fragment, 20 mM EthR, 150 mM NaCl, 20 mM Tris-HCl (pH 8.0), 2.5x SYPRO® Orange, 50 µL final 
volume. ITC conditions: buffer 300 mM NaCl, 20 mM Tris-HCl (pH 8.0), glycerol (matched to 
EthR stock). Compounds (100 mM in DMSO) were diluted to 0.75 mM in buffer. EthR (75 µM) 
prepared in buffer with 10% DMSO. SPR solutions: running buffer 2 mM MgCl2, 10 mM Tris-HCl 
(pH 7.5), 0.1 mM EDTA, 200 mM NaCl, 2% DMSO. EthR prepared as 2 µM in running buffer. 
Compounds were prepared at varying concentrations in running buffer. 
#  
ΔTM 
(°C) 
KD 
(µM) 
IC50 
(µM) 
106 
 
12.5 
[5 mM] 
25 >100 
104 
 
4.2 
[1 mM] 
21 20.0 
 
 
2.4 Fragment growing by modification of the thioamide group 
 
Modification of the thioamide functionality of compound 104 (section 2.3) was explored where 
this was incorporated into a thiazole ring to investigate the necessity of the amide NH2 
hydrogen-bond donating group, while providing a potential handle for fragment-growing into 
the deeper region of the EthR binding pocket. The first compound synthesised was a thiazole 
(110) which was synthesised by reacting sodium sulfate with the 2-(bromomethyl)thiazole, 
produced from 2-(hydroxymethyl)thiazole with phosphorous tribromide (Scheme 10). The 
second compound, a thiophene (111) was synthesised using the same method, where  
2-(hydroxymethyl)thiophene was used as the starting material. The thiazole 110 gave a ΔTM of 
+5.0 °C [1 mM], and subsequent SPR testing recorded an IC50 of 11 µM. The thiophene 111 
produced a stronger thermal stabilisation with a ΔTM of +9.0 °C [1 mM], in addition to a KD of  
12 µM by ITC and IC50 of 9 µM suggesting that the nitrogen is not essential for the activity of the 
molecule. 
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Scheme 10: Synthesis of compounds 107-111. 
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Figure 30: (A) – Overlay of X-ray crystal structures of 65 (pink) and 111 (orange);  
(B) - H-bonding interactions between the sulfonyl oxygens of 111 and Asn179 of EthR at 
distances of 2.9 and 3.4 Å (red dashed lines). Potential interactions with the amide carbonyl of 
Tyr148, and with the hydroxyl of Thr149 (orange arrows) shown. 
 
Three potential interactions of compound 111 were identified from the X-ray crystal structure 
(Figure 30). The meta-carbon of the phenyl ring is 4.1 Å from the amide carbonyl Tyr148, while 
the carbons ortho to the biphenyl linkage is 3.2 and 3.7 Å from the hydroxyl of Thr149. In order 
to exploit the potential Tyr148 interaction, compound 114 was synthesised (Scheme 11). 
Although the KD of 114 was found to be 8 µM, this improvement in affinity was not supported by 
an improvement in IC50 of 15 µM over that of 111. This suggests that the improvement in 
binding affinity was not translated into an improved functional interaction. The synthesis of 
compounds with a 2-pyridyl ring in place of the 3-pyridyl ring of 111 was attempted, however 
due to the de-boronyation of 2-pyridylboronic acids under Suzuki conditions, and the failure of 
2-pyridylboronate-MIDA esters,103-105 neither of these proved successful via the methods 
employed. 
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Previous work by Frenois et al.43 has shown that hexadecyloxtanoate resides deeper in the 
binding pocket of EthR than the fragments thus far examined. In an attempt to probe deeper 
into the EthR binding pocket, compound 120 was synthesised (Scheme 11), providing an 
extended, flexible hydrophobic group. Screening of compounds 119 and 120 produced  TM 
values of +3.8 and +1.8 °C [1 mM] respectively, with a IC50 of 12 µM for compound 120 (Sherine 
Thomas). This suggests that this is a potential means for extending the compounds from the 
thioamide nitrogen while still maintaining potency. 
 
 
 
Scheme 11: (A) Synthesis of compound 114; (B) Synthesis of 120, the thiol (98) was acylated 
with ethyl bromoacetate, then the thioester (115) oxidised to the sulfone (116) using Oxone . 
Suzuki cross-coupling chemistry was used to add the second benzene ring before the ester was 
hydrolysed to the acid (118). Hexylamine was added by COMU coupling and the amide 
converted to the thioamide 120 with Lawesson s reagent  
 
112 113 
114 
98 115 
116 
117 118 
119 120 
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A 
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2.5 Conclusions 
 
The use of both fragment merging and growing strategies has been applied to two fragments 
previously identified through a fragment screen against EthR. The first fragment (64) was 
elaborated using a fragment merging approach where the use of structural biology was key in 
the development of novel compounds. The best compound in this series was compound 79, 
which had a KD of 7.4 µM, however due to the synthetic complexity of this series, they were 
discontinued. 
The second fragment (65) examined contained an aryl-sulfone core, and was elaborated by 
fragment-merging strategies with fragment 103. This led to compound 104 with a KD of 21 µM 
and an IC50 of 20 µM. The oxidation states of the sulfur were explored and this indicated that 
only the sulfone was beneficial to binding, confirming the importance of the sulfone interaction 
with Asn179 seen in the X-ray crystal structure (Scheme 8). 
On changing of the thioamide into a thiazole ring (compound 110) the IC50 decreased to 11 µM, 
while the corresponding thiophene (compound 111) demonstrated an IC50 of 9 µM. The thiazole 
and thiophene rings provided greater stability against oxidation for the sulfur group compared 
to the thioamide, without compromising the functional activity of the scaffold. On substituting 
the biphenyl ring system with a 4-(pyridine-3-yl)benzene group (compound 114), this did not 
provide an improvement in affinity. 
This chapter has explored the linking of adjacent fragments within the EthR binding pocket, in 
addition to the use of sulfone-containing compounds to provide an anchor through the 
interaction with Asn179 of EthR to allow for growth into the EthR binding pocket. The 
thioamide was further investigated, and by fixing the sulfur into a 5-membered ring generated a 
compound which was more stable and offered further vectors for elaboration. While both of the 
fragment series discussed in this chapter offered increased affinity upon elaboration, these were 
not explored further as other fragment growing strategies were prioritised, and these will be 
discussed in chapters 3 and 4. 
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3.0 Fragment growing strategies for targeting EthR 
3.1 Piperazines as a privileged structure in drug discovery 
 
This chapter will discuss fragment-growing strategies to target EthR. A piperazine scaffold 
derived from a fragment hit 66 provides the focus of the fragment-growing strategy where 
growth is achieved in the EthR binding pocket by the addition of a linker to the piperazine NH 
and modification of the 5-(trifluoromethyl)pyridine group (Figure 31). This resulted in 
compounds which are shown to provide a boosting of the effectiveness of ethionamide against 
M.tb. 
 
Figure 31: Fragment 66 bound to EthR. This fragment hit was used as the basis for the 
fragment-growing strategies. Arrow indicates the direction of the primary growth vector 
examined, extending from the NH of the piperazine. 
 
The piperazine heterocyclic ring is widely utilised in drug discovery as it provides a useful 
synthetic handle for elaboration from both nitrogens. It has been found to improve the solubility 
of drugs while providing additional H-bond acceptors.106 Several drugs containing the 
piperazine scaffold are known for their psychoactive effects, others have become well known 
Asn176 
Asn179 
Trp138 
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such as Viagra (Sildenafil, 121), and in the treatment of a variety of conditions ranging from 
depression and anxiety to hypertension, malaria and epilepsy (Figure 32).107 
 
Figure 32: Structures of drugs that contain a piperazine scaffold. 
 
Christopher et al.108 examined the use of fragment-based approaches for targeting the  
 1-Adrenergic Receptor   1AR) where SPR was used to identify fragments 126 and 127 
containing a piperazine ring. The binding pocket of  1AR is lined by hydrophobic residues 
(tryptophan, phenylalanine, tyrosine, valine and alanine) with a polar region at the bottom of 
the pocket. A library of 650 fragments was screened against both  1AR and Adenosine A2A 
receptor. Fragments 126 and 127 were identified which were selective for  1AR, and KDs of  
16 µM and 6 µM were measured respectively by SPR. Structure-activity relationships were 
explored to evaluate changes to the aromatic group, and compound 128 showed the greatest Ki 
by their assay at 68 nM. Protein X-ray crystallography of this compound with  1AR indicated 
that the indole was forming a H-bonding interaction with Ser211, while the NH of the piperazine 
forms interactions with Asn329 and Asp121 (Figure 33).108 
125 
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Figure 33: Structures of fragments 126-128. Compound 128 bound to β 1-Adrenergic Receptor 
(PDB: 3ZPQ). Only the monomer is shown. Inset – compound 128 bound to β1AR showing 
residues near the fragment and H-bonding interactions (green dashed lines).108 
 
The strategies described in this chapter use a piperazine scaffold to provide dual vectors for 
fragment growth oriented along the EthR binding pocket, allowing fragments to be grown 
deeper and shallower within the binding site. 
Asp121 
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3.2 Fragment identification and merging 
 
Fragment 66 was previously identified in a fragment screen against EthR and shown by X-ray 
crystallography (Dr Vitor Mendes) to bind in two orientations (Figure 34). The two orientations 
overlap at the piperazine ring, with the 5-trifluoromethylpyridine rings facing either deeper 
into the pocket, or towards the solvent exposed end of the binding pocket (Figure 34). This 
fragment gave a ΔTM of +4.3 °C as determined by differential scanning fluorimetry (DSF), and an 
affinity (KD) of 35 µM with EthR by ITC. 
 
Figure 34: (A) - X-ray crystal structure of compound 66 bound to EthR. Only the monomer is 
shown; (B) - Structure of compound 66; (C) - X-ray crystal structure of compound 66 (green 
and pink) bound to EthR showing the two binding poses where the CF3 group faces into the 
pocket (green) and out of the pocket (pink). In both orientations, the piperazine ring occupies 
the same position. 
 
In order to examine the dual binding mode of 66, compound 130 was synthesised (Scheme 12) 
by alkylation of the NH of compound 66 with 2-bromo-5-trifluoromethylpyridine. A ΔTM of 
+7.3 °C [1 mM] was determined by DSF and an IC50 of 2.2 µM was measured by SPR. This 
fragment merging strategy shows that building from both nitrogens of the piperazine can 
provide compounds with increased affinity and could be used as a strategy to develop novel 
inhibitors of EthR. 
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Scheme 12: Synthesis of compound 130. Fragment 66 was merged with 2-bromo-5-
trifluoromethylpyridine (129) to yield the merged compound 130, which retains elements of 
both binding poses from fragment 66. 
 
3.3 Fragment growing strategy 
 
3.3.1 Amine linkers 
With the knowledge that the binding site of EthR is largely hydrophobic,35,37 a series of 
compounds were synthesised based on the piperazine fragment hit 66 (Scheme 13) to 
investigate the possibility of growing the fragment from the NH of the piperazine ring. A benzyl 
group with various substitutions at the meta or para positions or 4-methylpyridine ring was 
added in this position by N-alkylation with appropriate aryl methylbromides in the presence of 
Et3N. These reactions proceeded with yields of 49-89%. 
These compounds were examined using DSF and showed only a slight increase in melting 
temperature (TM), with a maximum increase of +3.8 °C for compound 137 [2 mM] and +2.5 °C 
for compound 134 [1 mM]. Compound 137 was examined by ITC, and a KD of 24 µM was 
determined, with only a slight improvement over 66 (35 µM). The IC50 of this compound  
(Dr Michal Blaszczyk) against DNA-bound EthR was measured by SPR at 66 µM, while 
compounds 132, 134 and 135 gave IC50s >100 µM (Table 3). 
66 129 130 
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Scheme 13: Synthesis of compounds 132-138. Fragment 66 was coupled to various aryl 
methylbromides in the presence of triethylamine with mild heating. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
66 131 132 
133 134 
135 136 
137 138 
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Table 3: Table of DSF, ITC, and SPR results for compounds 132-138. DSF of fragment 66 
performed by Narin Hengrung, Department of Biochemistry. DSF solutions: 1,2, or 10 mM 
fragment, 20 mM EthR, 150 mM NaCl, 20 mM Tris-HCl (pH 8.0), 2.5x SYPRO® Orange, 50 µL final 
volume. ITC conditions: buffer 300 mM NaCl, 20 mM Tris-HCl (pH 8.0), glycerol (matched to 
EthR stock). Compounds (100 mM in DMSO) were diluted to 0.75 mM in buffer. EthR (75 µM) 
prepared in buffer with 10% DMSO. SPR solutions: running buffer 2 mM MgCl2, 10 mM Tris-HCl 
(pH 7.5), 0.1 mM EDTA, 200 mM NaCl, 2% DMSO. EthR prepared as 2 µM in running buffer. 
Compounds were prepared at varying concentrations in running buffer. 
#  
R = 
ΔTM 
(°C) 
KD 
(µM) 
IC50 
(µM) 
66   
+4.3 
[10 mM] 
35.0 - 
132 
 
+1.3 
[1 mM] 
- > 100 
133 
 
+0.2 
[1 mM] 
- - 
134 
 
+2.5 
[1 mM] 
- > 100 
135 
 
+1.1 
[1 mM] 
- > 100 
136 
 
+2.1 
[1 mM] 
- - 
137 
 
+3.8 
[2 mM] 
24.3 66.2 
138 
 
+2.8 
[2 mM] 
- - 
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Two compounds (140 and 141) were synthesised where the linker between the piperazine and 
aromatic rings was extended by a methylene group (Scheme 14). These compounds were 
docked into EthR using GOLD (Figure 35) to attempt to predict possible binding interactions, 
before further biophysical analysis was performed. DSF indicated that both 137 and 141 had a 
greater increase in melting temperature, with compound 141 producing a ΔTM of +3.0 °C  
[1 mM], and a KD of 1.3 µM with EthR (Table 4). Observing that both 138 and 137 possess an 
m-fluorobenzene, and compound 137 also had a m-trifluoromethyl substituent, a number of 
compounds were synthesised where the meta groups were modified (142, 143 and 146, 
Scheme 14). 
 
Figure 35: Docked structures of compounds 140 (blue), 141 (pink), and 137 (yellow) overlaid 
in the EthR binding pocket showing the similarities in the position of the docked CF3 groups. 
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Scheme 14: Synthesis of 140-143, 145 and 146. Compounds 140-143 were synthesised with 
appropriate aryl ethyl bromides under basic conditions, while compound 146 was synthesised 
by EDC-mediated coupling of 2-(3-fluorophenyl)acetic acid (144) to fragment 66 to produce the 
intermediate amide 145, followed by reduction to the amine with borane-dimethyl sulfide 
(BMS). 
 
 
 
 
 
 
 
 
66 139 140 
141 142 
143 
66 144 145 
146 
   60 
Table 4: Biophysical results for compounds 140-143, 146. DSF solutions: 1 or 2 mM fragment, 
20 mM EthR, 150 mM NaCl, 20 mM Tris-HCl (pH 8.0), 2.5x SYPRO® Orange, 50 µL final volume. 
ITC conditions: buffer 300 mM NaCl, 20 mM Tris-HCl (pH 8.0), glycerol (matched to EthR stock). 
Compounds (100 mM in DMSO) were diluted to 1 mM in buffer. EthR (50 µM) prepared in buffer 
with 10% DMSO. SPR solutions: running buffer 2 mM MgCl2, 10 mM Tris-HCl (pH 7.5), 0.1 mM 
EDTA, 200 mM NaCl, 2% DMSO. EthR prepared as 2 µM in running buffer. Compounds were 
prepared at varying concentrations in running buffer. 
#  
R = 
ΔTM 
(°C) 
KD 
(µM) 
IC50 
(µM) 
140 
 
+0.9 
[1 mM] 
- - 
141 
 
+3.0 
[1 mM] 
1.3 > 100 
142 
 
+2.8 
[2 mM] 
- - 
143 
 
+1.8 
[2 mM] 
- - 
146 
 
+2.0 
[2 mM] 
- 92.9 
 
 
3.3.2 Amide linkers 
The results of DSF screening of compound 145, which was synthesised as an intermediate to the 
synthesis of 146, suggested that an amide linker in place of the amine would be tolerated, with 
compound 145 giving a ΔTM of +8.5 °C [2 mM]. A methyl amide (compound 147) was 
synthesised using acetyl chloride to determine if the amide alone would be tolerated. Screening 
of this compound by DSF gave a ΔTM of +3.3 °C [1 mM] with an IC50 of 31.4 µM by SPR. Three 
additional compounds incorporating an amide (148-150) were synthesised (Scheme 15) in 
order to allow a comparison of the SAR upon inclusion of the amide carbonyl. The yields ranged 
from 40% to 98%. 
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A comparison of the amides with their corresponding amines (e.g. compound 141 and 
compound 149) shows a trend towards an increase in  TM for the amides, while the carbamate 
151 appears to be less well tolerated when compared to its equivalent amide 148 (Table 5). 
Compound 150 had a  TM of +12.8 °C, and when screened by SPR, had an IC50 below the 
threshold of the assay, with 58% inhibition at the minimum concentration (0.3 µM). 
 
Scheme 15: Synthesis of compounds 147-151. Synthesis of compounds 147 and 148 was 
performed by coupling the acid chlorides to fragment 66, while compounds 149 and 150 were 
synthesised by EDC-mediated coupling of appropriate acids to fragment 66. Synthesis of 
compound 151 was completed by coupling phenylchloroformate to fragment 66 in the presence 
of triethylamine and mild heating. 
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Table 5: Table of DSF, ITC and SPR results for compounds 145, 147-151. DSF solutions: 1 or 2 
mM fragment, 20 mM EthR, 150 mM NaCl, 20 mM Tris-HCl (pH 8.0), 2.5x SYPRO® Orange, 50 µL 
final volume. ITC conditions: buffer 300 mM NaCl, 20 mM Tris-HCl (pH 8.0), glycerol (matched 
to EthR stock). Compounds (100 mM in DMSO) were diluted to 0.75 mM in buffer. EthR (75 µM) 
prepared in buffer with 10% DMSO. IC50 was unable to be determined for compound 150, 
therefore percent inhibition at the lowest assay concentration is reported. SPR solutions: 
running buffer 2 mM MgCl2, 10 mM Tris-HCl (pH 7.5), 0.1 mM EDTA, 200 mM NaCl, 2% DMSO. 
EthR prepared as 2 µM in running buffer. Compounds were prepared at varying concentrations 
in running buffer. 
#  
R = 
ΔTM 
(°C) 
KD 
(µM) 
IC50 
(µM) 
147 
 
+3.3 
[1 mM] 
- 31.4 
148 
 
+8.3 
[2 mM] 
6.1 7.2 
149 
 
+6.5 
[2 mM] 
27.2 51.1 
150 
 
+12.8 
[1 mM] 
9.6 58% (0.3 µM) 
145 
 
+8.5 
[2 mM] 
48.3 3.4 
151 
 
+5.5 
[2 mM] 
18.0 - 
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X-ray crystal structures of compounds 148 and 150 were solved and these show that the 
molecules bind in the opposite orientation to that proposed by the docking. The X-ray crystal 
structures show the trifluoromethyl group is directed towards the solvent-exposed end of the 
pocket, and a H-bond is formed between the amide carbonyl group and the NH of Asn179, 
similar to that observed for the sulfone compounds (Figure 36). 
 
Figure 36: X-ray crystal structure of 104 (pink) 148 (blue) and 150 (grey), showing the  
H-bonding interaction between Asn179 and the amide carbonyl/sulfone (purple dashed line). 
This interaction is highly conserved with this chemical series and provides a key anchor point 
for compound design. 
 
A series of compounds were synthesised where the amide linker was extended by an additional 
methylene group (Scheme 16) in order to allow greater flexibility. These compounds were 
synthesised using either EDC coupling of the appropriate carboxylic acids or by heating the acid 
chloride or chloroformate in the presence of triethylamine with the corresponding amine. DSF 
indicated strong thermal stabilisation by these compounds (152-155), with compound 155 
generating the highest ΔTM of +12.8 °C [1 mM]. 
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#  
R = 
ΔTM 
(°C) 
KD 
(µM) 
IC50 
(µM) 
152 
 
+7.0 
[2 mM] 
14.7 42.9 
153 
 
+9.3 
[2 mM] 
3.1 4.3 
154 
 
+9.8 
[1 mM] 
5.0 1.3 
155 
 
+12.8 
[1 mM] 
0.9 
73% 
(0.3 µM) 
Scheme 16: Synthesis of compounds 152-155. Compounds 152 and 153 were synthesised 
either by coupling of fragment 66 with 3-phenylpropanoyl chloride or benzyl chloroformate in 
the presence of triethylamine with mild heating. Compounds 154 and 155 were synthesised 
from fragment 66 and appropriate arylpropionic acids by EDC-mediated coupling. Table of 
results (DSF, ITC and SPR) for compounds 152-155; DSF solutions: 1 or 2 mM fragment, 20 mM 
66 
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EthR, 150 mM NaCl, 20 mM Tris-HCl (pH 8.0), 2.5x SYPRO® Orange, 50 µL final volume. ITC 
conditions: buffer 300 mM NaCl, 20 mM Tris-HCl (pH 8.0), glycerol (matched to EthR stock). 
Compounds (100 mM in DMSO) were diluted to 0.75 mM in buffer. EthR (75 µM) prepared in 
buffer with 10% DMSO. Where IC50s were below the assay threshold, percent inhibition is 
reported at the lowest assay concentration. SPR solutions: running buffer 2 mM MgCl2, 10 mM 
Tris-HCl (pH 7.5), 0.1 mM EDTA, 200 mM NaCl, 2% DMSO. EthR prepared as 2 µM in running 
buffer. Compounds were prepared at varying concentrations in running buffer. 
 
The IC50s were measured for compounds 152, 155 and 120 using SPR, and these ranged from 
42.9 µM for compound 152 to <0.3 µM for compound 155 (73% inhibition at 0.3 µM). This 
suggests that the carbamate 152 is less well tolerated in comparison to the equivalent amide 
153 (4.3 µM), while the presence of a pyridine or thiophene ring terminating the flexible linker 
was preferred, with compound 154 containing a pyridine ring having an IC50 of 1.3 µM and 
compound 155 possessing a thiophene having an IC50 of <0.3 µM. 
 
3.3.3 Examination of the CF3 position on the pyridine ring as a vector for 
elaboration 
A further potential site for optimisation was the pyridine ring, and modification of this region 
would allow for a growth vector directed towards the top of the binding pocket. Compounds 
161 and 163 were synthesised so as to determine the importance of the CF3 and pyridine 
nitrogen respectively. The aryl-piperazines were coupled to 2-thiophenepropionic acid using 
EDC in yields from 73-86%. As 1-(pyridin-2-yl)piperazine was not available at the time from 
commercial sources, compound 161 was prepared by coupling 2-thiophenepropionic acid to  
N-Boc-piperazine, followed by deprotection and alkylation with 2-fluoropyridine under mild 
basic conditions (Scheme 17). 
Removal of the CF3 group from the pyridne ring of compound 155 was shown to be not 
detrimental to the binding of the compound as evidenced by the SPR results of compound 161 
(63% inhibition at 0.3 µM) compared to 155 (73% inhibition at 0.3 µM), while removal of the 
pyridine nitrogen reduced the IC50 of compound 163 to 0.8 µM when compared to 155. When 
the pyridine ring was replaced with a phenyl ring (164), the IC50 (0.7 µM) was similar to 
compound 163, suggesting that the nitrogen is important for binding which is in agreement 
with the previous reports.39 
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# 
R’ = 
ΔTM 
(°C) 
KD 
(µM) 
IC50 
(µM) 
161 
 
+13.3 
[1 mM] 
2.3 63% (0.3 µM) 
163 
 
+9.5 
[1 mM] 
14.8 0.8 
164 
 
+10.8 
[1 mM] 
2.4 0.7 
165 
 
+12.8 
[1 mM] 
1.7 61% (0.3 µM) 
156 157 158 
159 160 161 
162 157 163 
164 165 
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Scheme 17: Synthesis of compounds 158-165 to determine the importance of the 
trifluoromethylpyridine group and its potential as a growth vector. Biophysical data for 
compounds 161, 163-165. DSF solutions: 1 mM fragment, 20 mM EthR, 150 mM NaCl, 20 mM 
Tris-HCl (pH 8.0), 2.5x SYPRO® Orange, 50 µL final volume. ITC conditions: buffer 300 mM NaCl, 
20 mM Tris-HCl (pH 8.0), glycerol (matched to EthR stock). Compounds (100 mM in DMSO) 
were diluted to 0.75 mM in buffer. EthR (75 µM) prepared in buffer with 10% DMSO. Where 
IC50s were below the assay threshold, percent inhibition at the lowest assay concentration are 
reported. SPR solutions: running buffer 2 mM MgCl2, 10 mM Tris-HCl (pH 7.5), 0.1 mM EDTA, 
200 mM NaCl, 2% DMSO. EthR prepared as 2 µM in running buffer. Compounds were prepared 
at varying concentrations in running buffer. 
 
The introduction of a pyrimidine ring as a replacement of the pyridine ring (165, Scheme 17) 
revealed that this additional heteroatom did not produce any significant change in the percent 
inhibition compared to 161 (61% versus 63% inhibition). 
An X-ray crystal structure of 161 revealed potential H-bonding interactions with the backbone 
carbonyl groups of Met102, Trp103, Tyr148 or Thr 149 (Figure 37). This prompted the 
synthesis of compounds 167-171 (Scheme 18), in an attempt to probe the possible interaction 
through H-bonding by the addition of an NH functionality. Compound 169 was synthesised 
using a Pd-mediated Buchwald-Hartwig coupling of 5-bromo-7-azaindole (166), with N-Boc-
piperazine (156), followed by removal of the Boc protecting group and EDC coupling of the 
resulting salt with 2-thiophenepropionic acid (157). Compounds 170 and 171 were 
synthesised by an analogous method with appropriate bromoindoles, giving the compounds 
169, 170 and 171 in yields ranging from 37-52% over the final 2 steps. 
 
Figure 37: X-ray crystal 
structure of 161 showing 
nearby residues. Arrows 
indicate possible locations 
for H-bonding interactions 
with EthR. 
 
Asn176 
Asn179 
Trp138 
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Tyr148 
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   68 
The three compounds showed a decrease in  TM compared to compound 161, as well as poorer 
KDs (14-20 µM) (Table 6, Figure 38). The IC50s for the indole compounds 170 and 171, 
measured by SPR, were between 6 and 7 µM, while the azaindole 169 was 19 µM (Table 6). 
 
Scheme 18: Synthesis of compounds 167-174. These compounds were synthesised from 
arylbromide starting materials, coupled via Buchwald-Hartwig chemistry to N-Boc-piperazine 
(156). The resulting Boc amines were deprotected under acidic conditions and coupled to  
2-thiophenepropionic acid (157) using EDC. 
 
 
166 156 167 
168 157 169 
170 171 
172 173 
174 
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Table 6: Table of DSF, ITC, and SPR results for compounds 169-174. DSF solutions: 1 mM 
fragment, 20 mM EthR, 150 mM NaCl, 20 mM Tris-HCl (pH 8.0), 2.5x SYPRO® Orange, 50 µL final 
volume. ITC conditions: buffer 300 mM NaCl, 20 mM Tris-HCl (pH 8.0), glycerol (matched to 
EthR stock). Compounds (100 mM in DMSO) were diluted to 0.75 mM in buffer. EthR (75 µM) 
prepared in buffer with 10% DMSO. SPR solutions: running buffer 2 mM MgCl2, 10 mM Tris-HCl 
(pH 7.5), 0.1 mM EDTA, 200 mM NaCl, 2% DMSO. EthR prepared as 2 µM in running buffer. 
Compounds were prepared at varying concentrations in running buffer. 
# 
R’ = 
ΔTM 
(°C) 
KD 
(µM) 
IC50 
(µM) 
169 
 
+5.8 
[1 mM] 
20.3 18.9 
170 
 
+7.5 
[1 mM] 
14.0 6.4 
171 
 
+7.5 
[1 mM] 
15.6 6.9 
172 
 
+8.8 
[1 mM] 
No binding 12.9 
173 
 
+4.0 
[1 mM] 
No binding 48.0 
174 
 
+11.8 
[1 mM] 
3.0 2.1 
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Figure 38: ITC traces of compounds (A) - 161; (B) - 163; (C) - 164; (D) - 165; (E) - 170;  
(F) - 171; (G) – 174. 
 
The KDs for the azaindole and indole compounds 169-171 (KDs 20.3, 14.0 and 15.6 µM) showed 
a decrease in binding affinity when compared with compounds 161 (KD 2.3 µM) and 164  
(KD 2.4 µM). Compounds 172-174 were synthesised to investigate the effect of reversing the 
  
 
E F 
G 
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hydrogen bonding potential by substituting a benzofuran for the indole, and changing the 
electronics of the ring by addition of electron-withdrawing groups. Compounds 172 and 174 
were synthesised using the same route as compounds 169-171 (Scheme 18) to investigate the 
potential for H-bonding with the main-chain NH of Trp103 (compounds 173 and 174) and the 
effect of electron-withdrawing groups on the benzene ring (compound 172). These compounds 
produced  TMs of +8.8 °C [1 mM] and +11.8 °C [1 mM] respectively. When tested by ITC, 
compound 172 did not produce any heats of binding (Table 6), while 174 gave a KD of 3 µM. 
Despite this, compound 172 yielded an IC50 of 12.9 µM and compound 174 gave an IC50 of  
2.1 µM by SPR. This suggested that the presence of the hydrogen bond acceptor of compound 
174 is preferred to the electron withdrawing groups of compound 172 or the hydrogen bond 
donors of compounds 169-171. 
Compound 173 was synthesised to contain a benzisoxazole however, this was found to be 
unstable towards the reaction conditions employed and resulted in ring opening to form the 
hydroxybenzonitrile. The compound still provided interesting functionality in the hydroxyl and 
nitrile groups, however the DSF indicated a  TM of only +4 °C [1 mM], with SPR recording an 
IC50 of 48 µM. 
 
3.4 Ethionamide boosting assay 
 
A number of compounds were screened using the resazurin microtiter assay (REMAssay) 
(Professor Stuart Cole Laboratory, EPFL). The compounds were screened alone and in 
combination with ethionamide (ETH) at a fixed concentration of 1 µM, with varying 
concentrations of ETH to determine if the compounds would boost ethionamide activity (testing 
carried out by Anthony Vocat, EPFL). Cell viability was measured by fluorometric analysis of 
resorufin, produced as a metabolite of resazurin in viable cells. 
The results indicated that the indole and azaindole compounds 169-171 did not boost ETH 
efficacy, with MIC results in the range of 25-26 µM (Figure 39). Compound 165, containing the 
pyrimidine had an MIC of 6.4 µM. Contrary to the KD values, the presence of the pyridine 
nitrogen had little effect, with compound 163 giving an MIC of 1.7 µM, the same as compound 
155. Meanwhile the removal of the CF3 group in addition to the pyridine nitrogen lowered the 
MIC of compound 164 to 1.1 µM. The benzoxazole compound 174 also had an MIC of 1.1 µM, 
making 164 and 174 the most potent boosters of ethionamide screened. 
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# Structure 
IC50 (µM) 
[REMAssay] 
MIC (µM) 
[REMAssay] 
6 
 
24.5 30.3 
66 
 
22.7 25 
148 
 
21.2 23.6 
152 
 
11.6 13.3 
150 
 
3.5 5.2 
153 
 
12 12.7 
154 
 
18.4 25 
174 
 
174
   75 
155 
 
1.5 1.7 
161 
 
2.4 3 
163 
 
1.6 1.7 
164 
 
0.6 1.1 
165 
 
3.7 6.4 
169 
 
12.7 25 
170 
 
15 25.2 
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171 
 
23.4 25.7 
172 
 
1.6 1.7 
173 
 
13.5 25 
174 
 
0.6 1.1 
Figure 39: REMAssay MIC plots (provided by Anthony Vocat, EPFL). Red lines indicate fitting to 
ETH only control curve, black lines indicate cell viability in the presence of 1 µM test compound 
at varying concentrations of ETH. Movement of the inflection point of the black line to the left of 
the red line indicates ETH boosting. Table of IC50 and MIC values calculated from the REMAssay. 
Values are the average of two replicates. REMAssay solutions: M.tb. (H37Rv) was prepared at an 
OD of 0.0001 in 7H9 broth with 10% albumin-dextrose-catalase, 0.2% glycerol and 0.05% 
Tween-20. Ethionamide was diluted with the above solution at 2-fold dilutions and test 
compounds added at 1 µM. After incubation, 0.025% resazurin was added and the metabolite 
resorufin fluorescence read (λex-em 560-590 nm) after overnight incubation. 
 
The REMAssay results show that through a fragment growing strategy from the original 
fragment hit 66, compounds 164 and 174 were synthesised which each gave a 30 fold boosting 
effect of the ethionamide MIC. 
   77 
 
3.5 Conclusions 
 
The elaboration of fragment hit 66 with an IC50 of 35 µM to a compound with an IC50 of < 0.3 µM 
(compound 155) was described using fragment growing strategies. X-ray crystallography was 
key in guiding the development of these compounds. The elaboration strategies were achieved 
through two vectors on the original fragment hit 66. The free NH of fragment 66 was used as a 
synthetic handle for extending the molecule deeper into the EthR binding pocket, while the 
(trifluoromethyl)pyridine was replaced with several alternative motifs to improve the  
H-bonding capacity of this region of the molecule. 
It was found that the addition of a linker containing an amide bond to the piperazine proved 
beneficial, where compound 153 gave a KD of 3.1 µM with EthR. X-ray crystallography suggests 
that this improvement was primarily through the introduction of a hydrogen bond between the 
amide carbonyl and Asn179 of EthR. The aryl group at the termination of the linker was 
examined, resulting in a 2-thiophene group (compound 155) providing an affinity for EthR of 
0.9 µM. 
Removal of the trifluoromethyl group produced a minor decrease in affinity, with compound 
161 yielding a KD of 2.3 µM compared to compound 155 with a KD of 0.9 µM. By replacing the  
5-(trifluoromethyl)pyridine group with a 7-azaindole (169), or indole (compounds 170 and 
171), the IC50 was reduced from < 0.3 µM (compound 155) to 18.9 µM (169), 6.4 µM (170) and 
6.9 µM (171). When the 5-(trifluoromethyl)pyridine group was replaced with a benzofuran 
(compound 174), an IC50 of 2.1 µM was obtained. 
The screening of these compounds in the REMAssay to examine the ethionamide boosting 
ability identified that the benzofuran compound (174) yielded an MIC of 1.1 µM, along with the 
benzene derivative (164), while the 5-(trifluoromethyl)pyridine  compound (155) gave an MIC 
of 1.7 µM, all boosting the efficacy ethionamide by approximately 30 times. 
This work provides a starting point for the development of efficient small molecule therapeutics 
which, co-administered with ethionamide could boost the efficacy of this second line anti-
tubercular drug by interacting with both available binding sites of the EthR dimer and inhibiting 
the ability of this repressor to bind to its DNA target. There remains further scope for growing 
and linking strategies to reach deeper into the EthR binding pocket. 
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4.0 Extended and bivalent molecules for stabilising the 
EthR dimer in a non-active conformation 
4.1 Bifunctional molecules in drug discovery 
 
This chapter describes the strategy of linking two molecules of compound 155 described 
previously (section 3.3.3) with linkers to bridge the two binding pockets of the dimeric EthR 
structure. The hypothesis is that this could allow the dimer to be stabilised in the non-active 
conformation. This approach has been examined previously in proteins such as transthyretin 
(TTR),109 bromodomains and extraterminal bromodomain (BET),110 and for the drug 
isoniazid (INH) 111 where researchers looked to improve clearance and bioavailability. 
Bifunctional molecules have been examined for improving the plasma clearance of the 
amyloidogenic protein transthyretin. Transthyretin is a homotetrameric protein where a build-
up of this can lead to systemic amyloidosis, a condition that can prove fatal. Mangione et al.109 
proposed that by linking two TTR homotetramers, the body would recognise the abnormal 
structure and improve the clearance of TTR. The small molecule 2-((3,5-
dichlorophenyl)amino)benzoic acid, was used as the active warhead, which was linked by 
polyproline or polypiperidine linker to form palindromic compounds (Figure 40A and B). Mass 
spectrometry indicated that the compounds were successful in forming stable, crosslinked 
complexes with over 95% of TTR complexed.109 The authors proposed that two possible 
structures existed for the protein-ligand complex   a barbell-type structure where two 
tetramers are linked linearly by one drug molecule (Figure 40C), and a bracelet-type structure, 
where the two tetramers are linked with two drug molecules into a ring (Figure 40D). 
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Figure 40: (A) – Structure of the polyproline linked ligand; (B) – Structure of the polypiperidine 
linked ligand; (C) – Proposed docked ‘barbell-like’ structure of the octameric transthyretin 
complex, linked by one polyproline linker (n = 9). The rigidity of this linker prevents the 
cyclisation of the complex; (D) – Proposed ‘bracelet-like’ structure of the octameric 
transthyretin complex, linked by two polypiperidine linker compounds (n = 4, m = 4), forming a 
ring.109 
 
Despite successfully forming the octameric complex as observed by mass spectroscopy, it was 
found that plasma clearance was not improved in the complexes when compared to tetrameric 
transthyretin. 109 
Tanaka et al. utilised bifunctional ligands to improve the affinity of molecules targeting the BET 
transcriptional coactivators.110 Three possible orientations for linking compound 177 to the 
polyethylene glycol (PEG) linker were proposed, generating two palindromic ‘homodimers’ 
(178 and 179) and one ‘heterodimer’ (180) (Figure 41).110 
A 
B 
C D 
175 
176 
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Figure 41: Structure of compound 177 and linked compounds 178, 179 and 180. Compound 
177 was known to bind to BET. Compound 180 (heterodimer) was synthesised to examine the 
potential for PEG-linked compounds to bind multiple BET domains simultaneously. X-ray 
crystal structure of 178 (n = 7) bound to two BET monomers (PDB: 5JWM).110 
177 
178 
179 
180 
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The homodimers 178 and 179 failed to show an increase in activity in both the biochemical 
(IC50 177 = 21 nM, 178 = 158 nM, 179 = 1 nM) and cellular assays (IC50 177 = 72 nM,  
178 = 42 nM, 179 = 24 nM). The heterodimer 180 (6S,2R and 6R,2S; n = 1) was therefore 
utilised for further study, in addition to a monofunctional 177-PEG (2S) molecule and a 
bifunctional compound with 6S,2S stereochemistry. Size exclusion chromatography indicated 
that compound 180 (n = 1; 6S,2S) was dimerising BET by showing a decrease in the elution 
volume corresponding to a larger compound size, while 180 (n = 1; 6R,2R) and single warhead 
(177) did not alter the elution volume of BET indicating no change in volume of the compound. 
These results were supported by ITC, where compound 180 (n = 1, 6S,2S) was shown to bind 
BET with a 1:2 stoichiometry (KD 17 nM), while compound 177 bound with a 1:1 ratio  
(KD 40 nM).110 
A further series of compounds were synthesised with various linker lengths up to 7 PEG units 
where the warheads were attached in various combinations by either the    position of the ester 
of the diazepine or the    position of the thiophene. It was determined that the PEG7 linker with 
both warheads attached at the ester functional group (178; 6S,6S) had comparable activity (IC50 
3 nM, biochemical assay) to the previous heterodimer 180 derivatives, however this had better 
pharmacokinetic properties. An X-ray crystal structure of compound 178 (n = 7; 6S,6S) was 
obtained (Figure 41), showing that it bound to two BET molecules while retaining the binding 
mode of 177.110 
A further exploration of bivalent molecules was the use of PEGylated Isoniazid for delivery into 
M.tb., which was examined by Kakkar et al.111 Two INH moieties linked by a PEG linker with 4, 
11 or 14 repeated units (Figure 42), were examined to see whether the cytotoxicity, which is 
noted with Isoniazid use, can be reduced. PEG was selected for the linker due to its structural 
simplicity and low toxicity and excretion profiles.111 
 
Figure 42: Structure of the bis-Isoniazid-PEG conjugate showing the clearance times with the 
increasing PEG chain length.111 
 
181 
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It was demonstrated that the INH-PEG conjugates showed improved cytotoxicity, although 
compound 181 variants gave a minimum inhibitory concentration (MIC) of 0.6 nM compared to 
0.9 nM for INH alone. The bis-INH compounds were shown to have longer half-lives in blood, 
t½ 2.1 hr (181; n = 14) compared to t½ 50 min (INH). The increase in the half-lives of the 
compounds also corresponded to an increase in molecular weight. Furthermore, the PEG-INH 
conjugates were shown to have greater uptake by infected tissue than INH alone.111 
Looking at the utilisation of bifunctional molecules in the above strategies, the goal was to see 
whether this novel inhibition strategy could be applied to EthR. The aim was to explore whether 
binding to both pockets of the EthR dimer could result in increased inhibition of the EthR-DNA 
interaction, resulting in an increase in ethionamide efficacy. 
 
4.2 Replacement of the CF3 group to facilitate growth towards the 
solvent-exposed end of the binding pocket of EthR 
 
Compound 155, which was previously discussed in section 3.3, was selected as the starting 
point to examine the potential for building extended molecules. The strategy involves 
replacement of the CF3 group and addition of alkyl and PEG chains to extend the molecule 
towards the open end of the binding pocket. This approach will be used to link the two binding 
pockets of the EthR dimer, to establish whether EthR can be stabilised in a non-active, ligand-
bound conformation. 
 
Figure 43: Structure of compound 155 showing the vector for linking the two EthR monomers. 
 
Having determined that the CF3 component of the piperazine-series compounds such as 155 
could be removed with little or no detriment to activity (section 3.3.3, compound 155 73% 
inhibition at 0.3 µM, compound 161 63% inhibition at 0.3 µM), the replacement of this with 
alternative functional groups designed to grow out of the binding pocket was developed. 
A hexylamine group was introduced onto the pyridine ring in the 5-position (Figure 44) to 
determine if a linear hydrophobic group would be tolerated. This compound was synthesised in 
155 
   83 
four synthetic steps where EDC coupling of the acid was followed by removal of the Boc 
protecting group with TFA and addition of the 5-bromo-2-fluoropyridine under basic conditions 
gave the core scaffold. The hexylamine group was introduced using Buchwald chemistry and the 
product 183 was isolated in a yield of 7%. 
 
 
Figure 44: Synthesis of compounds 182 and 183. N-Boc-piperazine (156) was coupled to 
2-thiophenepropionic acid (157) with EDC, then the Boc protecting group removed with TFA. 
5-bromo-2-fluoropyridine was aminated with the TFA salt (159), then hexylamine added via 
palladium-catalysed Buchwald chemistry. 
 
Upon screening using DSF, compound 183 was found to give a  TM of +8.5 °C [1 mM], with a KD 
of 4.8 µM determined by ITC. X-ray crystallography (Dr Michal Blaszczyk) confirmed that the 
hexylamine was oriented towards the solvent exposed end of the pocket (Scheme 19A), showing 
that the strategy of building towards the solvent exposed end of the pocket is possible. 
In order to explore whether other linkers were tolerated, and to simplify the chemistry, 
compounds 187-189 were synthesised (Scheme 19B) where a carboxylic acid was introduced 
(188) to provide a more convenient synthetic handle. Compounds 187 and 189, when 
measured by DSF gave a  TM of +13.3 °C [1 mM] and +11.0 °C [1 mM] respectively, while 
compound 188 gave a  TM of +9.3 °C [1 mM]. Upon examination by ITC against EthR, 
156 157 158 
183 
159 
182 
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compounds 187 and 189 gave KDs of 4.8 and 3.9 µM respectively, however no heats of binding 
to EthR were detected for compound 188. The IC50s of these compounds against EthR bound to 
immobilised promoter DNA were determined by SPR (Sherine Thomas) and this showed that 
compound 188 was not as potent as compounds 187 and 189 with values of 11.3, 0.5 and 
0.6 µM respectively. These compounds served as useful starting points in order to develop the 
bivalent ligands. 
 
 
 
Scheme 19: (A) - X-ray crystal structure of compound 183 (purple) bound to EthR, with Arg159 
shown (orange) (Dr Michal Blaszczyk); (B) - Synthetic scheme showing the introduction of an 
amide on the 5-position of the pyridine ring. Methyl 6-bromonicotinate (184) was aminated 
with N-Boc-piperazine (156), which was then deprotected with HCl. The salt (186) was coupled 
to 2-thiophenepropionic acid with EDC, before the ester (187) was cleaved to the acid (188) 
with LiOH. The acid was reacted with methanolic ammonia with EDC to produce the amide 189. 
Asn176 Arg159 
Helix 7 
A 
B 
184 156 185 
186 157 187 
188 189 
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As compounds 187-189 showed good affinities in SPR and ITC, they were screened to 
determine whether they boosted the ethionamide effect. The compounds were screened against 
TB (H37Rv) using the REMAssay (Anthony Vocat, EPFL) and compound 188 gave an MIC of 
25 µM, compound 189 15.8 µM and compound 187 showed the greatest boosting activity at 
5.2 µM (Table 7). The compounds were tested at 1 µM against M.tb. grown in supplemented 7H9 
broth with ethionamide at varying concentrations. After 6 days of incubation at 37 °C, resazurin 
was added, and incubated overnight, at which time the fluorescence of the resazurin metabolite 
resorufin is recorded. 
 
Table 7: Biophysical results for compounds 187-189. DSF solutions: 1 mM fragment, 20 mM 
EthR, 150 mM NaCl, 20 mM Tris-HCl (pH 8.0), 2.5x SYPRO® Orange, 50 µL final volume. ITC 
conditions: buffer 300 mM NaCl, 20 mM Tris-HCl (pH 8.0), glycerol (matched to EthR stock). 
Compounds (100 mM in DMSO) were diluted to 0.75 mM in buffer. EthR (75 µM) prepared in 
buffer with 10% DMSO. SPR performed by Sherine Thomas. SPR solutions: running buffer 2 mM 
MgCl2, 10 mM Tris-HCl (pH 7.5), 0.1 mM EDTA, 200 mM NaCl, 2% DMSO. EthR prepared as 2 µM 
in running buffer. Compounds were prepared at varying concentrations in running buffer. 
REMAssay performed by Anthony Vocat (EPFL). REMAssay solutions: M.tb. (H37Rv) was 
prepared at an OD of 0.0001 in 7H9 broth with 10% albumin-dextrose-catalase, 0.2% glycerol 
and 0.05% Tween-20. Ethionamide was diluted with the above solution at 2-fold dilutions and 
test compounds added at 1 µM. After incubation, 0.025% resazurin was added and the 
metabolite resorufin fluorescence read (λex-em 560-590 nm) after overnight incubation. 
 
# 
 
R = 
ΔTM 
(°C) 
KD (ITC) 
(µM) 
IC50 (SPR) 
(µM) 
IC50 
(REMAssay) 
(µM) 
MIC 
(REMAssay) 
(µM) 
187 
 
+ 13.3 
[1 mM] 
4.8 0.5 4.2 5.2 
188 
 
+ 9.3 
[1 mM] 
no heats 11.3 19.3 25 
189 
 
+ 11.0 
[1 mM] 
3.9 0.6 13 15.8 
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In order to further extend the molecules towards the top of the binding pocket, the X-ray crystal 
structure of compound 183 was examined for potential interactions (Scheme 19A). The residue 
Arg159, which is located at the top of helix 7, could offer the possibility for a  -cation 
interaction with an aromatic ring.112 Utilising the acid functional group of compound 188 and 
with the knowledge that both the ester (compound 187) and amide (compound 189) had sub-
micromolar IC50 values (Table 7), compounds 190 and 191 were synthesised (Scheme 20). 
Compound 190 was synthesised by formation of an activated ester of compound 188 with 
2,4,6-trichlorobenzyl chloride followed by transesterification with 2-(2-
(benzyloxy)ethoxy)ethan-1-ol which gave the product 190 in 14% yield. Compound 191 was 
synthesised by EDC coupling of compound 188 with 4-phenylbutan-1-amine where the product 
191 was isolated in a 14% yield. 
 
Scheme 20: Synthesis of 190 and 191. These compounds aimed to exploit the presence of an 
asparagine residue at the solvent-exposed end of the EthR binding pocket. Both compounds 
were synthesised from the acid 188, with compound 190 proceeding via the activated ester 
formed with 2,4,6-trichlorobenzyl chloride, with subsequent transesterification with 
2-(2-(benzyloxy)ethoxy)ethanol. Compound 191 was synthesised by EDC coupling with 
4-phenylbutanamine. 
 
  
188 
190 
191 
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Screening of compound 190 against EthR by DSF was found to give a  TM of +8.8 °C [1 mM], 
while compound 191 did not produce a measurable  TM curve. Despite this, sub-micromolar 
IC50s were determined by SPR (Sherine Thomas), where compound 190 gave an IC50 of 0.6 µM 
and compound 191 an IC50 of 0.3 µM, some of the strongest binding compounds developed 
during the course of this work. 
 
4.3 Stabilisation of the dimeric form of EthR 
 
It was previously established that the binding of small molecules within the binding cavity of 
EthR induces a conformational change, which inhibits the binding of EthR.32 As the protein 
forms a dimer in solution in the absence of the target DNA,38 compounds were envisioned which 
would be able to link the binding sites of two EthR monomers to stabilise the dimeric structure 
in an inactive conformation. 
From consideration of the X-ray crystal structure of compound 183 bound to EthR, the distance 
between the two binding sites (Figure 45) was measured to be approximately 71-78 Å. This 
suggests that a polyethylene glycol (PEG) linker of approximately 900-1000 Da (20-22 PEG 
units) would be appropriate to link the two binding sites. Three PEG linkers were obtained   
PEG-600 (13 PEG units, 47 Å), PEG-1000 (22 PEG units, 79 Å), and PEG-1500 (34 PEG units, 
122 Å), in addition to block polymer Jeffamine-ED900 (192). The PEG-1500 was selected to 
provide a linker which would have additional flexibility, while the PEG-600 was chosen to 
produce a compound which would be too short to reach both binding sites. The synthesis of the 
PEG-linked molecules was attempted by two routes. The first was the conversion of the 
carboxylic acid to the acid chloride followed by displacement with the PEG alcohol. The second 
involved the formation of the activated ester with 2,4,6-trichlorobenzylchloride and attempted 
transesterification with the PEG alcohol. Both of these routes proved unsuccessful, however the 
Jeffamine-linked compound 193 was synthesised by COMU coupling. Upon examination of this 
compound by DSF, a  TM of +6.5 °C [1 mM] was measured, and an IC50 of 11.8 µM was measured 
by SPR. These results indicate that these molecules disrupt the EthR-DNA interaction. 
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Figure 45: (A) - Structure of the EthR dimer showing two molecules of compound 183 (purple), 
indicating the separation of the two substrate binding sites. The black arrows indicate the 
distance measured from the amine of one molecule of 183 to the amine of the second molecule 
of 183 as the desired position for joining of the linker. (B) - Synthesis of compound 193. 
Jeffamine ED-900 was coupled to compound 188 with COMU to yield compound 193. 
A 
B 
192 
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The Jeffamine-linked compound 193 was examined by mass spectrometry (Daniel Chan, 
Department of Chemistry) in order to determine how 193 was binding to the EthR dimer. The 
results indicated that compound 193 was able to bind one or two units per dimer, while some 
tetrameric species were also observed in the presence of the ligand, suggesting that the ligand is 
capable of binding across two EthR dimers. The binding of one molecule of 193 per EthR dimer 
could occur through two possible binding modes. The first is where the ligand occupies both 
binding sites of the dimer (Figure 46A), while the second is where the ligand binds to one 
monomer, leaving the other site unoccupied, with one end of the ligand free (Figure 46B). 
Reduction in the signal of the EthR-DNA complex was seen in the presence of promoter DNA 
and the compound, indicating that the DNA binding is reduced in the presence of the ligand. 
    
      
 
Figure 46: Potential binding modes of compound 193 to EthR. (A) – 1 molecule of compound 
193 per EthR dimer; (B) – 1 molecule of 193 per dimer of EthR; (C) – 2 molecules of 193 
binding to one EthR dimer; (D) – 1 molecule of compound 193 binding two dimers of EthR; 
(E) – Mass spectrometry data (Daniel Chan) showing the various states of the EthR-193 
complex in the absence of promotor DNA. 
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Compound 193 was developed and shown to be able to bind to the dimer state of EthR and 
inhibit the EthR-DNA interaction. This has demonstrated a plausible strategy for targeting EthR. 
Although in the early stages, this approach could lead to highly potent compounds for use as 
ethionamide boosters and future work would be needed to develop this strategy further. 
 
4.4 Conclusions 
 
The CF3 group of compound 155 which binds to the solvent exposed end of the EthR ligand 
binding pocket has been shown to be a potential vector for extending molecules outside the 
EthR binding pocket. Compound 183 was synthesised to examine whether a hexyl chain would 
be tolerated as the molecule approached the solvent exposed end of the binding pocket and it 
was observed that this bound with a KD of 4.8 µM. X-ray crystallography confirmed that 183 
maintained the expected binding mode with the alkyl chain positioned facing out of the pocket. 
The use of an amide in place of the amine was explored and compounds 187-189 were 
developed to determine the influence of these functional groups at the 5-position of the pyridine 
ring. Biophysical assays showed that the acid (188) was less tolerated than ester (187) or 
amide (189) functional groups, and both the ester and amide substituted compounds gave 
similar affinities by ITC (KD 4.8 µM and 3.9 µM) and SPR (IC50 0.5 µM and 0.6 µM). A further 
strategy was employed to see whether the Arg159, which is found at the end of the binding 
cavity could be targeted, and compounds 191 and 190 were designed to include a phenyl group 
at the end of a chain. Compounds 190 and 191 yielded sub-micromolar IC50s by SPR (0.6 µM 
and 0.3 µM respectively), showing that this strategy was successful and that compounds which 
occupy the top of the binding pocket can pick up further interactions. 
The bivalent compound 193 was developed and when screened by SPR gave an IC50 of 11 µM. 
This compound was also examined using mass spectrometry, which demonstrated that this 
bifunctional compound can successfully bind to and inhibit EthR. However, further work is 
needed to determine the optimal linker length for these compounds. 
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5.0 Experimental 
5.0.1 Solvents and Reagents 
Reagents and anhydrous solvents purchased from commercial sources were used as received. 
Solvents were used as received from commercial sources, with the exception DCM, toluene, and 
methanol, which were distilled over calcium hydride, and THF, which was distilled over calcium 
hydride with LiAlH4 and triphenylphosphine. 
5.0.2 Nuclear Magnetic Resonance Spectroscopy 
NMR were recorded on a Bruker DPX-400 MHz or Bruker Avance 500 MHz Cryo Ultrashield and 
processed with NMR Kiosk (Bruker), Topspin (Bruker), or NMR processor (academic edition; 
Advanced Chemistry Development Labs). 
5.0.3 Liquid-Chromatography Mass-Spectrometry 
LCMS were recorded on a Waters Alliance HT machine using a 2795 separation module and 
2996 photodiode detector array connected to a Waters micromass ZQ quadrupole mass 
spectrometer, or a Waters Acquity HClass UPLC fitted with TUV and SQ detectors. Both systems 
operate on MassLynx software (Waters Ltd.). Samples were run using a gradient of water 
              formic acid  in acetonitrile over a period of 8 min. (Alliance) or 4 min. (Acquity) 
5.0.4 High Resolution Mass Spectrometry 
High resolution MS were recorded with a Waters LCT Premier Micromass machine with an 
Agilent 1100 series LC system. Samples were run using a gradient of water               
formic acid) in acetonitrile over a period of 8 min. 
5.0.5 Infrared Spectroscopy 
IR spectra were obtained on a PerkinElmer Spectrum One Fourier transform IR 
spectrophotometer with ATR using Spectrum version 5.0.1 (PerkinElmer Inc.) and processed 
within the operating software, or using KnowItAll Informatics System 2013 (academic edition; 
Bio-Rad Laboratories, Inc.). Scanning range was 4000-650 cm-1, with 4 transients per spectrum. 
5.0.6 Flash Column Chromatography 
Chromatographic purification was carried out on either an Isolera One or Isolera Four 
chromatography system (Biotage) using pre-packed KP-SIL columns (4, 10, 12, 24, 25, 40 or 
50 g) and solvent systems as per the synthetic procedures. 
5.0.7 Microwave Reactions 
Microwave reactions were performed with a Biotage Initiator.  
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5.0.8 Thin Layer Chromatography 
TLC was carried out on pre-prepared glass-backed silica plates from Merck, and visualised with 
ultraviolet light (  = 256 nm), or with ninhydrin, iodine or potassium permanganate stains as 
necessary.  
5.0.9 Melting Point Analysis 
Melting point analyses was performed with a Griffin Melting Point Apparatus (MPA350.BM2.5) 
from Gallenkamp and are uncorrected. 
5.0.10 Computational Docking 
Docking was performed using GOLD Suite version 5.3 (CCDC Software Limited) on EthR 
(PDB: 1T56) with a 10 Å binding site centred around CE2 of Phe110. Docking used the 
chemscore_kinase configuration template in conjunction with the CHEMPLP scoring function. 
Ligands were generated in ChemDraw (CambridgeSoft) and prepared for docking using 
Discovery Studio 4 (Accelrys Software Inc.) or VegaZZ version 3.1.0.21 (A. Pedretti and  
G. Viscoli). 
5.0.11 Protein Preparation 
EthR was expressed in Escherichia Coli BL21 (DE3) (Novagen) with the EthR gene cloned into a 
pHAT5 vector (BamHI/EcoRI). Overnight culture was added to LB media (25 mL/L) and the 
bacteria grown into exponential phase (37 °C, 230 rpm) before being induction with IPTG 
(0.5-1 mM) for 3 hours. The culture was centrifuged (4,200 g, 15 minutes, 4 °C) and the 
resulting cell pellets suspended in lysis buffer (50 mM HEPES pH 7.5, 150 mM NaCl, EDTA-free 
complete protease inhibitor cocktail (Roche); 30 mL/1L culture pellet) and lysed by sonication 
(10x 30 seconds). After centrifugation (35,000 g, 1 hour, 4 °C), the HIS-tagged EthR was 
captured with a Ni2+ charged HiTrap IMAC Fast Flow Column (5 mL, GE Healthcare), washed 
with wash buffer (50 mM HEPES pH 7.5, 150 mM NaCl, 20 mM imidazole; 50 mL) and eluted 
with elution buffer (50 mM HEPES pH 7.5, 150 mM NaCl, 250 mM imidazole. Final purification 
was performed by gel filtration (Superdex 200) and the purified protein concentrated by 
centrifugation (4,500 g, 4 °C; 10 kDa Amicon Ultra concentrator). Protein concentration was 
determined by amino acid analysis, confirmed by UV A280 (Nanodrop 2000c; Thermo Scientific 
Inc.). 
Protein preparation was carried out in the Department of Biochemistry by Dr Sachin Surade, Dr 
Michal Blaszczyk and Dr Vitor Mendes. Amino acid analysis was carried out by the Amino Acid 
Analysis Service in the Department of Biochemistry. 
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5.0.12 Thermal Shift Assay (Differential Scanning Fluorimetry) 
Thermal shift were obtained using an iQ5 (Bio-Rad Laboratories, Inc.), CFX Connect (Bio-Rad 
Laboratories, Inc.), or Thermal Cycler LC480 (Roche). Testing was performed in a 96 well 
format with all samples run in duplicate. Fragments were typically prepared as 100 mM stocks 
in DMSO. Sample wells contained the fragment of interest (1 mM), NaCl (150 mM), Tris-HCl 
(20 mM, pH 8.0), SYPRO® Orange (2.5x) and EthR (20 µM). The samples were heated at 0.5 °C 
increments from 25 °C (Bio-Rad) or 37 °C (Roche) to 95 °C, and fluorescence read after each 
increment ( ex 490 nm,  em 575 nm). The first derivative of the fluorescence reading was 
calculated, wherein the minima corresponded to the melting temperature. These were 
compared with the controls to determine the change in melting temperature in the presence of 
the test compounds. 
5.0.13 Isothermal Titration Calorimetry 
ITC were produced on a MicroCal ITC200 operating with Origin 7 software (OriginLab). 
Fragments were typically prepared as 100 mM stock solutions in DMSO. The ITC syringe 
solution contained the fragment of interest at a concentration of 0.5-1.0 mM in NaCl (300 mM), 
Tris-HCl (20 mM, pH 8.0), glycerol (to match the concentration in the EthR stock) and a final 
concentration of 10% DMSO (in some cases, 15% was used to increase solubility of the 
fragments). The cell solution contained EthR (75-100 µM), NaCl (300 mM) Tris-HCl (20 mM, 
pH 8.0) and 10% DMSO (or 15% as noted above). The fragment was titrated into the protein 
solution in 1.0-2.0 µL aliquots over 25-36 injections (the first injection 0.4 µL) with a 
120 second interval between injections. The raw data was processed in Origin 7 (OriginLab) and 
fitted using a single site model to give the KD and thermodynamic values. 
5.0.14 Surface Plasmon Resonance 
SPR was carried out on a BIAcore T100 using the EthA promotor DNA immobilised on a CM5 
chip (BIAcore) with a biotin/streptavidin linkage. Biotinylated DNA (with pUC19 DNA as a 
control) was flowed over the streptavidin-coated chip to produce a stable resonance reading. 
EthR (2 µM) and the test fragment (at varying concentration) were flowed at 20 µL/min in 
running buffer (2mM MgCl2, 10 mM Tris-HCl pH 7.5, 0.1 mM EDTA, 200 mM NaCl, 2% DMSO) for 
120 seconds, followed by a dissociation time of 150 seconds. The difference in resonance 
compared to the stable reading to give the binding level. Between samples, the chip was 
regenerated for 60 seconds with 20 µL/min 0.03% SDS in running buffer. IC50 values were 
calculated as the concentration which gave a binding level of 50% compared to the maximum 
binding level. 
SPR was carried out in the Department of Biochemistry by Dr Sachin Surade, Dr Michal 
Blaszczyk, Dr Vitor Mendes and Ms Sherine Thomas.  
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5.0.15 X-Ray Crystallography 
EthR crystals were grown using the hanging-drop vapour-diffusion method using previously 
described conditions (35) using 2 µL protein solution (>20 mg/mL EthR, 500 mM NaCl, 20 mM 
Tris-HCl pH 8.0, 10% v/v glycerol) and 4 µL reservoir (1.8-2.2 M ammonium sulfate, 100 mM 
MES-Na pH 6-7, 5-10% v/v glycerol, 7-10% 1,4-dioxane) at 16 °C. Crystals were washed in 
1,4-dioxane-free mother liquor for a few hours, then soaked for 1-16 hours in fragment 
solutions (1-10 mM fragment, 1.8 M ammonium sulfate, 100 mM MES-Na pH 6.75, 12.5% v/v 
glycerol) prepared from 100 mM DMSO stock solutions. Soaked crystals were cryoprotected 
with mother liquor supplemented with 20% v/v ethylene glycol, then frozen in liquid nitrogen. 
Data collection was performed at the European Synchrotron Radiation Facility (Grenoble, 
France), Diamond Light Source (Harwell, UK) or the Department of Biochemistry, University of 
Cambridge (X8 Proteum, Bruker). X-ray diffraction data was processed with CCP4 suite, indexed 
and integrated with Mosflm and scaled with Scala. Molecular replacement using PDB: 1T56 was 
performed with Phaser, and refined using Refmac5. Fitting was performed manually with Coot. 
X-ray crystallography was carried out by Dr Sachin Surade, Dr Michal Blaszczyk and Dr Vitor 
Mendes, Department of Biochemistry, University of Cambridge. 
5.0.16 Resazurin Microtiter Assay (REMAssay) 
Determination of ethionamide MIC boosting activity was performed in duplicate using the 
REMAssay (resazurin microtiter assay) as described by Palomino et al.113 Liquid culture of 
M.tb. H37Rv was prepared at an OD of 0.0001 in 7H9 broth (Difco) supplemented with 10% 
albumin-dextrose-catalase (ADC), 0.2% glycerol and 0.05% Tween-80. 2-fold serial dilutions of 
ethionamide were prepared in 96-well plates alone or supplemented with a fixed concentration 
of EthR inhibitors (1 µM). As control, EthR inhibitors were also tested alone in 
2-fold serial dilutions. Plates were incubated for 6 days at 37 °C before the addition of 0.025% 
resazurin. After overnight incubation the fluorescence of the resazurin metabolite resorufin was 
measured ( ex 560 nm;  em 590 nm) (Tecan Infinite M200 microplate reader). IC50 and MIC were 
calculated using GraphPad Prism software. 
REMAssay was carried out by Anthony Vocat of Prof  Stewart Cole s laboratory, Ecole 
Polytechnique Fédérale de Lausanne, Switzerland. 
5.0.17 Other 
Protein properties were estimated from the amino acid sequence (Rv3855, genome.tbdb.org) 
using Proteins version 2.5 (Programme Collection for Structural Biology and Biophysical 
Chemistry; A. Hofmann and N. Hu.).  
   95 
5.1 Synthesis 
 
5-(Furan-2-yl)-N-{[5-(furan-2-yl)-1,2-oxazol-3-yl]methyl}-1,2-oxazole-
3-carboxamide (79) 
 
Acid 78 (53 mg, 0.3 mmol) and amine 77 (48 mg, 0.3 mmol) were dissolved in anhydrous DCM 
(2.5 mL) under argon, and DIPEA (0.25 mL, 1.4 mmol) added. The reaction was allowed to stir 
for 5 minutes, and then COMU (0.128 g, 0.3 mmol) added. The reaction was allowed to stir at 
room temperature for 16 hours, and then the solvent was evaporated. The residue was 
redissolved in EtOAc (10 mL), washed with water (2 x 10 mL) and dried over Na2SO4, and the 
EtOAc evaporated in vacuo. The resulting powder was purified by flash column chromatography 
(2-8% MeOH/DCM), and residual impurities removed by washing with water (15 mL), yielding 
the product 79 as a yellow solid (65 mg, 0.2 mmol, 69%). 
1H NMR (400 MHz, CDCl3    ppm       d  J = 6.1 Hz, 2H), 6.49 (s, 1H), 6.52 (dd, J = 3.5, 1.8 Hz, 
1H), 6.56 (dd, J = 3.5, 1.8 Hz, 1H), 6.88 (s, 1H), 6.90 (d, J = 3.5 Hz, 1H), 6.96 (d, J = 3.5 Hz, 1H), 
7.32 (br. s, 1H), 7.52 (dd, J = 1.8, 0.7 Hz, 1H), 7.58 (dd, J = 1.8, 0.7 Hz, 1H); 13C NMR (100 MHz, 
CDCl3    ppm                          111.4, 111.9, 112.1, 142.4, 143.0, 144.3, 144.8, 158.3, 
158.9, 160.7, 162.4, 163.3; LCMS r.t. 2.01 min, found 326.2 [M+H]+; HRMS calc C16H12N3O5 
326.0777, found [M+H]+ 326.0783; TLC r.t. 0.88 (10% MeOH/DCM); IR (cm-1) 3338 (m), 3111 
(m), 1675 (s), 1562 (s), 1447 (s), 1261 (s); MP 144-145 °C; Purity 97% (LCMS). 
Bis((5-(furan-2-yl)isoxazol-3-yl)methyl)amine (81) 
 
Alcohol 80 (30 mg, 0.2 mmol) was dissolved in anhydrous DCM (2 mL) under nitrogen and DMF  
(5 drops) added. The reaction was cooled on ice before oxalyl chloride (0.15 mL, 1.8 mmol) 
added slowly. The mixture was stirred at 0 °C for 5 minutes, the allowed to warm to room 
temperature over 1 hour before the solvent was evaporated in vacuo, and used without further 
purification. 
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The alkyl chloride was dissolved in anhydrous DMF (2.5 mL) was added dropwise to a solution 
of amine 77 (47 mg, 0.3 mmol) in anhydrous DMF (2.5 mL), and heated at 80 °C for 4 hours. The 
resulting mixture was diluted with DCM (10 mL), washed with water (15 mL) and back 
extracted with DCM (15 mL). The combined organic phases were washed with NaHCO3 (2x, 
30 mL) and brine (30 mL), then dried over MgSO4 and evaporated. The crude material was then 
purified by flash column chromatography (0-5% MeOH/DCM), yielding a white solid of 81 
(3 mg, 0.01 mmol, 3%). 
1H NMR (400 MHz, CDCl3    ppm       s   H         s   H   6.53-6.57 (m, 4H), 6.93 (dd,  
J = 3.5, 0.6 Hz, 2H), 7.55 (dd, J = 1.8, 0.6 Hz, 2H); 13C NMR (100 MHz, CDCl3    ppm             
98.6, 110.9, 112.0, 136.2, 144.4, 161.2; HRMS calc 312.0984 C16H14N3O4, found 312.0979 
[M+H]+; TLC r.f. 0.55 (10% MeOH/DCM); Purity >95% (NMR). 
It was found that this compound was found to be unstable under LCMS conditions. 
[5-(Furan-2-yl)-1,2-oxazol-3-yl]methanol (80)114  
 
Acid 78 (27 mg, 0.2 mmol) was dissolved in anhydrous THF (2 mL) under nitrogen and LiAlH4 
(0.40 mL, 2.5 M in THF, 1.0 mmol) added dropwise. The reaction was stirred a room 
temperature for 3 hours, then quenched with MeOH (1 mL) and NaOH (0.1 mL, 10% aq), and the 
solvent evaporated in vacuo, yielding the alcohol 80 (23 mg, 0.1 mmol, 87%). 
1H NMR (400 MHz, CDCl3)   ppm 4.81 (s, 2H), 6.51 (s, 1H), 6.55 (dd, J = 3.5, 1.8 Hz, 1H), 6.91 (d,  
J = 3.5 Hz, 1H), 7.55 (d, J = 1.8 Hz, 1H); 13C NMR (100 MHz, CDCl3)   ppm 57.0, 97.8, 110.6, 111.9, 
143.1, 144.2, 162.0, 167.8; LCMS r.t. 1.52 min, found 166.1 [M+H]+; TLC r.f. 0.60 (10% 
MeOH/DCM); IR (cm-1) 3354 (br. w), 1616 (s), 1435 (m), 1345 (s). 
Benzamidoxime (83)23,101,115  
 
Hydroxylamine hydrochloride (1.01 g, 14.5 mmol) was dissolved in ethanol (15 mL) with 
benzonitrile (1.00 mL, 9.7 mmol). DIPEA (2.7 mL, 15.5 mmol) was added and the mixture 
heated at reflux for 1 hour. The solvent was evaporated in vacuo and the clear oil remaining was 
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dissolved in ethyl acetate (25 mL) and washed with water (2 x 25 mL) then brine (25 mL). The 
organic phase was dried over MgSO4, filtered and concentrated to dryness in vacuo yielding a 
clear, colourless oil which solidified on standing to produce the product (83) as a white solid 
(0.941 g, 7.4 mmol, 76%). This was used without further purification. 
1H NMR (400 MHz, DMSO-d6    ppm 5.80 (s, 2H), 7.29-7.42 (m, 3H), 7.62-7.74 (m, 2H), 9.63  
(s, 1H); 13C NMR (100 MHz, DMSO-d6    ppm 125.7, 128.4, 129.2, 133.7, 151.2; LCMS r.t. 1.81 
min, found 137.1 [M+H]+; TLC r.f. 0.51 (10% MeOH/DCM); IR (cm-1) 3452 (m), 3359 (s), 3210 
(m), 1646 (s), 1578 (m), 1386 (m). 
tert-Butyl ((3-phenyl-1,2,4-oxadiazol-5-yl)methyl)carbamate (85a) 
 
 N-Boc-glycine hydrochloride (0.385 g, 2.2 mmol) and HBTU (0.918 g, 2.4 mmol) were dissolved 
in anhydrous DMF (5 mL) and DIPEA (1.15 mL, 6.6 mmol) was added. After stirring for 
5 minutes, 83 (0.300 g, 2.2 mmol) was added and the reaction stirred at room temperature for 
4 hours. The reaction mixture was then poured into water (50 mL) and the resulting white 
precipitate filtered and dissolved in DMF (10 mL). The solution was heated at 120 °C for 
4 hours, then allowed to cool, water (15 mL) added and extracted into ethyl acetate (30 mL). 
The organic layer was washed with HCl (5% aq, 2 x 15 mL) and brine (15 mL), before being 
dried over MgSO4, filtered and evaporated to dryness in vacuo, yielding 85a as a white solid 
(0.303 g, 1.1 mmol, 50%). 
1H NMR (400 MHz, CDCl3    ppm 1.48 (s, 9H), 4.64 (d, J = 5.0 Hz, 2H), 5.26 (br. s, 1H), 7.38-7.52 
(m, 3H), 8.07 (d, J = 6.5 Hz, 2H); 13C NMR (100 MHz, CDCl3    ppm                                 
128.8, 131.3, 155.4, 168.4, 176.5; LCMS r.t. 2.07 min, found 220.1 [M - tert-butyl + 2H]+; HRMS 
calc C14H18N3O3 276.1348, found [M+H]+ 276.1352; TLC r.f. 0.26 (20% EtOAc/hexane); IR (cm-1) 
3365 (m), 1679 (s), 1523 (s). 
(3-Phenyl-1,2,4-oxadiazol-5-yl)methanamine (85) 
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Compound 85a (0.100 g, 0.4 mmol) in methanol (5 mL) was cooled to 0 °C, before HCl (3.0 mL, 
1.25 M in methanol) was added. The reaction was stirred at 0 °C for 0.5 hour, then allowed to 
warm to room temperature. The solvent was removed in vacuo to yield the product 85 as a 
white solid (53 mg, 0.3 mmol, 83%). The product was used without further purification. 
1H NMR (400 MHz, DMSO-d6    ppm 4.58 (s, 2H), 7.43-7.54 (m, 3H), 8.03-8.10 (m, 2H), 8.95  
(br. s, 2H); 13C NMR (100 MHz, DMSO-d6    ppm                                          174.8; 
LCMS r.t. 2.71 min, found 176.2 [M+H]+; HRMS calc C9H10N3O 176.0824, found [M+H]+ 176.0820; 
TLC r.f. 0.57 (10% MeOH/CHCl3); IR (cm-1) 3350 (w, br.), 2875 (w, br.), 1604 (m), 1446 (s), 
1350 (s). 
Ethyl 3-phenyl-1,2,4-oxadiazole-5-carboxylate (87)101  
 
Benzamidoxime 83 (0.100 g, 0.7 mmol) was dissolved in dry DCM (5 mL) and pyridine  
(0.07 mL, 0.9 mmol) added. The mixture was cooled to 0 °C before monoethyloxalyl chloride 
(0.10 mL, 0.9 mmol) was added dropwise. The mixture was stirred at 0°C for 2 hours, then 
concentrated in vacuo. The residue was redissolved in DCM (10 mL) and washed with saturated 
sodium bicarbonate solution (2 x 10 mL). The organic phase was dried over Na2SO4, filtered and 
dried in vacuo yielding the product 87 as a yellow solid (40 mg, 0.2 mmol, 25%). 
1H NMR (400 MHz, CDCl3    ppm 1.50 (t, J = 7.2 Hz, 3H), 4.58 (q, J = 7.2 Hz, 2H), 7.60-7.70 (m, 
3H), 8.05-8.16 (m, 2H); 13C NMR (100 MHz, CDCl3)   ppm 14.0, 63.9, 125.6, 127.6, 128.9, 131.8, 
154.1, 166.6, 169.4; LCMS r.t. 2.07 min, found 219.1 [M+H]+; TLC r.f. 0.70 (33% EtOAc/40-60 
petrol ether); IR (cm-1) 1741 (s), 1560 (m), 1445 (s), 1319 (s). 
Isobutyl ((3-phenyl-1,2,4-oxadiazol-5-yl)methyl) carbonate (91) 
 
Glycolic acid (0.100 g, 1.3 mmol) in toluene (35 mL) was cooled to 0 °C, and triethylamine 
(0.37 ml, 2.6 mmol) and isobutyl chloroformate (0.34 mL, 2.6 mmol) added. The reaction was 
stirred at 0 °C for 10 minutes, before benzamidoxime (83) (0.178 g, 1.3 mmol) and powdered 
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activated 4 Å molecular sieves (0.5 g) were added. The reaction was heated under reflux 
overnight, after which the reaction was allowed to cool, filtered and concentrated to dryness in 
vacuo. The residue was purified by flash column chromatography (30-70% EtOAc/40-60 petrol 
ether) to yield the product 91 (0.309 g, 1.1 mmol, 86%). 
1H NMR (400 MHz, CDCl3    ppm 0.99 (d, J = 6.9 Hz, 6H), 1.93-2.11 (m, 1H), 4.04 (d, J = 6.7 Hz, 
2H), 5.42 (s, 2H), 7.44-7.57 (m, 3H), 8.05-8.14 (m, 2H); 13C NMR (100 MHz, CDCl3)   ppm 18.7, 
27.7, 59.3, 75.1, 126.2, 127.5, 128.8, 131.4, 154.5, 168.4, 173.5; LCMS r.t. 2.30 min found 277.2 
[M+H]+; HRMS calc C14H17N2O4 277.1188, found [M+H]+ 277.1177; TLC r.f. 0.78 (25% EtOAc/40-
60 petrol ether); IR (cm-1) 2960 (w), 1753 (s), 1248 (s, br.). 
(3-Phenyl-1,2,4-oxadiazol-5-yl)methanol (92)116 
 
Carbonate 91 (75 mg, 0.3 mmol) was dissolved in MeOH (4 mL) and NaOH (0.15 mL, 2.0 M) was 
added. The reaction was stirred at ambient temperature for 1.5 hours, then acidified to pH 4 
with HCl, (0.1 mL, 1.0 M in MeOH). The product was extracted with EtOAc (10 mL) and dried in 
vacuo to yield the product 92 as a white powder (40 mg, 0.2 mmol, 85%). 
1H NMR (400 MHz, CDCl3)   ppm 3.38 (br. s, 1H), 4.97 (s, 2H), 7.45-7.56 (m, 3H), 8.02-8.10 (m, 
2H); 13C NMR (100 MHz, CDCl3)   ppm 56.5, 126.2, 127.4, 128.9, 131.5, 168.1, 178.3;  
LCMS r.t. 1.61 min, found 177.1 [M+H]+; HRMS calc C9H9N2O2 177.0664, found [M+H]+ 177.0661; 
TLC r.f. 0.60 (10% MeOH/DCM); IR (cm-1) 3275 (m, br.), 1456 (m), 1366 (s). 
Bis((3-phenyl-1,2,4-oxadiazol-5-yl)methyl)amine (93) 
 
Alcohol 92 (61 mg, 0.3 mmol) was dissolved in anhydrous DCM (15 mL) under nitrogen and 
cooled to 0 °C. Oxalyl chloride (0.27 mL, 3.3 mmol) was added dropwise and the solution stirred 
for 5 minutes before being allowed to warm to room temperature where it was stirred for 
1 hour, after which the solvent was evaporated in vacuo. Amine 85 (91 mg, 0.3 mmol) was 
dissolved in anhydrous DMF (15 mL) under nitrogen and the alkyl chloride added dropwise. 
The reaction mixture was heated at 80 °C for two hours. The reaction mixture was cooled, 
extracted with DCM (15 mL) and washed with water (30 mL), NaHCO3 (30 mL) and brine  
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(30 mL), before the solvent was evaporated in vacuo. The resulting crude compound was 
purified by flash column chromatography (0-5% MeOH/DCM), yielding the product 93 as a 
white solid (65 mg, 0.2 mmol, 59%). 
1H NMR (400 MHz, CDCl3    ppm 4.75 (s, 4H), 7.42-7.57 (m, 6H), 8.01-8.16 (m, 4H); 13C NMR 
(100 MHz, CDCl3    ppm 33.3, 126.1, 127.5, 128.9, 131.5, 168.9, 174.3; HRMS calc 334.1304 
C18H16N5O2, found 334.1299 [M+H]+; TLC r.f. 0.57 (10% EtOAc/40-60 petrol ether); IR (cm-1) 
3036 (w), 1598 (m), 1445 (m), 1361 (s); MP 37-38 °C; Purity >95% (NMR). 
It was found that this compound was unstable under LCMS and HRMS conditions. 
Ethyl 5-phenyl-1,2,4-oxadiazole-3-carboxylate (96)101 
 
Amidoxime 95 (0.102 g, 0.8 mmol) was dissolved in DCM (7.0 mL) with DMF (3 drops) and 
cooled to -15 °C, then DIPEA (0.18 mL, 1.1 mmol) was added. Benzoyl chloride (0.08 mL, 
0.7 mmol) was added and the reaction stirred for 30 minutes, then warmed up to room 
temperature where it was stirred overnight. The reaction mixture was poured into cold water 
(0 °C, 40 mL), extracted with DCM (40 mL) and dried over MgSO4 before being evaporated to 
dryness in vacuo. The resulting material was dissolved in DMF (10 mL) and heated to 120 °C 
overnight, then diluted with water (25 mL) and extracted with DCM (2 x 30 mL). The organic 
phases were combined and dried over MgSO4, concentrated in vacuo, then purified by flash 
column chromatography (30-50% EtOAc/40-60 petrol ether) to yield the product 96 as a 
yellow crystalline solid (0.134 g, 0.6 mmol, 80%). 
1H NMR (400 MHz, CDCl3    ppm 1.46 (t, J = 7.2 Hz, 3H), 4.54 (q, J = 7.2 Hz, 2H), 7.52-7.59 (m, 
2H), 7.61-7.68 (m, 1H), 8.19-8.26 (m, 2H); 13C NMR (100 MHz, CDCl3)   ppm 14.1, 63.0, 123.2, 
128.3, 129.2, 133.5, 157.8, 162.4, 177.2; LCMS r.t. 2.11 min, found 219.2 [M+H]+; HRMS calc 
C11H11N3O3 219.0770, found [M+H]+ 219.0779; TLC r.f. 0.76 (5% MeOH/DCM); IR (cm-1) 2992 
(w, br.), 1734 (m), 1607 (m), 1557 (m), 1475 (m), 1450 (m), 1377 (m), 1353 (m), 1215 (s);  
MP 48-49 °C. 
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5-Phenyl-1,2,4-oxadiazole-3-carboxylic acid (97)101 
 
Ester 96 (28 mg, 0.1 mmol) was dissolved in a mixture of THF (10 mL), water (2.5 mL) and 
EtOH (2.5 mL) before LiOH monohydrate (32 mg, 0.8 mmol) was added and the reaction was 
stirred for 1.5 hours, until TLC indicated complete reaction of the starting material. The reaction 
was acidified with HCl (0.5 mL, 3.0 M), diluted with water (10 mL) and then extracted with DCM 
(2 x 30 mL). The combined organic phase was dried in vacuo, yielding the product 97 as a 
yellow solid (15 mg, 0.1 mmol, 62%). 
1H NMR (400 MHz, DMSO-d6    ppm 7.66-7.74 (m, 2H), 7.76-7.83 (m, 1H), 8.16-8.25 (m, 2H);  
13C NMR (100 MHz, DMSO-d6)   ppm 128.0, 128.2, 128.7, 129.6, 133.1, 133.7, 158.6; LCMS r.t. 
1.87 min, found 191.1 [M+H]+; TLC r.f. 0.00 (33% EtOAc/40-60 petrol ether); IR (cm-1) 3500 (w, 
br.), 2937 (w, br.), 1728 (m), 1604 (m), 1556 (s), 1449 (m), 1248 (s), 1200 (s). 
2-((4-Bromophenyl)thio)acetamide (99) 
 
4-Bromothiophenol (0.511 g, 2.6 mmol), 2-bromoacetamide (0.714 g, 5.2 mmol), K2CO3 (0.375 g, 
2.6 mmol) and 3 Å molecular sieves (1.00 g) were suspended in acetone (15 mL) and the 
reaction heated to 50 °C overnight. The reaction was mixture allowed to cool, filtered and 
washed with acetone (30 mL) and the solvent evaporated under reduced pressure. The white 
solid was re-suspended in DCM (60 mL), washed with sodium bicarbonate (2 x 30 mL), water  
(2 x 30 mL) and brine (30 mL). The organic phase was dried over MgSO4, filtered and 
evaporated in vacuo, yielding the product 99 as white crystalline solid (0.551 g, 2.2 mmol, 83%). 
1H NMR (400 MHz, acetone-d6    ppm       s   H         br  s   H         br  s   H      1-7.38 (m, 
2H), 7.44-7.52 (m, 2H); 13C NMR (100 MHz, acetone-d6    ppm                                   
170.5; LCMS r.t. 1.65 min, found 265.9; HRMS calc C8H9NOSBr 245.9588, found [M+H]+ 
245.9599; TLC r.f. 0.36 (5% MeOH/DCM); IR 3401 (m), 3172 (m, br), 1642 (s), 1473 (m), 1384 
(s); MP 138-139 °C; Purity >98% (LCMS). 
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2-((4-Bromophenyl)sulfinyl)acetamide (100) 
 
Compound 99 (0.1004 mg, 0.4 mmol) was dissolved in MeOH (2.0 mL) and THF (2.0 mL) with 
stirring. Oxone  (0.182 g, 0.6 mmol) in water (3.0 mL) was added dropwise, and the mixture 
stirred at room temperature for 21 hours. The reaction mixture was filtered and evaporated 
under reduced pressure. The solid formed was re-suspended in DCM (20 mL), washed with 
water (10 mL) and brine (2 x 10 mL) and the organic solvent was evaporated in vacuo. The 
material was purified by flash column chromatography (3-7% MeOH/DCM), yielding the 
product 100 as a white solid (52 mg, 0.2 mmol, 48%). 
1H NMR (400 MHz, DMSO-d6)   ppm     -3.73 (m, 1H), 3.76-3.86 (m, 1H), 7.32 (br. s., 1H), 7.58 
(br. s. 1H), 7.63 (d, J = 8.5 Hz, 2H), 7.80 (d, J = 8.5 Hz, 2H); 13C NMR (125 MHz, DMSO-d6    ppm 
62.4, 124.5, 126.3, 1322.1, 143.6, 165.6; LCMS r.t. 1.32 min, found 262.0 (Br79) + 264.0 (Br81) 
[M+H]+; HRMS calc C8H9NO2SBr79 261.9537, found [M+H]+ 261.9537; TLC r.f. 0.13 (5% 
MeOH/DCM); IR (cm-1) 3770 (w, br.),1668 (s); Purity 95% (LCMS). 
2-((4-Bromophenyl)sulfonyl)acetamide (101)117 
 
Compound 99 (99 mg, 0.4 mmol) was dissolved in MeOH (2.0 mL) and THF (2.0 mL) and stirred 
for 5 minutes at ambient temperature. Oxone  (0.49 g, 1.6 mmol) was dissolved in water  
(3.0 mL), and added dropwise to the solution. The mixture was stirred at room temperature 
overnight. The reaction was filtered and was then evaporated in vacuo. The solid material which 
was obtained was dissolved in DCM (40 mL), washed with water (2 x 20 mL) and brine (20 mL), 
then the organic phase was evaporated under reduced pressure, yielding the product 101 as a 
white solid (79 mg, 0.3 mmol, 71%). 
1H NMR (400 MHz, DMSO-d6    ppm       s   H         br. s, 1H), 7.60 (br. s, 1H), 7.77-7.82 (m, 
2H), 7.85-7.90 (m, 2H); 13C NMR (100 MHz, DMSO-d6    ppm                                   
163.1; LCMS r.t. 1.43 min, found 277.94 [M+H]+; HRMS calc C8H9NO3SBr 277.9487, found [M+H]+ 
277.9488; TLC r.f. 0.25 (5% MeOH/DCM); IR (cm-1) 3395 (w), 3170 (w), 1691 (s), 1306 (s); MP 
152-154 °C; Purity 96% (LCMS). 
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2-((4-Bromophenyl)sulfonyl)ethanethioamide (102) 
 
Compound 99 (0.100 g, 0.4 mmol) was suspended in dry THF (20 mL) and Lawesson s reagent 
(0.170 g, 0.4 mmol) added with dry THF (10 mL). The mixture was then heated to reflux for 
3 hours before the solvent was evaporated in vacuo. The resulting solid was dissolved in DCM 
(40 mL), washed with water (2 x 40 mL) and brine (40 mL) and the organic layer was 
evaporated in vacuo. The crude product was purified by flash column chromatography (0-10% 
MeOH/DCM), yielding the product 102 as a yellow solid (42 mg, 0.1 mmol, 39%). 
1H NMR (400 MHz, DMSO-d6    ppm       s   H       -7.83 (m, 2H), 7.84-7.90 (m, 2H), 9.41  
(br. s, 1H), 9.85 (br. s, 1H); 13C NMR (100 MHz, DMSO-d6    ppm                                   
191.4; LCMS r.t. 1.69 min found 294.0 [M+H]+; HRMS calc C8H9NO232S279Br 293.9253, found 
[M+H]+ 293.9243; TLC r.f. 0.43 (5% MeOH/DCM); IR (cm-1) 3422 (m), 3329 (m), 3230 (w), 2928 
(w, br), 1626 (m), 1596 (m), 1576 (m), 1422 (s), 1299 (s), 1257 (s); MP 179-180 °C; Purity 
>98% (LCMS). 
Caution: Stench, both Lawesson s reagent and the product should be kept in a fumehood at all 
times. 
2-(Biphenyl-4-ylsulfonyl)acetamide (106)118 
 
Phenylboronic acid (33 mg, 0.3 mmol), sodium carbonate (32 mg, 0.3 mmol) and Pd(PPh3)4 
(35 mg, 10 mol%) were dissolved in toluene/EtOH (5.0 mL, 1:1) with compound 101 (75 mg, 
0.3 mmol) and heated under microwave conditions at 100 °C for 60 minutes. This was filtered 
through Celite  and evaporated in vacuo. The crude product was purified by flash column 
chromatography (5-10% MeOH/DCM), yielding the product 106 as a yellow solid (45 mg, 
0.2 mmol, 61%). 
1H NMR (400 MHz, MeCN-d3)   ppm 4.08 (s, 2H), 6.03 (br. s, 1H), 6.49 (br. s, 1H), 7.42-7.57 (m, 
3H), 7.69-7.75 (m, 2H), 7.85-7.90 (m, 2H), 7.95-8.01 (m, 2H); 13C NMR (100 MHz, DMSO-d6    
ppm 47.7, 127.3, 127.4, 128.8, 128.9, 129.3, 131.6, 138.6, 145.5; LCMS r.t. 1.71 min, 
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found 276.2 [M+H]+; HRMS calc C14H13NO3SNa 298.0514, found [M+Na]+ 298.0528; TLC r.f. 0.42 
(10% MeOH/DCM); IR (cm-1) 3394 (m), 3194 (w), 1664 (s), 1317 (s); Purity 98% (LCMS). 
2-(Biphenyl-4-ylsulfonyl)ethanethioamide (104) 
 
Compound 106 (55 mg, 0.2 mmol) was dissolved in anhydrous THF (7.5 mL) and Lawesson s 
reagent (85 mg, 0.2 mmol) in dry THF (7.5 mL) was added and the reaction mixture heated to 
reflux for 3 hours. The solvent was evaporated under reduced pressure. The solid was dissolved 
in DCM (20 mL), washed with water (2 x 20 mL) and brine (20 mL) then evaporated in vacuo. 
The remaining solid was extracted with DCM (20 mL), filtered and evaporated in vacuo. The 
resulting material was purified by flash column chromatography (0-10% MeOH/DCM) and the 
product dried under reduced pressure to yield the product 104 as a white solid (32 mg, 
0.1 mmol, 53%). 
1H NMR (400 MHz, DMSO-d6)   ppm 4.62 (s, 2H), 7.42-7.57 (m, 3H), 7.72-7.85 (m, 2H), 7.90-8.02 
(m, 4H), 9.40 (br. s, 1H), 9.85 (br. s, 1H); 13C NMR (100 MHz, DMSO-d6    ppm                     
128.7, 129.1, 129.2, 137.2, 138.2, 145.3, 191.6; LCMS r.t. 1.92 min; found 292.1 [M+H]+; HRMS 
calc C14H14NO2S2 292.0466, found [M+H]+ 292.0489; TLC r.f. 0.70 (10% MeOH/DCM);  
IR (cm-1) 3397 (br. w), 3310 (br. w), 3211 (br. w), 2924 (w), 1630 (m), 1594 (m), 1448 (m), 
1399 (m), 1291 (m), 1258 (m); Purity 97% (LCMS). 
Caution: Stench, both Lawesson s reagent and the product should be kept in a fumehood at all 
times. 
2-Bromomethyl-1,3-thiazole (109)119 
 
1,3-Thiazol-2-ylmethanol (0.106 g, 0.9 mmol) was dissolved in chloroform (1.00 mL) and PBr3 
(0.03 mL, 0.3 mmol) added slowly. The reaction mixture was heated at reflux for 1 hour, then 
diluted with Na2CO3 (satd., 10 mL) and extracted with chloroform (2 x 10 mL). The organic 
phases were dried over MgSO4 and evaporated in vacuo to yield the product 109 as a yellow oil, 
which was used without further purification. 
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1H NMR (400 MHz, CDCl3    ppm       s   H         d  J = 3.3 Hz, 1H), 7.74 (d, J = 3.3 Hz, 1H); 
13C NMR (100 MHz, CDCl3    ppm                       5.5; TLC r.f. 0.69 (neat EtOAc). 
2-(Bromomethyl)thiophene (109a)120 
 
Synthesised using the same procedure as compound 109 using 2-thiophenemethanol (0.08 mL, 
0.9 mmol). 
Yellow oil; 1H NMR (400 MHz, CDCl3    ppm       s   H         dd  J = 5.0, 3.5 Hz, 1H) 7.14 (d, J = 
3.5 Hz, 1H), 7.34 (dd, J = 5.0, 0.9 Hz, 1H). 
2-       -Biphenyl)-4-ylsulfonyl)methyl)thiazole (110) 
 
Biphenyl-4-sulfonic acid (75 mg, 0.3 mmol) was suspended in DMF (2.0 mL) with pyridine 
(0.03 mL, 0.4 mmol) and compound 109 (0.15 g, 0.8 mmol) was added in DMF (2.0 mL). The 
reaction was stirred at room temperature overnight, before being diluted with DCM (15 mL), 
washed with HCl (3.0 M, 15 mL), saturated sodium bicarbonate (15 mL), and brine (15 mL). The 
organic phase was evaporated and the residue purified by flash column chromatography (neat 
DCM) to yield the product 110 as a white crystalline solid (18 mg, 0.1 mmol, 7%). 
1H NMR (400 MHz, CDCl3    ppm       s   H       -7.52 (m, 4H), 7.56-7.65 (m, 2H), 7.66-7.75 
(m, 3H), 7.76-7.82 (m, 2H); 13C NMR (100 MHz, CDCl3    ppm            , 127.4, 127.8, 128.7, 
129.1, 136.0, 138.9, 143.1, 147.1, 155.9; LCMS r.t.2.12 min, found 315.9[M+H]+; HRMS calc C16H-
14NO2S2 316.0466, found [M+H]+ 316.0483; TLC r.f. 0.76 (5% MeOH/DCM); IR (cm-1) 2989 (w), 
2923 (w), 1733 (w), 1594 (m), 1492 (m), 1478 (m), 1394 (m), 1314 (s), 1206 (m); MP 143-146 
°C (decomposes); Purity 87% (LCMS). 
2-[(Biphenyl-4-ylsulfonyl)methyl]thiophene (111) 
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Biphenyl-4-sulfinic acid (75 mg, 0.3 mmol) was suspended in DMF (2.0 mL) with pyridine 
(0.03 mL, 0.4 mmol) before compound 109a (0.15 g, 0.8 mmol) was added in DMF (2.0 mL). The 
reaction mixture was stirred at ambient temperature for 6 hours. The mixture was diluted with 
DCM (15 mL), washed with HCl (3.0 M, 15 mL), sodium bicarbonate (15 mL) and brine (15 mL), 
dried over Na2SO4 and dried under reduced pressure. The residue was purified by flash column 
chromatography (10-50% EtOAc/petrol ether) to yield the product 111 as a yellow solid (9 mg, 
0.03 mmol, 9% over 2 steps). 
1H NMR (400 MHz, CDCl3    ppm       s   H         d  J = 3.5 Hz, 1H), 6.96 (dd, J = 5.1, 3.5 Hz, 
1H), 7.30 (d, J = 5.1 Hz, 1H), 7.40-7.53 (m, 3H), 7.59-7.64 (m, 2H), 7.70 (d, J = 8.4 Hz, 2H), 7.77 (d, 
J = 8.4 Hz, 2H); 13C NMR (100 MHz, CDCl3    ppm                                                 
129.1, 129.2, 130.3, 136.0, 139.0, 146.8; LCMS r.t. 2.33 min, found 336.6 [M+Na]+; 
HRMS calc C17H14O2S2Na 337.0327, found [M+Na]+ 337.0323; TLC r.f. 0.60 (33% EtOAc/petrol 
ether); IR (cm-1) 2986 (br. w), 2913 (w), 1595 (m), 1479 (w), 1400 (w), 1305 (s), 1258 (m); 
 MP 127-129 °C; Purity 90% (LCMS). 
2-(((4-Bromophenyl)sulfonyl)methyl)thiophene (112) 
 
2-(Bromomethyl)thiophene (109a) (0.34 g, 2.0 mmol) was suspended in DCM (6.0 mL) under 
nitrogen, and sodium 4-bromobenzenesulfinate (0.30 g, 1.2 mmol) was added, followed by DMF 
(1.00 mL) and pyridine (0.30 mL, 3.6 mmol). The reaction mixture was heated to reflux for 
4 hours, then evaporated to dryness. The residue was suspended in brine (20 mL) and extracted 
with DCM (20 mL). The organic phase was purified by flash column chromatography (10-30% 
EtOAc/40-60 petrol ether) yielding the product 112 as a colourless crystalline solid (94 mg, 
0.3 mmol, 15%). 
1H NMR (400 MHz, CDCl3    ppm       s   H         d  J = 3.5 Hz, 1H), 6.96 (dd, J = 5.1, 3.5 Hz, 
1H), 7.30 (dd, J = 5.1, 1.2 Hz, 1H), 7.55 (d, J = 8.7 Hz, 2H), 7.63 (d, J = 8.7 Hz, 2H); LCMS r.t. 2.15 
min, found 338.7 (Br79) + 340.8 (Br81) [M+Na]+; HRMS calc C11H9S2O2Br79Na 338.9120, found 
[M+Na]+ 338.9114; TLC  r.f. 0.58 (33% EtOAc/40-60 petrol ether); IR (cm-1) 2970 (w), 2915 (w), 
1575 (m), 1468 (w), 1389 (m), 1310 (s), 1250 (s); MP 114-116 °C; Purity 95% (LCMS). 
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3-(4-((Thiophen-2-ylmethyl)sulfonyl)phenyl)pyridine (114) 
 
Compound 112 (66 mg, 0.2 mmol) was dissolved in DMF (2.6 mL). While degassing with 
nitrogen, pyridine-3-boronic acid (29 mg, 0.2 mmol), K2CO3 (89 mg, 0.6 mmol) in water 
(1.3 mL), and Pd(PPh3)4 (23 mg, 10 mol%) were added. The reaction mixture was heated to 
90 °C for 2 hours  then filtered through Celite  and evaporated  then purified by flash column 
chromatography (0-5% MeOH/DCM) to yield the product 114 as a yellow solid (14 mg, 
0.04 mmol, 22%). 
1H NMR (400 MHz, CDCl3)   ppm 4.58 (s, 2H), 6.92 (d, J = 3.5 Hz, 1H), 6.97 (dd, J = 5.1, 3.5 Hz, 
1H), 7.31 (dd, J = 5.1, 1.3 Hz, 1H), 7.44 (dd, J = 7.8, 4.8 Hz, 1H), 7.70 (d, J = 8.6 Hz, 2H), 7.82  
(d, J = 8.6 Hz, 2H), 7.91 (dt, J = 7.8, 2.0 Hz, 1H), 8.69 (dd, J = 4.8, 1.8 Hz, 1H), 8.88 (d, J = 1.8 Hz, 
1H); 13C NMR (100 MHz, CDCl3    ppm     , 77.2, 123.8, 127.3, 127.6, 127.7, 128.4, 129.5, 130.3, 
134.7, 137.0, 143.4, 148.4, 149.8; LCMS r.t. 1.75 min, found 316.0 [M+H]+; HRMS calc 
C16H14NO2S2 316.0466, found [M+H]+ 316.0487; TLC r.f. 0.60 (5% MeOH/DCM);  
IR (cm-1) 2915 (w), 1307 (m); MP 122-126 °C; Purity >98% (LCMS). 
Ethyl 2-((4-bromophenyl)thio)acetate (115)121 
 
A mixture of 4-bromothiophenol (0.5 g, 2.6 mmol), K2CO3 (1.01 g, 7.3 mmol) and ethyl 
bromoacetate (0.35 mL, 3.2 mmol) in acetone (10.0 mL) was heated to reflux for 5 hours. The 
reaction was then cooled and filtered, and the solvent evaporated under reduced pressure. The 
residue was dissolved in DCM (20 mL), washed with water (2 x 15 mL) and brine (15 mL), and 
again evaporated under reduced pressure. The resulting material was purified by flash column 
chromatography (0-5% MeOH/DCM) to yield the product 115 as a clear, colourless oil (0.269 g, 
1.0 mmol, 38%). 
1H NMR (400 MHz, CDCl3    ppm       t  J = 7.2 Hz, 3H), 3.62 (s, 2H), 4.18 (q, J = 7.2 Hz, 2H), 7.29 
(d, J = 8.6 Hz, 2H), 7.43 (d, J = 8.6 Hz, 2H); 13C NMR (100 MHz, CDCl3    ppm                   
121.0, 131.5, 132.0, 134.2, 169.3; LCMS r.t. 4.68 min, found 277.4 [M+H]+; TLC r.f. 0.78  
(33% EtOAc/40-60 petrol ether). 
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Ethyl 2-((4-bromophenyl)sulfonyl)acetate (116)121 
 
Compound 115 (0.269 g, 1.0 mmol) was dissolved in a 1:1 mixture of MeOH/THF (10.8 mL). 
Oxone  (1.12 g, 1.8 mmol) was dissolved in water (7.2 mL) and added dropwise to the 
MeOH/THF solution. The reaction as stirred at room temperature for 3 days, then filtered and 
evaporated in vacuo. The residue was taken up in DCM (30 mL), washed with H2O (2 x 30 mL) 
brine (30 mL) and evaporated under reduced pressure to yield the product 116 as colourless 
crystals (0.184 g, 0.6 mmol, 61%). 
1H NMR (400 MHz, CDCl3    ppm       t  J = 7.1 Hz, 3H), 4.08-4.16 (m, 4H), 7.70 (d, J = 8.6 Hz, 
2H), 7.79 (d, J = 8.6 Hz, 2H); 13C NMR (100 MHz, CDCl3    ppm                                 
132.4, 137.5, 162.1; LCMS r.t 4.10 min, found 307.7 [M-H]-; TLC r.f. 0.17 (10% EtOAc/40-60 
petrol ether); IR (cm-1) 3094 (w), 3012 (w), 2951 (w), 1731 (s), 1572 (m), 1463 (m), 1408 (m), 
1388 (m), 1318 (m), 1270 (s), 1223 (m); MP 49-51 °C. 
Ethyl 2-([1,1'-biphenyl]-4-ylsulfonyl)acetate (117)121 
 
Compound 116 (51 mg, 0.2 mmol) and phenylboronic acid (48 mg, 0.4 mmol) were placed in a 
flask with Pd(OAc)2 (4 mg, 10 mol%), triphenylphosphine (13 mg, 0.04 mmol) and K2CO3 
(71 mg, 0.5 mmol). The flask was charged with nitrogen before the material was dissolved in 
anhydrous DMF (1.5 mL). The reaction mixture was heated to 90 °C for 20 hours, then poured 
into cold HCl (3 mL, 1.0 M). This solution was extracted with EtOAc (10 mL) and the organic 
phase washed with brine (10 mL), dried over Na2SO4 and evaporated to dryness in vacuo. The 
residue was purified by flash column chromatography (10-20% EtOAc/40-60 petrol ether) to 
yield the product 117 as colourless crystals (23 mg, 0.1 mmol, 45%). 
1H NMR (400 MHz, CDCl3    ppm 1.23 (t, J = 7.1 Hz, 3H), 4.14-4.22 (m, 4H), 7.41-7.54 (m, 3H), 
7.59-7.66 (m, 2H), 7.76-7.83 (m, 2H), 7.99-8.06 (m, 2H); 13C NMR (100 MHz, CDCl3    ppm       
61.1, 62.4, 127.4, 127.8, 128.8, 129.1, 137.2, 139.0, 147.3, 162.4; TLC r.f. 0.48 (33% EtOAc/40-60 
petrol ether); IR (cm-1) 3010 (w), 2944 (w), 1723 (s), 1593 (m), 1480 (w), 1397 (m), 1368 (m), 
1324 (s), 1284 (s); MP 106-108 °C; Purity >95% (NMR). 
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2-([1,1'-Biphenyl]-4-ylsulfonyl)acetic acid (118)122 
 
Compound 117 (0.101 g, 0.4 mmol) was dissolved in MeOH/THF (5:1, 6.0 mL) and NaOH (2.5 M, 
1.4 mL, 3.5 mmol) added. The reaction was heated to 50 °C for 4 hours, then the mixture was 
washed with DCM (3 x 15 mL), acidified (3.0 M HCl, 0.2 mL) and extracted with DCM (3 x 
50 mL). The DCM extracts were combined, dried over Na2SO4 and evaporated under reduced 
pressure to yield the product 118 as a white powder (81 mg, 0.3 mmol, 88%). 
1H NMR (400 MHz, CDCl3)   ppm 4.21 (s, 2H), 7.41-7.54 (m, 3H), 7.59-7.66 (m, 2H),  
7.79 (d, J = 8.5 Hz, 2H), 8.03 (d, J = 8.5 Hz, 2H); Purity >95% (NMR). 
2-([1,1'-Biphenyl]-4-ylsulfonyl)-N-hexylacetamide (119) 
 
Compound 118 (81 mg, 0.3 mmol) was dissolved in dry DCM (8.0 mL). COMU (0.137 g, 
0.3 mmol) was added, followed by DMF (8 drops), DIPEA (0.24 mL, 1.3 mmol) and hexylamine 
(0.05 mL, 0.6 mmol). The reaction was stirred at ambient temperature for 20 hours, then 
evaporated in vacuo and the resulting powder purified by flash column chromatography 
(30-60% EtOAc/40-60 petrol ether) to yield the product 119 as a white powder (57 mg, 
0.2 mmol, 54%). 
1H NMR (400 MHz, CDCl3    ppm        t  J = 6.6 Hz, 3H), 1.23-1.40 (m, 6H), 1.53 (quin, J = 7.2 
Hz, 2H), 3.28 (q, J = 6.8 Hz, 2H), 4.08 (s, 2H), 6.83 (br. t, J = 5.7 Hz, 1H), 7.40-7.52 (m, 3H),  
7.57-7.65 (m, 2H), 7.77 (d, J = 8.5 Hz, 2H), 7.97 (d, J = 8.5 Hz, 2H); 13C NMR (100 MHz, CDCl3    
ppm 14.0, 22.5, 26.5, 29.2, 31.4, 40.2, 62.0, 127.4, 127.9, 128.6, 128.8, 129.0, 136.6, 138.9, 147.3, 
160.4; LCMS r.t. 2.30 min, found 360.3 [M+H]+; HRMS calc C20H26NO3S 360.1633, found [M+H]+ 
360.1614; TLC r.f. 0.52 (33% EtOAc/40-60 petrol ether); IR (cm-1) 3307 (br, w), 2928 (br, w), 
2853 (w), 1659 (s), 1538 (m), 1290 (s); MP 114-115 °C. 
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2-([1,1'-Biphenyl]-4-ylsulfonyl)-N-hexylethanethioamide (120) 
 
Compound 119 (30 mg, 0.1 mmol) and Lawesson s reagent (59 mg, 0.1 mmol) were dissolved in 
dry THF (5.0 mL) under inert atmosphere. The reaction was heated at reflux for 2 hours, then 
solvent was evaporated in vacuo and the residue purified by passing it through a pad of silica 
with DCM to yield the product 120 as a yellow powder (14 mg, 0.04 mmol, 42%). 
1H NMR (400 MHz, CDCl3    ppm     -0.96 (m, 3H), 1.25-1.46 (m, 6H), 1.69 (quin, J = 7.3 Hz, 
2H), 3.58-3.67 (m, 2H), 4.57 (s, 2H), 7.39-7.53 (m, 3H), 7.61 (d, J = 7.2 Hz, 2H), 7.76 (d, J = 8.3 Hz, 
2H), 7.87-7.96 (m, 2H), 8.53 (br. s, 1H); 13C NMR (100 MHz, CDCl3    ppm                         
31.3, 46.9, 69.1, 127.4, 127.8, 128.8, 128.9, 129.0, 135.5, 138.8, 147.4, 187.1; LCMS r.t. 2.51 min, 
found 376.3 [M+H]+; HRMS calc C20H26NO2S2 376.1405, found [M+H]+ 376.1386; TLC r.f. 0.62 
(neat DCM); IR (cm-1) 3302 (br, w), 2934 (br, w), 2839 (br, w), 1595 (s)1502 (m), 1439 (m), 
1299 (m), 1258 (s); MP 160-165 °C; Purity 98% (LCMS). 
1,4-Bis(5-(trifluoromethyl)pyridine-2-yl)piperazine (130) 
 
A solution of fragment 66 (0.15 g, 0.7 mmol), 2-bromo-5-trifluoromethylpyridine (0.15 g, 
0.7 mmol) and K2CO3 (0.10 g, 0.7 mmol) in acetonitrile (7.5 mL) and DMF (0.50 mL) was heated 
at reflux under nitrogen for 20 hours. The reaction mixture was then evaporated under reduced 
pressure, diluted with water (10 mL) and extracted with DCM (3 x 10 mL). The combined 
organic phases were purified by flash column chromatography (15-30% EtOAc/40-60 petrol 
ether) to yield the product 130 as a white crystalline solid (0.120 g, 0.3 mmol, 49%). 
1H NMR (400 MHz, CDCl3    ppm       s   H         d  J = 9.0 Hz, 2H), 7.68 (dd, J = 9.0, 2.2 Hz, 
2H), 8.44 (s, 2H); 13C NMR (100 MHz, CDCl3    ppm                     q  J = 33.1 Hz), 124.5 (q, J 
= 270.5 Hz), 134.6 (d, J = 3.5 Hz), 145.8 (d, J = 4.3 Hz), 160.1; LCMS r.t. 2.64 min, found 377.2 
[M+H]+; HRMS calc C16H15N4F6 377.1195, found [M+H]+ 377.1183; TLC r.f. 0.74  
(33% EtOAc/40-60 petrol ether); IR (cm-1) 1609 (m), 1508 (m), 1319 (m), 1231 (m);  
MP 210-212 °C; Purity >98% (NMR). 
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1-[4-(Trifluoromethyl)benzyl]-4-[5-(trifluoromethyl)pyridine-2-yl] 
piperazine (132) 
 
Fragment 66 (0.110 g, 0.5 mmol) and triethylamine (0.07 mL, 0.5 mmol) were dissolved in 
absolute ethanol and heated to 55 °C. To this solution was added 
4-trifluoromethylbenzylbromide (0.113 g, 0.5 mmol), and the reaction stirred at 55 °C for 
18 hours. The reaction mixture was evaporated under reduced pressure, then the residue was 
dissolved in H2O (5 mL) and extracted with DCM (4 x 5 mL). The combined organic phases were 
dried in vacuo and purified by flash column chromatography (30-50% EtOAc/40-60 petrol 
ether) yielding the product 132 as a white powder (0.157 mg, 0.4 mmol, 85%). 
1H NMR (400 MHz, CDCl3    ppm       t  J = 5.1 Hz, 4H), 3.61 (s, 2H), 3.67 (t, J = 5.1 Hz, 4H), 6.63 
(d, J = 9.0 Hz, 1H), 7.49 (d, J = 8.0 Hz, 2H), 7.58-7.66 (m, 3H), 8.40 (s, 1H); 13C NMR (100 MHz, 
CDCl3)   ppm                                 d  J = 3.5 Hz), 129.2, 134.4 (d, J = 3.5 Hz), 142.1, 
145.7 (d, J = 4.3 Hz), 160.4; LCMS r.t. 1.73 min, found 390.2 [M+H]+; HRMS calc C18H18N3F6 
390.1399, found [M+H]+ 390.1386; TLC r.f. 0.77 (50% EtOAc/40-60 petrol ether);  
IR (cm-1) 2822 (w, br.), 1610 (m), 1507 (w), 1419 (w), 1311 (s), 1248 (m); MP 75-78 °C;  
Purity 96% (LCMS). 
1-(Pyridin-4-ylmethyl)-4-[5-(trifluoromethyl)pyridin-2-yl]piperazine 
(133) 
 
Synthesised using the same procedure as compound 132, using 4-(bromomethyl)pyridine 
hydrobromide (0.111 g, 0.4 mmol). 
Orange solid (0.112 g, 0.4 mmol, 81%); 1H NMR (400 MHz, CDCl3    ppm       t, J = 5.1 Hz, 4H), 
3.56 (s, 2H), 3.67 (t, J = 5.1 Hz, 4H), 6.63 (d, J = 9.0 Hz, 1H), 7.31 (d, J = 5.4 Hz, 2H), 7.62 (dd, J = 
9.0, 2.4 Hz, 1H), 8.40 (s, 1H), 8.57 (d, J = 5.4 Hz, 2H); 13C NMR (100 MHz, CDCl3    ppm             
61.7, 105.5, 115.2 (q, J = 32.9 Hz) 123.8, 124.5 (q, J = 271.4 Hz), 134.5 (d, J = 2.6), 145.7 (q, J = 4.3 
Hz), 147.2, 149.9, 160.3; LCMS r.t. 1.25 min, found 323.3 [M+H]+; HRMS calc C16H18N4F3 
   112 
323.1484, found [M+H]+ 323.1477; TLC r.f. 0.55 (10% MeOH/DCM); IR (cm-1) 2933 (w, br.), 
2819 (w, br.), 1613 (m), 1316 (s), 1284 (m), 1254 (m); MP 100-101 °C ; Purity >98% (LCMS). 
4-({4-[5-(Trifluoromethyl)pyridin-2-yl]piperazin-1-yl}methyl) 
benzonitrile (134) 
 
Synthesised using the same procedure as compound 132, using 4-(bromomethyl)benzonitrile 
(85 mg, 0.5 mmol). 
Colourless crystalline solid (0.139 g, 0.4 mmol, 89%); 1H NMR (400 MHz, CDCl3)   ppm 2.54 (t,  
J = 5.1 Hz, 4H), 3.60 (s, 2H), 3.66 (t, J = 5.1 Hz, 4H), 6.60-6.67 (m, 1H), 7.49 (d, J = 8.3 Hz, 2H), 
7.59-7.67 (m, 3H), 8.39 (s, 1H); 13C NMR (100 MHz, CDCl3    ppm                                 
115.2 (q, J = 32.1 Hz), 118.8, 124.5 (q, J = 269.6 Hz), 129.4, 132.2, 134.4 (d, J = 3.5 Hz), 143.8, 
145.7 (q, J = 4.3 Hz), 160.3; LCMS r.t. 1.51 min, found 347.2 [M+H]+; HRMS calc C18H18N4F3 
347.1484, found [M+H]+ 347.1482; TLC r.f. 0.48 (50% EtOAc/40-60 petrol ether); IR (cm-1) 
2819 (w, br.), 2225 (w), 1608 (s), 1507 (s), 1416 (m), 1314 (s), 1249 (s); MP 99-102 °C; Purity 
98% (LCMS). 
Methyl 4-({4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}methyl) 
benzoate (135) 
 
Synthesised using the same procedure as compound 132, using methyl 4-
(bromomethyl)benzoate (0.103 g, 0.5 mmol). 
Colourless crystalline solid (0.144 g, 0.4 mmol, 84%); 1H NMR (400 MHz, CDCl3)   ppm 2.55  
(t, J = 5.1 Hz, 4H), 3.61 (s, 2H), 3.66 (t, J = 5.1 Hz, 4H), 3.92 (s, 3H), 6.62 (d, J = 9.0 Hz, 1H), 7.44 
(d, J = 8.2 Hz, 2H), 7.62 (dd, J = 9.0, 2.5 Hz, 1H), 8.02 (d, J = 8.2 Hz, 2H), 8.39 (s, 1H); 13C NMR  
(100 MHz, CDCl3    ppm                                       q  J = 32.1 Hz), 124.6  
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(q, J = 269.6 Hz), 128.9, 129.2, 129.6, 134.4 (d, J = 2.6 Hz), 143.3, 145.7 (q, J = 4.3 Hz), 160.4, 
167.0; LCMS r.t. 1.53 min, found 380.2 [M+H]+; HRMS calc C19H21O2N3F3 380.1580, found [M+H]+ 
380.1567; TLC r.f. 0.62 (50% EtOAc/40-60 petrol ether); IR (cm-1) 2830 (w, br.), 1713 (s), 1609 
(s), 1506 (m), 1415 (m), 1315 (s), 1257 (s); MP 99-100 °C; Purity >98% (LCMS). 
Methyl [4-({4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}methyl) 
phenyl]acetate (136) 
 
Synthesised using the same procedure as compound 132, using methyl  
4-(bromomethyl)phenylacetate (0.109 g, 0.4 mmol). 
White solid (84 mg, 0.2 mmol, 49%); 1H NMR (400 MHz, CDCl3)   ppm 2.57 (t, J = 5.0 Hz, 4H), 
3.57 (s, 2H), 3.62-3.71 (m, 6H), 3.73 (s, 3H), 6.64 (d, J = 9.1 Hz, 1H), 7.29 (s, 2H), 7.31-7.38  
(m, 2H), 7.63 (dd, J = 9.1, 2.5 Hz, 1H), 8.37-7.46 (m, 1H); 13C NMR (100 MHz, CDCl3    ppm       
44.7, 52.1, 52.7, 62.7, 105.5, 115.0 (q, J = 32.1 Hz), 124.6 (q, J = 268.8 Hz), 129.2, 129.4, 132.9, 
134.4 (d, J = 2.6 Hz), 136.6, 145.7 (q, J = 4.3 Hz), 145.8, 160.4, 172.1; LCMS r.t. 1.50 min, found 
394.3 [M+H]+; HRMS calc C20H23O2N3F3 394.1737, found [M+H]+ 394.1724; TLC r.f. 0.42 (50% 
EtOAc/40-60 petrol ether); IR (cm-1) 2828 (w, br.), 1735 (m), 1611 (m), 1507 (m), 1321 (s), 
1255 (s); MP 67-69 °C; Purity >98% (LCMS). 
1-[3-Fluoro-5-(trifluoromethyl)benzyl]-4-[5-(trifluoromethyl)pyridin-
2-yl]piperazine (137) 
 
Synthesised using the same procedure as compound 132, using 3-fluoro-5-
(trifluoromethyl)benzyl bromide (0.08 mL, 0.5 mmol). 
Yellow solid (0.183 g, 0.5 mmol, 87%); 1H NMR (400 MHz, CDCl3    ppm       t  J       Hz   H   
3.62 (s, 2H), 3.70 (t, J = 5.0 Hz, 4H), 6.66 (d, J = 9.1 Hz, 1H), 7.36 (s, 1H), 7.40-7.52 (m, 1H), 7.65 
(dd, J = 9.1, 1.9 Hz, 1H), 8.42 (s, 1H); 13C NMR (100 MHz, CDCl3    ppm 44.6, 52.7, 61.9, 105.5, 
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111.7 (dd, J = 24.3, 4.3 Hz), 115.2 (q, J = 32.1 Hz), 119.0 (d, J = 21.7 Hz), 121.1 (t, J = 3.5 Hz), 
123.3 (q, J = 269.6 Hz), 124.6 (q, J = 270.5 Hz), 132.4 (qd, J = 32.9, 8.7 Hz), 134.5 (d, J = 2.6 Hz), 
142.3 (d, J = 6.9 Hz), 145.7 (q, J = 4.3 Hz), 160.3, 162.6 (d, J = 248.8 Hz); 19F NMR (376 MHz, 
CDCl3    ppm -61.2, -62.7, -111.1; LCMS r.t. 1.92 min, found 408.3 [M+H]+; HRMS calc C18H17F7N3 
408.1311, found [M+H]+ 408.1288; TLC r.f. 0.75 (33% EtOAc/40-60 petrol ether); IR (cm-1) 
2832 (br. w), 1614 (m), 1326 (m), 1225 (m); MP 40-44 °C; Purity 95% (LCMS). 
1-(3-Fluorobenzyl)-4-[5-(trifluoromethyl)pyridin-2-yl]piperazine 
(138) 
 
Synthesised using the same procedure as compound 132, using 3-fluorobenzyl bromide 
(0.06 mL, 0.5 mmol). 
White solid (0.149 g, 0.4 mmol, 85%) 1H NMR (400 MHz, CDCl3    ppm 2.58 (t, J = 5.0 Hz, 4H), 
3.58 (s, 2H), 3.68 (t, J = 5.0 Hz, 4H), 6.63 (d, J = 9.1 Hz, 1H), 6.93-7.01 (m, 1H), 7.07-7.17 (m, 1H), 
7.62 (dd, J = 9.1, 2.5 Hz, 1H), 8.39 (s, 1H); 13C NMR (100 MHz, CDCl3    ppm 44.5, 52.6, 62.3, 
105.5, 114.2 (d, J = 20.8 Hz), 115.1 (q, J = 33.1 Hz), 115.8 (d, J = 20.8 Hz), 124.6 (q, J = 270.0 Hz; 
d, J = 2.6 Hz), 129.8 (d, J = 7.8 Hz), 134.4 (d, J = 2.6 Hz), 140.1, 145.7 (q, J = 4.3 Hz), 160.3, 162.9 
(d, J = 245.4 Hz); LCMS r.t. 1.52 min, found 340.2 [M+H]+; HRMS calc C17H18N3F4 340.1437, found 
[M+H]+ 340.1436; TLC r.f. 0.62 (33% EtOAc/40-60 petrol ether); IR (cm-1) 2817 (w), 1609 (s), 
1508 (m), 1416 (m), 1319 (s), 1244 (s); MP 50-53 °C; Purity 92% (LCMS). 
1-{2-[4-(Trifluoromethyl)phenyl]ethyl}-4-[5-(trifluoromethyl) 
pyridin-2-yl]piperazine (140) 
 
Synthesised using the same procedure as compound 132, using 
4-(trifluoromethyl)phenethylbromide (0.07 mL, 0.4 mmol). 
Off-white crystalline solid (81 mg, 0.2 mmol, 47%); 1H NMR (400 MHz, CDCl3)   ppm     -2.76 
(m, 6H), 2.86-2.97 (m, 2H), 3.62-3.75 (m, 4H), 6.65 (d, J = 9.1 Hz, 1H), 7.34 (d, J = 8.0 Hz, 2H), 
7.56 (d, J = 8.0 Hz, 2H), 7.63 (dd, J = 9.1, 2.5 Hz, 1H), 8.41 (d, J = 0.7 Hz, 1H); 13C NMR (100 MHz, 
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CDCl3    ppm                           5.6, 115.2 (q, J = 32.9 Hz), 124.3 (q, J = 271.4 Hz), 124.6 (q, 
J = 269.6 Hz), 125.3 (q, J = 3.5 Hz), 129.0, 134.5 (d, J = 2.6 Hz), 144.2, 145.7 (q, J = 4.3 Hz), 160.3; 
LCMS r.t. 1.68 min, found 404.3 [M+H]+; HRMS calc C19H20N3F6 404.1561, found [M+H]+ 
404.1556; TLC r.f. 0.53 (50% EtOAc/40-60 petrol ether); IR (cm-1) 2815 (w, br.), 1610 (m), 1508 
(m), 1414(m), 1314 (s), 1254 (m); MP 95-99 °C; Purity 96% (LCMS). 
1-{2-[3-(Trifluoromethyl)phenyl]ethyl}-4-[5-(trifluoromethyl) 
pyridin-2-yl]piperazine (141) 
 
Synthesised using the same procedure as compound 132, using 
3-(trifluoromethyl)phenethylbromide (0.07 mL, 0.4 mmol). 
White crystalline solid (56 mg, 0.1 mmol, 32%); 1H NMR (400 MHz, CDCl3)   ppm     -2.72 (m, 
6H), 2.85-2.96 (m, 2H), 3.62-3.75 (m, 4H), 6.65 (dd, J = 9.1 Hz, 1H), 7.37-7.54 (m, 4H), 7.63 (dd, J 
= 9.1, 2.4 Hz, 1H), 8.41 (d, J = 0.7 Hz, 1H); 13C NMR (100 MHz, CDCl3    ppm                         
105.6, 115.2 (q, J = 32.1 Hz), 123.0 (d, J = 4.3 Hz), 124.2 (q, J = 271.4 Hz), 124.5 (q, J = 270.5 Hz), 
125.4 (q, J = 3.5 Hz), 128.8, 130.7 (q, J = 31.2 Hz), 132.1, 134.4 (d, J = 3.5 Hz), 141.0, 145.7 (q, J = 
4.3 Hz), 160.4; LCMS r.t. 1.66 min, found 404.3 [M+H]+; HRMS calc C19H20N3F6 404.1561, found 
[M+H]+ 404.1559; TLC r.f. 0.61 (50% EtOAc/40-60 petrol ether); IR (cm-1) 2819 (w, br), 1613 
(m), 1314 (m), 1249 (m); MP 50-52 °C; Purity >98% (LCMS). 
1-Phenethyl-4-(5-(trifluoromethyl)pyridine-2-yl)piperazine (142) 
 
Synthesised using the same procedure as compound 132, using 2-bromoethyl)benzene 
(0.07 mL, 0.5 mmol). 
Colourless crystalline solid (60 mg, 0.2 mmol, 41%); 1H NMR (400 MHz, MeOD)   ppm 2.59-2.71 
(m, 6H), 2.81-2.91 (m, 2H), 3.70 (t, J = 5.2 Hz, 4H), 6.88 (d, J = 9.1 Hz, 1H), 7.14-7.33 (m, 5H), 
7.72 (dd, J = 9.1, 2.5 Hz, 1H), 8.34 (s, 1H); 13C NMR      MHz  MeOD    ppm                   
61.7, 107.6, 127.3, 129.6, 129.9, 135.8, 141.4, 146.5 (d, J = 4.3 Hz), 162.1; LCMS r.t. 1.52 min, 
found 336.3 [M+H]+; HRMS calc C18H21F3N3 336.1688, found [M+H]+ 336.1708; TLC r.f. 0.30 
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(33% EtOAc/40-60 petrol ether); IR (cm-1) 2820 (br. w), 2159 (br. w), 1608 (m), 1507 (m), 
1422 (m), 1314 (s), 1249 (s); MP 79-81 °C; Purity >98% (LCMS). 
1-(3-Methylphenethyl)-4-(5-(trifluoromethyl)pyridin-2-yl)piperazine 
(143) 
 
Synthesised using the same procedure as compound 132, using 3-methylphenethyl bromide 
(0.08 mL, 0.5 mmol) and fragment 66 (0.100g, 0.4 mmol). 
Off-white solid (38 mg, 0.1 mmol, 25%); 1H NMR (400 MHz  MeOD    ppm       s   H    
2.59-2.69 (m, 6H), 2.77-2.87 (m, 2H) 3.70 (t, J = 5.2 Hz, 4H), 6.88 (d, J = 9.1 Hz, 1H), 6.96-7.08 (m, 
3H), 7.15 (t, J = 7.5 Hz, 1H), 7.72 (dd, J = 9.1, 2.4 Hz, 1H), 8.34 (br. s, 1H); 13C NMR (100 MHz, 
MeOD    ppm                                                                                        
162.1; LCMS r.t. 3.80 min, found 350.1 [M+H]+; HRMS calc C19H23N3F3 350.1844, found [M+H]+ 
350.1835; TLC r.f. 0.53 (50% EtOAc/40-60 petrol ether); IR (cm-1) 2821 (br. w), 1613 (m), 1506 
(w), 1317 (s), 1252 (s); MP 62-65 °C; Purity 98% (LCMS). 
2-(3-Fluorophenyl)-1-{4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1-
yl}ethanone (145) 
 
3-fluorophenylacetic acid (0.23 g, 1.4 mmol) was dissolved in DCM (15.0 mL), and EDC (0.42 g, 
2.2 mmol), DIPEA (0.33 mL, 1.9 mmol) and DMAP (17 mg, 10 mol%) added. To this stirring 
solution was added fragment 66 (0.30 g, 1.3 mmol) and the solution stirred at room 
temperature for 3 hours. The reaction mixture was diluted with DCM (15 mL) and washed with 
saturated sodium bicarbonate (2 x 30 mL) and brine (2 x 30 mL). The organic phase was 
concentrated to dryness and purified by flash column chromatography (20-50% EtOAc/40-60 
petrol ether) to yield the product 145 as a colourless crystalline solid (0.180 g, 0.5 mmol, 38%). 
1H NMR      MHz  MeOD    ppm     -3.78 (m, 8H), 3.86 (s, 2H), 6.87 (d, J = 9.1 Hz, 1H),  
6.94-7.13 (m, 3H), 7.27-7.38 (m, 1H), 7.73 (dd, J = 9.1, 2.2 Hz, 1H), 8.35 (s, 1H); 13C NMR  
     MHz  MeOD    ppm                                      114.8 (d, J = 21.7 Hz), 116.7  
(q, J = 32.9 Hz), 117.0 (d, J = 21.7 Hz), 126.0 (d, J = 2.6 Hz), 126.2 (q, J = 268.8 Hz), 131.6  
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(d, J = 8.7 Hz), 135.9 (d, J = 2.6 Hz), 139.2 (d, J = 7.8 Hz), 145.6 (q, J = 4.3 Hz), 161.8, 164.6  
(d, J = 244.5 Hz), 172.0; LCMS r.t. 1.92 min, found 368.2 [M+H]+; HRMS calc C18H18F4N3O 
368.1386, found [M+H]+ 368.1342; TLC r.f. 0.53 (50% EtOAc/40-60 petrol ether); IR (cm-1) 
2924 (br. w), 1643 (s), 1612 (s), 1512 (m), 1444 (m), 1417 (m), 1315 (m), 1251 (m), 1231 (m); 
MP 125-126 °C; Purity >98% (LCMS). 
1-[2-(3-Fluorophenyl)ethyl]-4-[5-(trifluoromethyl)pyridin-2-yl] 
piperazine (146) 
 
Compound 145 (79.8 mg, 0.2 mmol) was dissolved in anhydrous THF (6.0 mL) under argon. 
Borane dimethylsulfide (0.04 mL, 0.4 mmol) was added and the reaction stirred for 5 hours at 
room temperature. The reaction was quenched with HCl (3.0 M, 2.0 mL), diluted with H2O 
(20 mL) and extracted with DCM (2 x 40 mL). The organic phases were combined and 
evaporated to dryness. The resulting solid was purified by flash column chromatography 
(30-60% EtOAc/40-60 petrol ether) and the product 146 was isolated as a colourless 
crystalline solid (50 mg, 0.1 mmol, 66%), 
1H NMR (400 MHz, CDCl3    ppm     -2.89 (m, 2H), 2.99-3.07 (m, 2H), 3.17-3.30 (m, 4H),  
3.88-4.02 (m, 4H), 6.67 (d, J = 9.0 Hz, 1H), 6.90-6.99 (m, 2H), 7.02 (d, J = 7.8 Hz, 1H), 7.28-7.34 
(m, 1H), 7.70 (dd, J = 9.0, 2.3 Hz, 1H), 8.44 (s, 1H); 13C NMR 25.9, 39.9, 57.5, 85.9, 105.7, 113.8  
(d, J = 20.7 Hz), 115.8 (d, J = 20.7 Hz), 116.3 (q, J = 33.2 Hz), 124.3 (q, J = 270.3 Hz), 124.5  
(d, J = 2.5 Hz), 130.3 (d, J = 8.3 Hz), 134.8 (d, J = 3.3 Hz), 140.5 (d, J = 6.6 Hz), 145.8 (q, J = 4.1 Hz), 
159.8, 163.0 (d, J = 247.1 Hz); LCMS r.t. 2.13 min, found 354.2 [M+H]+; HRMS calc C18H20F4N3 
354.1593, found [M+H]+ 354.1617; TLC r.f. 0.89 (50% EtOAc/40-60 petrol ether); IR (cm-1) 
2925 (br., w), 2356 (br., w), 1610 (s), 1521 (m), 1509 (m), 1431 (m), 1321 (s), 1254 (s);  
MP 111-113 °C; Purity 97% (LCMS). 
1-(4-(5-(Trifluoromethyl)pyridine-2-yl)piperazin-1-yl)ethan-1-one 
(147) 
 
Compound 66 (0.100 g, 0.4 mmol) was dissolved in dry DCM (1.00 mL) under argon and acetyl 
chloride (0.06 mL, 0.9 mmol) was added. The mixture was stirred for 2 hours at ambient 
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temperature, then diluted with DCM (10 mL), washed with saturated sodium bicarbonate 
(10 mL), HCl (3.0 M, 10 mL) and brine (10 mL). The combined aqueous phases were neutralised 
with NaOH (2.5 M) and extracted with DCM (20 mL). The final DCM phase was dried in vacuo, 
yielding the product 147 as white crystals (0.118 g, 0.4 mmol, >98%). 
1H NMR (400 MHz, CDCl3    ppm       s   H       -3.62 (m, 4H), 3.69-3.78 (m, 4H), 6.64  
(d, J = 8.9 Hz, 1H), 7.64 (dd, J = 8.9, 2.4 Hz, 1H), 8.39 (s, 1H); 13C NMR (100 MHz, CDCl3    ppm 
21.3, 40.7, 44.2, 44.5, 45.7, 105.6, 115.7 (q, J = 32.9 Hz), 124.4 (q, J = 271.4 Hz), 134.7, 145.7, 
160.0, 169.2; LCMS r.t. 1.77 min, found 274.2 [M+H]+; HRMS calc C12H15N3OF3 274.1162, found 
[M+H]+ 274.1155; TLC r.f. 0.40 (5% MeOH/DCM); IR (cm-1) 1635 (m), 1611 (m), 1558 (w), 1514 
(m), 1422 (m), 1343 (w), 1316 (m), 1285 (m), 1239 (m); MP 128-130 °C; Purity > 98% (LCMS). 
2-Phenyl-1-(4-(5-(trifluoromethyl)pyridine-2-yl)piperazin-1-yl)ethan-
1-one (148) 
 
Compound 66 (0.100 g, 0.4 mmol) was dissolved in DCM (3.0 mL) before triethylamine  
(0.07 mL, 0.5 mmol) and phenylacetyl chloride (0.05 mL, 0.4 mmol) were added. The reaction 
was stirred at room temperature for 1 hour, then the solvent was evaporated under reduced 
pressure. The remaining solid was dissolved in DCM (10 mL), washed with HCl (3.0 M, 10 mL), 
saturated sodium bicarbonate solution (10 mL) and brine (10 mL). The organic phase was dried 
in vacuo and purified by flash column chromatography (EtOAc/40-60 petrol ether) to yield the 
product 148 as a white, crystalline solid (65 mg, 0.2 mmol, 49%). 
1H NMR (400 MHz, acetone-d6    ppm     -3.73 (m, 8H), 3.82 (s, 2H), 6.91 (d, J = 9.1 Hz, 1H), 
7.18-7.27 (m, 1H), 7.28-7.35 (m, 4H), 7.76 (dd, J = 9.1, 2.5 Hz, 1H), 8.39 (dd, J = 1.5, 0.8 Hz, 1H); 
13C NMR (100 MHz, acetone-d6    ppm 41.6, 42.4, 45.7, 45.8, 46.7, 107.6, 115.9 (q, J = 32.1 Hz), 
126.4 (q, J = 268.8 Hz), 127.9, 129.8, 130.3, 135.8 (d, J = 3.5 Hz), 137.4, 146.8 (q, J = 4.3 Hz), 
161.9, 170.4; LCMS r.t. 2.15 min, found 350.2 [M+H]+; HRMS calc C18H19ON3F3 350.1475, found 
[M+H]+ 350.1460; TLC r.f. 0.33 (50% EtOAc/40-60 petrol ether); IR (cm-1) 2863 (w), 2163 (br. 
w), 2026 (br. w), 1633 (m), 1613 (m), 1421 (m), 1324 (s), 1247 (m); MP 121-123 °C;  
Purity 94% (LCMS).  
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2-(3-(Trifluoromethyl)phenyl)-1-(4-(5-(trifluoromethyl)pyridine-2-
yl)piperazin-1-yl)ethan-1-one (149) 
 
Synthesised using the same procedure as compound 145, using 3-(trifluoromethyl)phenyl 
acetic acid (0.103 g, 0.5 mmol). 
White, crystalline solid (86 mg, 0.2 mmol, 45%); 1H NMR (400 MHz, MeCN-d3    ppm       br  s  
8H), 3.83 (s, 2H), 6.79 (d, J = 9.1 Hz, 1H), 7.45-7.62 (m, 4H), 7.74 (dd, J = 9.1, 2.2 Hz, 1H), 8.41  
(s, 1H); 13C NMR (100 MHz, MeCN-d     ppm                   45.3, 46.0, 107.2, 115.5  
(q, J = 32.9 Hz), 124.3 (d, J = 4.3 Hz), 125.5 (q, J = 271.4 Hz), 126.1 (q, J = 270.5 Hz), 127.1  
(d, J = 4.3 Hz), 130.2, 130.9 (q, J = 32.1 Hz), 134.5, 135.5 (d, J = 2.6 Hz), 138.5, 146.5 (q, J = 4.3 
Hz), 161.5, 169.9; LCMS r.t. 2.32 min, found 418.2 [M+H]+; HRMS calc C19H18F6N3O 418.1354, 
found [M+H]+ 418.1375; TLC r.f. 0.57 (50% EtOAc/40-60 petrol ether); IR (cm-1) 1649 (m), 
1610 (m), 1514 (w), 1418 (br. m), 1327 (s), 1315 (s), 1232 (m); MP 96-99 °C;  
Purity 98% (LCMS). 
2-(Thiophen-2-yl)-1-(4-(5-(trifluoromethyl)pyridine-2-yl)piperazone-1-
yl)ethan-1-one (150) 
 
Synthesised using the same procedure as compound 145, using 2-thiopheneacetic acid (72 mg, 
0.5 mmol). 
Yellow crystalline solid (0.113 g, 0.3 mmol, 74%); 1H NMR (400 MHz, CDCl3    ppm     -3.69 
(m, 6H), 3.73-3.83 (m, 2H), 3.97 (s, 2H), 6.63  (d, J = 9.0 Hz, 1H), 6.91-6.94 (m, 1H), 6.95-6.99  
(m, 1H), 7.22 (dd, J = 5.1, 1.3 Hz, 1H), 7.66 (dd, J = 9.0, 2.5 Hz, 1H), 8.40 (s, 1H);  
13C NMR (100 MHz, CDCl3    ppm                                             q  J = 32.9 Hz), 124.4 
(q, J = 268.8 Hz), 124.9, 126.1, 126.9, 134.7, 136.1, 145.7, 160.0, 168.7; LCMS r.t. 2.21 min, found 
356.2 [M+H]+; HRMS calc C16H16ON3F3SN 378.0858, found [M+Na]+ 378.0849; TLC r.f. 0.33 (50% 
EtOAc/40-60 petrol ether); IR (cm-1) 1638 (m), 1611 (s), 1513 (m), 1422 (m), 1323 (s),  
1242 (m); MP 102-103 °C; Purity >95% (NMR). 
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Phenyl 4-(5-(trifluoromethyl)pyridine-2-yl)piperazine-1-carboxylate 
(151) 
 
Synthesised using the same procedure as compound 132, using phenylchloroformate (0.07 mL, 
0.5 mmol). 
White solid (60 mg, 0.2 mmol, 40%); 1H NMR (400 MHz, acetone-d6    ppm       br  s   H        
(br. s, 6H), 6.97 (d, J = 9.0 Hz, 1H), 7.12-7.25 (m, 3H), 7.39 (t, J = 7.9 Hz, 2H), 7.80 (d, J = 9.0 Hz, 
1H), 8.44 (s, 1H); 13C NMR (100 MHz, acetone-d6    ppm               22.8, 126.0, 130.0, 135.4 
(d, J = 3.5 Hz), 146.3 (q, J = 4.3 Hz), 152.7, 154.2, 161.4; LCMS r.t. 2.31 min, found 352.2 [M+H]+; 
HRMS calc C17H17N3O2F3 352.1273, found [M+H]+ 352.1317; TLC r.f. 0.55 (33% EtOAc/40-60 
petrol ether); IR (cm-1) 2858 (w), 2159 (br. w), 1735 (m), 1712 (m), 1608 (m), 1507 (m), 1419 
(m), 1339 (m), 1323 (m), 1235 (m); MP 120-125 °C; Purity 95% (LCMS). 
Benzyl 4-[5-(trifluoromethyl)pyridin-2-yl]piperazine-1-carboxylate 
(152) 
 
Synthesised using the same procedure as compound 132, using benzyl chloroformate (0.07 mL, 
0.5 mmol). 
White crystalline solid (0.190 g, 0.5 mmol, >98%); 1H NMR (400 MHz, CDCl3    ppm 3.58-3.74 
(m, 8H), 5.19 (s, 2H), 6.64 (d, J = 9.0 Hz, 1H), 7.30-7.46 (m, 5H), 7.66 (dd, J = 9.0, 2.5 Hz, 1H), 8.41 
(d, J = 0.8 Hz, 1H); 13C NMR (100 MHz, CDCl3    ppm 43.2, 44.4, 67.4, 105.7, 115.7 (q, J = 33.8 
Hz), 124.4 (q, J = 270.5 Hz), 126.9, 128.0, 128.5, 134.6 (d, J = 2.6 Hz), 136.4, 145.7 (q, J = 4.3 Hz), 
155.2, 160.1; LCMS r.t. 2.39 min, found 366.2 [M+H]+; HRMS calc C18H19N3O2F3 366.1429, found 
[M+H]+ 366.1461; TLC r.f. 0.61 (33% EtOAc/40-60 petrol ether); IR (cm-1) 2838 (w), 1679 (s), 
1609 (m), 1504 (m), 1440 (m), 1329 (m), 1241 (m); MP 87-88 °C; Purity > 98% (LCMS). 
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3-Phenyl-1-(4-(5-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)propan-
1-one (153) 
 
Synthesised using the same procedure as compound 132, using 3-phenylpropionyl chloride 
(0.16 mL, 1.0 mmol). 
White crystalline solid (0.1175 g, 0.3 mmol, 73%); 1H NMR      MHz  MeOD    ppm     -2.79 
(m, 2H), 2.90-2.95 (m, 2H), 3.53 (br. s, 4H), 3.58-3.74 (m, 4H), 6.84 (d, J = 9.0 Hz, 1H), 7.12-7.31 
(m, 5H), 7.73 (dd, J = 9.0, 1.9 Hz, 1H), 8.34 (s, 1H); 13C NMR      MHz  MeOD    ppm             
42.5, 45.5, 45.6, 46.5, 107.6, 116.6 (q, J = 32.1 Hz), 126.2 (q, J = 270.5 Hz) 127.5, 129.7 (d, J = 6.1 
Hz), 135.9 (d, J = 3.5 Hz), 142.3, 146.5 (q, J = 4.3 Hz), 161.8, 173.8; LCMS r.t. 2.24 min, found 
364.3 [M+H]+; HRMS calc C19H21N3OF3 364.1637, found [M+H]+ 364.1661; TLC r.f. 0.26 (33% 
EtOAc/40-60 petrol ether); IR (cm-1) 2864 (br. w), 2158 (br. w), 1611 (s), 1416 (m), 1326 (m), 
1239 (s); MP 91-93 °C; Purity >98% (LCMS). 
3-(Pyridine-3-yl)-1-(4-(5-(trifluoromethyl)pyridin-2-yl)piperazin-1-
yl)propan-1-one (154) 
 
Synthesised using the same procedure as compound 145, using 3-pyridnepropionic acid 
(75 mg, 0.5 mmol). 
White crystalline solid (0.101 g, 0.3 mmol, 65%); 1H NMR (400 MHz, CDCl3    ppm 2.69  
(t, J = 7.6 Hz, 2H), 3.03 (t, J = 7.6 Hz, 2H), 3.47-3.56 (m, 2H), 3.56-3.62 (m, 2H), 3.63-3.71 (m, 2H), 
3.71-3.82 (m, 2H), 6.63 (d, J = 9.0 Hz, 1H), 7.22 (dd, J = 7.7, 4.8 Hz, 1H), 7.58 (dt, J = 7.7, 1.9 Hz, 
1H), 7.66 (dd, J = 9.0, 2.4 Hz, 1H), 8.40 (s, 1H), 8.46 (dd, J = 4.8, 1.6 Hz, 1H), 8.51 (d, J = 1.9 Hz, 
1H); 13C NMR (100 MHz, CDCl3    ppm 28.3, 34.5, 41.0, 44.2, 44.6, 44.9, 105.6, 115.9 (q, J = 33.8 
Hz), 123.4, 124.4 (q, J = 270.5 Hz), 134.7, 136.1, 136.4, 145.7, 147.8, 149.9, 159.9, 170.2; LCMS 
r.t. 1.75 min, found 365.2 [M+H]+; HRMS calc C18H20ONF3 365.1584, found [M+H]+ 365.1576; 
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TLC r.f. 0.22 (5% MeOH/DCM); IR (cm-1) 1613 (m), 1425 (m), 1319 (m), 1229 (s);  
MP 119-120 °C; Purity >95% (NMR). 
3-(Thiophen-2-yl)-1-(4-(5-(trifluoromethyl)pyridine-2-yl)piperazin-1-
yl)propan-1-one (155) 
 
Synthesised using the same procedure as compound 145, using 2-thiophenepropionic acid 
(81 mg, 0.5 mmol). 
White crystalline solid (0.141 g, 0.4 mmol, 73%); 1H NMR (400 MHz, CDCl3    ppm 2.74 (t, J = 7.6 
Hz, 2H), 3.25 (t, J = 7.6 Hz, 2H), 3.49-3.70 (m, 6H), 3.63 (t, J = 4.9 Hz, 2H), 6.64 (d, J = 9.0 Hz, 1H), 
6.82-6.88 (m, 1H), 6.93 (dd, J = 5.1, 3.4 Hz, 1H), 7.13 (dd, J = 5.1, 1.2 Hz, 1H), 7.67 (dd, J = 9.0, 2.5 
Hz, 1H), 8.41 (s, 1H); 13C NMR (100 MHz, CDCl3    ppm                                            
123.6, 124.9, 127.0, 134.8, 143.7, 145.8, 160.1, 170.5; LCMS r.t. 2.31 min, found 370.2 [M+H]+; 
HRMS calc C17H18ON3F3SNa 392.1015, found [M+Na]+ 392.1003; TLC r.f. 0.36 (50% EtOAc/40-
60 petrol ether); IR (cm-1) 1637 (m), 1610 (m), 15108 (m), 1421 (m), 1328 (m), 1316 (m), 1231 
(m);  
MP 82-84 °C; Purity >95% (NMR). 
tert-Butyl 4-(3-(thiophen-2-yl)propanoyl)piperazine-1-carboxylate 
(158) 
 
Synthesised using the same procedure as compound 145, using 2-thiophenepropionic acid 
(0.10 g, 0.6 mmol) and N-Boc-piperazine (0.10 g, 0.5 mmol). 
White crystalline solid (0.154 g, 0.5 mmol, 89%); 1H NMR (400 MHz, CDCl3    ppm       s   H   
2.67 (t, J = 7.5 Hz, 2H), 3.19 (t, J = 7.5 Hz, 2H), 3.29-3.50 (m, 6H), 3.53-3.68 (m, 2H), 6.80-6.85  
(m, 1H), 6.90 (dd, J = 5.1, 3.4 Hz, 1H), 7.11 (dd, J = 5.1, 1.1 Hz, 1H); 13C NMR (100 MHz, CDCl3)  
  ppm                                   , 123.4, 124.7, 126.8, 143.5, 154.4, 170.2; LCMS r.t. 2.06 
min, found 269.2 [M-tbu+2H]+; HRMS calc C16H24N2O3SNa 347.1400, found [M+Na]+ 347.1396; 
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TLC r.f. 0.40 (33% EtOAc/40-60 petrol ether); IR (cm-1) 2977 (w), 2364( w), 16779 (s), 1641 (s), 
1426 (m), 1359 (m), 1284 (m), 1268 (m), 1239 (m), 1221 (m); MP 82-83 °C;  
Purity >95% (NMR). 
1-(Piperazin-1-yl)-3-(thiophen-2-yl)propan-1-one TFA salt (159) 
 
Compound 158 (0.151 g, 0.5 mmol) was dissolved in DCM (2.5 mL) under N2, and TFA (0.05 mL, 
0.7 mmol) was added. The reaction was stirred at room temperature for 3 hours, then 
evaporated under reduced pressure yielding a light yellow oil, which was carried forward 
without further purification. 
1-(4-(Pyridin-2-yl)piperazin-1-yl)-3-(thiophen-2-yl)propan-1-one 
(161) 
 
Potassium carbonate (0.13 g, 0.9 mmol) was added to toluene (7.0 mL) under N2 before 
compound 159 (0.10 g, 0.3 mmol) and 2-fluoropyridine (0.03 mL, 0.3 mmol) were added. The 
solution was heated to reflux for 24 hours, at which time additional 2-fluoropyridine (0.30 mL, 
0.3 mmol) was added. The reaction was refluxed for a further 24 hours, then cooled and 
evaporated under reduced pressure. The residue was purified by flash column chromatography 
(20-50% EtOAc/40-60 petrol ether), and the relevant fractions combined and dried in vacuo, 
yielding the product 161 as a white crystalline solid (0.242 g, 0.8 mmol, 80%). 
1H NMR (400 MHz, CDCl3    ppm       t  J = 7.6 Hz, 2H), 3.23 (t, J = 7.6 Hz, 2H), 3.49 (t, J = 5.2 Hz, 
2H), 3.54 (s, 4H), 3.76 (t, J = 5.2 Hz, 2H), 6.60-6.70 (m, 2H), 6.85 (d, J = 3.4 Hz, 1H), 6.92  
(dd, J = 5.1, 3.4 Hz, 1H), 7.12 (dd, J = 5.1, 1.1 Hz, 1H), 7.50 (ddd, J = 8.6, 7.1, 1.9 Hz, 1H), 8.19  
(dd, J = 5.0, 1.1 Hz, 1H); 13C NMR (100 MHz, CDCl3    ppm                         45.1, 45.2, 107.1, 
113.8, 123.4, 124.7, 126.8, 137.6, 143.7, 147.9, 158.9, 170.2; LCMS r.t. 1.36 min, found 302.2 
[M+H]+; HRMS calc C16H20N3OS 302.1327, found [M+H]+ 302.1303; TLC r.f. 0.17 (50% EtOAc/40-
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60 petrol ether); IR (cm-1) 1641 (s), 1596 (m), 1477 (m), 1434 (s)1250 (m), 1230 (m),  
1217 (m); MP 58-59 °C; Purity >95% (NMR). 
3-(Thiophen-2-yl)-1-(4-(4-(trifluoromethyl)phenyl)piperazin-1-
yl)propan-1-one (163)123 
 
Synthesised using the same procedure as compound 145 using 2-thiophenepropionic acid 
(0.17 g, 1.1 mmol) and 1-(4-(trifluoromethyl)phenyl)piperazine (0.23 g, 1.0 mmol). 
White crystalline solid (0.318 g, 0.9 mmol, 86%); 1H NMR (400 MHz, CDCl3    ppm       
(t, J = 7.9 Hz, 2H), 3.15-3.31 (m, 6H), 3.60 (t, J = 5.3 Hz, 2H), 3.81 (t, J = 5.3 Hz, 2H), 6.83-6.88  
(m, 1H), 6.88-6.96 (m, 3H), 7.14 (dd, J = 5.1, 0.9 Hz, 1H), 7.51 (d, J = 8.7 Hz, 2H); 13C NMR  
(100 MHz, CDCl3    ppm                                                                 q, J = 3.5 
Hz), 126.9, 143.6, 152.8, 170.2; LCMS r.t. 2.35 min, found 369.2 [M+H]+; HRMS calc C18H20N2F3OS 
369.1248, found [M+H]+ 369.1212; TLC r.f. 0.45 (50% EtOAc/40-60 petrol ether); IR (cm-1) 
1630 (s), 1614 (s), 1439 (m), 1335 (s), 1227 (s), 1204 (s); MP 64-66 °C; Purity >95% (NMR). 
1-(4-Phenylpiperazin-1-yl)-3-(thiophen-2-yl)propan-1-one (164) 
 
Synthesised using the same procedure as compound 145 using 2-thiophenepropionic acid  
(0.17 g, 1.1 mmol) and 1-phenylpiperazine (0.15 mL, 1.0 mmol). 
Orange crystalline solid (0.240g, 0.8 mmol, 80%); 1H NMR (400 MHz, CDCl3    ppm     -2.78 
(m, 2H), 3.10 (t, J = 5.2 Hz, 2H), 3.15 (t, J = 5.2 Hz, 2H), 3.26 (t, J = 7.6 Hz, 2H), 3.58 (t, J = 5.1 Hz, 
2H), 3.81 (t, J = 5.1 Hz, 2H), 6.87 (dd, J = 3.3, 1.0 Hz, 1H), 6.90-6.98 (m, 4H), 7.14 (dd, J = 5.1,  
1.0 Hz, 1H), 7.30 (t, J = 7.8 Hz, 2H); 13C NMR (100 MHz, CDCl3    ppm                               
49.4, 116.4, 120.3, 123.3, 124.6, 126.7, 129.1, 143.6, 150.7, 169.9; LCMS r.t. 2.12 min, found 
301.3 [M+H]+; HRMS calc C17H21N2OS 301.1375, found [M+H]+ 301.1338; TLC r.f. 0.40 (50% 
EtOAc/40-60 petrol ether); IR (cm-1) 1843 (br. w), 1635 (s), 1600 (m), 1435 (m), 1386 (m), 
1333 (m), 12.79 (m), 1237 (m), ; MP 66-67 °C; Purity >95% (NMR). 
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1-(4-(Pyrimidin-2-yl)piperazin-1-yl)-3-(thiophen-2-yl)propan-1-one 
(165) 
 
Synthesised using the same procedure as compound 145, using 2-thiophenepropionic acid 
(0.17 g, 1.1 mmol) and 1-(2-pyrimidyl)piperazine (0.14 mL, 1.0 mmol). 
White crystalline solid (0.221g, 0.7 mmol, 73%); 1H NMR (400 MHz, CDCl3    ppm       
(t, J = 7.7 Hz, 2H), 3.24 (t, J = 7.7 Hz, 2H), 3.46-3.54 (m, 2H), 3.68-3.86 (m, 6H), 6.54 (t, J = 4.8 Hz, 
1H), 6.83-6.88 (m, 1H), 6.92 (dd, J = 5.1, 3.4 Hz, 1H), 7.13 (dd, J = 5.1, 1.1 Hz, 1H), 8.33  
(d, J = 4.8 Hz, 2H); 13C NMR (100 MHz, CDCl3    ppm                                            
123.5, 124.8, 126.9, 143.7, 157.7, 161.4, 170.3; LCMS r.t. 1.83 min, found 303.2 [M+H]+; HRMS 
calc C15H19N4OS 303.1280, found [M+H]+ 303.1259; TLC r.f. 0.19 (50% EtOAc/40-60 petrol 
ether); IR (cm-1) 1632 (s), 1584 (s), 1546 (m), 1507 (s), 1435 (s), 1358 (s), 1266 (m), 1216 (m); 
MP 98-100 °C; Purity >95% (NMR). 
tert-Butyl 4-(1H-pyrrolo[2,3-b]pyridin-5-yl)piperazine-1-carboxylate 
(167) 
 
RuPhos (19 mg, 10 mol%), N-Boc-piperazine (85 mg, 0.5 mmol), Pd(OAc)2 (9 mg, 10 mol%) and 
5-bromo-7-azaindole (76 mg, 0.4 mmol) were sealed in a vial under a nitrogen atmosphere, and 
LiHMDS (0.91 mL, 1.0 M in THF, 0.9 mol) was added. The reaction was heated to 62 °C for 
2 hours, then evaporated under reduced pressure and purified by flash column chromatography 
(0-5% MeOH/DCM) to yield the product 167 as yellow crystals (92 mg, 0.3 mmol, 79%). 
1H NMR (400 MHz, CDCl3)   ppm       s   H       -1.81 (m, 1H), 3.06-3.13 (m, 4H), 3.61-3.68 
(m, 4H), 6.43 (dd, J = 3.4, 2.0 Hz, 1H), 7.29-7.33 (m, 1H), 7.54 (d, J = 2.5 Hz, 1H), 8.17  
(d, J = 2.5  Hz, 1H); 13C NMR (100 MHz, CDCl3)   ppm                                               
136.9, 142.6, 145.0, 154.6; LCMS r.t. 1.80 min, found 303.3 [M+H]+; HRMS calc C16H23N4O2 
303.1821, found [M+H]+ 303.1793; TLC r.f. 0.19 (5% MeOH/DCM).  
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5-(Piperazin-1-yl)-1H-pyrrolo[2,3-b]pyridine hydrochloride (168) 
 
Compound 167 (0.177 g, 0.6 mmol) was dissolved in dioxane (2.4 mL) under inert atmosphere, 
before HCl (0.90 mL, 4.0 M in 1,4-dioxane) was added. The reaction was stirred for 4 hours at 
ambient temperature, then evaporated under reduced pressure to yield a white solid which was 
carried forward without further purification. 
1-(4-(1H-Pyrrolo[2,3-b]pyridin-5-yl)piperazin-1-yl)-3-(thiophen-2-
yl)propan-1-one (169) 
 
Synthesised using the same procedure as compound 145 using compound 157 (0.11 g, 
0.7 mmol) and compound 168 (0.15 g, 0.6 mmol). 
Off-white solid (77 mg, 0.2 mmol, 37%); 1H NMR (400 MHz, CDCl3    ppm       t  J = 7.6 Hz, 2H), 
3.05 (t, J = 5.0 Hz, 2H), 3.10 (t, J = 5.0 Hz, 2H), 3.26 (t, J = 7.6 Hz, 2H), 3.64 (t, J = 4.9 Hz, 2H), 3.85 
(t, J = 4.9 Hz, 2H), 6.44 (dd, J = 3.4, 2.0 Hz, 1H), 6.87 (dd, 3.4, 0.8 Hz, 1H), 6.94 (dd, J = 5.1, 3.4 Hz, 
1H), 7.14 (dd, J = 5.1, 1.1 Hz, 1H), 7.32 (t, J = 3.0 Hz, 1H), 7.52 (d, J = 2.5 Hz, 1H), 8.16  
(d, J = 2.5 Hz, 1H), 9.66 (br. s, 1H); 13C NMR (100 MHz, CDCl3    ppm                               
52.3, 100.6, 117.8, 120.1, 123.4, 124.8, 125.6, 126.9, 137.5, 142.5, 143.7, 144.8, 170.1; LCMS r.t. 
1.67 min, found 341.2 [M+H]+; HRMS calc C18H21N4OS 341.1436, found [M+H]+ 341.1418; 
TLC r.f. 0.18 (5% MeOH/DCM); IR (cm-1) 3131 (br. w), 2859 (br. w), 2797 (br. w), 1640 (s),  
1437 (s), 1344 (m), 1272 (m), 1217 (s); MP 139-140 °C; Purity >98% (LCMS). 
tert-Butyl 4-(1H-indol-5-yl)piperazine-1-carboxylate (167a) 
 
Synthesised using the same procedure as compound 167, using 5-Bromoindole (0.10 g, 
0.5 mmol). 
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Clear, purple oil (31 mg, 0.1 mmol, 20%); 1H NMR (400 MHz, CDCl3    ppm       s   H         
(t, J = 5.1 Hz, 4H), 3.64 (t, J = 5.1 Hz, 4H), 6.48 (td, J = 2.0, 1.0 Hz, 1H), 6.98 (dd, J = 8.8, 2.3 Hz, 
1H), 7.14-7.22 (m, 2H), 7.31 (d, J = 8.8 Hz, 1H), 8.26 (br. s, 1H); 13C NMR (100 MHz, CDCl3) 
  ppm              9.7, 102.3, 108.3, 111.5, 116.1, 124.7, 128.3, 131.6, 145.8, 154.8; 
LCMS r.t. 1.64 min, found 302.3 [M+H]+; HRMS calc C17H24N3O2 302.1869, found [M+H]+ 
302.1858; TLC r.f. 0.66 (50% EtOAc/40-60 petrol ether). 
5-(Piperazin-1-yl)-1H-indole hydrochloride (168a) 
 
Synthesised using the same procedure as compound 168 using 167a (30 mg, 0.1 mmol), and 
carried forward without further purification. 
1-(4-(1H-Indol-5-yl)piperazin-1-yl)-3-(thiophen-2-yl)propan-1-one 
(170) 
 
Synthesised using the same procedure as compound 145 using 2-thiophenepropionic acid 
(75 mg, 0.5 mmol) and compound 168a (0.12 g, 0.4 mmol). 
Brown oil (70 mg, 0.21 mmol, 49% over 2 steps); 1H NMR (400 MHz, CDCl3    ppm       
(t, J = 7.6 Hz, 2H), 3.05 (t, J = 5.1 Hz, 2H), 3.09 (t, J = 5.1 Hz, 2H), 3.26 (t, J = 7.6 Hz, 2H), 3.57-3.67 
(m, 2H), 3.84 (t, J = 5.2 Hz, 2H), 6.49 (ddd, J = 3.0, 2.1, 1.0 Hz, 1H), 6.87 (dd, J = 3.3, 1.0 Hz, 1H), 
6.85-6.98 (m, 2H), 7.12-7.21 (m, 3H), 7.31 (d, J = 8.8 Hz, 1H), 8.39 (br. s, 1H); 13C NMR (100 MHz, 
CDCl3    ppm                                                          115.9, 123.4, 124.7, 124.8, 
126.8, 128.2, 131.7, 143.7, 145.3, 170.1; LCMS r.t. 1.66 min, found 340.2 [M+H]+; HRMS calc 
C19H22N3OS 340.1484, found [M+H]+ 340.1492; TLC r.f. 0.39 (5% MeOH/DCM); IR (cm-1) 3256 
(br. m), 1627 (s), 1434 (s), 1230 (m); MP 112-114 °C; Purity 95% (LCMS). 
tert-Butyl 4-(1H-indol-6-yl)piperazine-1-carboxylate (167b) 
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Synthesised using the same procedure as compound 167, using 6-Bromoindole (0.10 g, 
0.5 mmol). 
Yellow solid (29 mg, 0.1 mmol, 19%); 1H NMR (400 MHz, CDCl3    ppm       s   H         
(t, J = 5.1 Hz, 4H), 3.63 (t, J = 5.1 Hz, 4H), 6.47 (t, J = 2.3 Hz, 1H), 6.86-6.92 (m, 2H), 7.11  
(dd, J = 3.1, 2.3 Hz, 1H), 7.54 (d, J = 8.3 Hz, 1H), 8.26 (br. s, 1H); 13C NMR (100 MHz, CDCl3    ppm 
28.5, 51.3, 79.8, 98.9, 102.2, 113.3, 121.0, 122.5, 123.2, 136.6, 147.8, 154.8; LCMS r.t. 1.86 min, 
found 302.3 [M+H]+; HRMS calc C17H24N3O2 302.1869, found [M+H]+ 302.1865; TLC r.f. 0.64 
(50% EtOAc/40-60 petrol ether). 
6-(Piperazin-1-yl)-1H-indole hydrochloride (168b) 
 
Synthesised using the same procedure as compound 168 using 167b (0.135 g, 0.4 mmol), and 
carried forward as a crude pink solid without further purification. 
1-(4-(1H-Indol-6-yl)piperazin-1-yl)-3-(thiophen-2-yl)propan-1-one 
(171) 
 
Synthesised using the same procedure as compound 145 using 2-thiophenepropionic acid 
(62 mg, 0.4 mmol) and compound 168b (81 mg, 0.3 mmol). 
Yellow crystalline solid (41 mg, 0.1 mmol, 52%); 1H NMR (400 MHz, CDCl3    ppm       
(t, J = 7.7 Hz, 2H), 3.07 (t, J = 5.0 Hz, 2H), 3.11 (t, J = 5.0 Hz, 2H), 3.27 (t, J = 7.7 Hz, 2H), 3.60  
(t, J = 5.0 Hz, 2H), 3.85 (t, J = 5.0 Hz, 2H), 6.48 (t, J = 2.3 Hz, 1H), 6.82-6.91 (m, 3H), 6.94  
(dd, J = 5.1, 3.5 Hz, 1H), 7.12 (t, J = 2.8 Hz, 1H), 7.15 (dd, J = 5.1, 1.0 Hz, 1H), 7.55 (d, J = 8.3 Hz, 
1H), 8.46 (br. s, 1H); 13C NMR (100 MHz, CDCl3    ppm                                           
102.1, 113.1, 121.1, 122.7, 123.3, 123.4, 124.7, 126.8, 136.6, 143.7, 147.3, 170.1; LCMS r.t. 1.87 
min, found 340.2 [M+H]+; HRMS calc C19H22N3OS 340.1484, found [M+H]+ 340.1477;  
TLC r.f. 0.28 (75% EtOAc/40-60 petrol ether); IR (cm-1) 3257 (br. w), 1627 (s), 1434 (s), 1230 
(s); MP 55-57 °C; Purity >98% (LCMS). 
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1-(3,5-Dichlorophenyl)piperazine hydrochloride (168c) 
 
Synthesised using the same procedure as compound 167 using 3,5-dichloroiodobenzene  
(0.50 g, 1.8 mmol) to produce the Boc-protected amine. This was used with the same procedure 
as compound 168 to synthesise the product 168c as a brown solid which was used without 
further purification. 
1-(4-(3,5-Dichlorophenyl)piperazin-1-yl)-3-(thiophen-2-yl)propan-1-
one (172) 
 
Synthesised using the same procedure as compound 145 using 2-thiophenepropionic acid 
(64 mg, 0.4 mmol) and compound 168c (94 mg, 0.4 mmol). 
Yellow oil (6 mg, 0.02 mmol, 4%); 1H NMR (400 MHz, CDCl3    ppm 2.73 (t, J = 7.5 Hz, 2H), 3.11 
(t, J = 5.0 Hz, 2H), 3.17 (t, J = 5.1 Hz, 2H), 3.24 (t, J = 7.5 Hz, 2H), 3.57 (t, J = 5.0 Hz, 2H), 3.78  
(t, J = 5.1 Hz, 2H), 6.73 (d, J = 1.6 Hz, 2H), 6.82-6.88 (m, 2H), 6.93 (dd, J = 5.1, 3.5 Hz, 1H), 7.14 
(dd, J = 5.1, 0.9 Hz, 1H); 13C NMR (100 MHz, CDCl3)   ppm 25.5, 35.1, 41.2, 45.0, 48.5, 70.6, 114.3, 
119.7, 123.6, 124.9, 126.9, 135.6, 143.6, 152.2, 170.2; LCMS r.t. 2.45 min, found 369.0 [M+H]+; 
HRMS calc C17H19N2OSCl2 369.0595, found [M+H]+ 369.0585; TLC r.f. 0.53 (50% EtOAc/40-60 
petrol ether); IR (cm-1) 3096 (w), 2833 (w), 1641 (s), 1581 (m), 1553 (m), 1467 (m), 1438 (s), 
1233 (s);  MP 95-97 °C; Purity >98% (LCMS). 
tert-Butyl 4-(4-cyano-3-hydroxyphenyl)piperazine-1-carboxylate 
(167d) 
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Synthesised using the same procedure as compound 167 using 5-bromo-1,2-isoxazole  
(0.15 g, 0.8 mmol). 
White powder (98 mg, 0.4 mmol, 49%); 1H NMR (500 MHz, CDCl3)   ppm 1.49 (s, 9H), 2.96-3.05 
(m, 4H), 3.58 (t, J = 5.1 Hz, 4H), 6.93 (d, J = 9.1 Hz, 1H), 6.98 (d, J = 2.9 Hz, 1H), 7.10 (dd, J = 9.1, 
2.9 Hz, 1H); 13C NMR (125 MHz, CDCl3)   ppm 28.4, 50.3, 80.4, 99.8, 116.6, 117.5, 120.1, 125.0, 
145.3, 153.1, 154.8; LCMS r.t. 1.95 min, found 302.2 [M-H]-; TLC r.f. 0.30 (50% EtOAc/40-60 
petrol ether). 
2-Hydroxy-4-(piperazin-1-yl)benzonitrile hydrochloride (168d) 
 
Synthesised using the same procedure as compound 168 using 167d (98 mg, 0.3 mmol), and 
the resulting white powder of 168d was carried forward without further purification. 
2-Hydroxy-4-(4-(3-(thiophen-2-yl)propanoyl)piperazin-1-
yl)benzonitrile (173) 
 
Synthesised using the same procedure as compound 145 using 2-thiophenepropionic acid  
(32 mg, 0.2 mmol) and compound 168d (64 mg, 0.2 mmol). 
Off-white solid (26.0 mg, 0.1 mmol, 47%); 1H NMR (400 MHz, DMSO-d6    ppm       t  J = 7.4 Hz, 
2H), 2.90-3.00 (m, 4H), 3.04 (t, J = 7.4 Hz, 2H), 3.49-3.63 (m, 4H), 6.85-6.95 (m, 3H), 7.09  
(d, J = 3.0 Hz, 1H), 7.19 (dd, J = 9.1, 3.0 Hz, 1H), 7.29 (dd, J = 5.0, 1.2 Hz, 1H); 13C NMR (100 MHz, 
DMSO-d6)   ppm 24.8, 34.0, 40.9, 44.6, 29.3, 49.7, 98.6, 116.9, 117.3, 119.5, 123.6, 124.4, 124.7, 
126.8, 143.8, 143.9, 154.0, 169.4; LCMS r.t. 1.82 min, found 342.1 [M+H]+; HRMS calc 
C18H20N3O2S 342.1276, found [M+H]+ 342.1289; TLC r.f. 0.10 (66% EtOAc/40-60 petrol ether); 
IR (cm-1) 3116 (br. m), 2920 (m), 2821 (w), 2223 (m), 1607 (m), 1509 (m), 1421 (m), 1272 (m), 
1228 (m), 1208 (s); MP 189-190 °C; Purity >98% (LCMS).  
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tert-Butyl 4-(benzofuran-5-yl)piperazine-1-carboxylate (167e) 
 
Synthesised using the same procedure as compound 167 using 5-bromo-1-benzofuran  
(0.30 mL, 2.8 mmol). 
Yellow oil (77 mg, 0.3 mmol, 9%); 1H NMR (400 MHz, CDCl3)   ppm 1.50 (s, 9H), 3.08  
(t, J = 5.0 Hz, 4H), 3.61 (t, J = 5.0 Hz, 4H), 6.69 (dd, J = 2.1, 0.8 Hz), 1H), 6.99 (dd, J = 8.9, 2.4 Hz, 
1H), 7.11 (d, J = 2.4 Hz, 1H), 7.41 (d, J = 8.9 Hz, 1H), 7.58 (d, J = 2.1 Hz, 1H); 13C NMR (100 MHz, 
CDCl3)   ppm 28.3, 28.4, 51.5, 79.8, 106.6, 108.8, 111.6, 116.7, 127.9, 145.5, 148.0, 150.4, 154.7; 
LCMS r.t. 2.30 min, found 247 [M-tBu+2H]+; TLC r.f. 0.89 (33% EtOAc/40-60 petrol ether). 
1-(Benzofuran-5-yl)piperazine hydrochloride (168e) 
 
Synthesised using the same procedure as compound 168 using 167e (77 mg, 0.3 mmol), with 
the resulting off-white powder of 168e used without further purification or analysis. 
1-(4-(Benzofuran-5-yl)piperazin-1-yl)-3-(thiophen-2-yl)propan-1-one 
(174) 
 
Synthesised using the same procedure as compound 145 using 2-thiophenepropionic acid  
(52 mg, 0.3 mmol) and compound 168e (66 mg, 0.3 mmol). 
Yellow oil (48 mg, 0.1 mmol, 50%); 1H NMR (400 MHz, CDCl3    ppm       t  J = 7.6 Hz, 2H), 3.05 
(t, J = 5.0 Hz, 2H), 3.10 (t, J = 5.0 Hz, 2H), 3.25 (t, J = 7.6 Hz, 2H), 3.60 (t, J = 5.0 Hz, 2H), 3.83  
(t, J = 5.0 Hz, 2H), 6.71 (d, J = 1.4 Hz, 1H), 6.87 (d, J = 2.8 Hz, 1H), 6.90-7.02 (m, 2H), 7.10  
(d, J = 2.2 Hz, 1H), 7.14 (d, J = 5.0 Hz, 1H), 7.42 (d, J = 8.9 Hz, 1H), 7.59 (d, J = 2.2 Hz, 1H);  
13C NMR (100 MHz, CDCl3    ppm                                 , 51.6, 106.5, 108.8, 111.6, 116.6, 
123.4, 124.7, 126.8, 127.9, 143.7, 145.5, 147.6, 150.5, 170.0; LCMS r.t. 2.12 min, found 341.0 
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[M+H]+; HRMS calc C19H21N2O2S 341.1324, found [M+H]+ 341.1328; TLC r.f. 0.15 (33% 
EtOAc/40-60 petrol ether); IR (cm-1) 2808 (br. w), 1632 (m), 1439 (s), 1279 (m), 1209 (m); MP 
72-73 °C; Purity >95% (NMR). 
1-(4-(5-Bromopyridin-2-yl)piperazin-1-yl)-3-(thiophen-2-yl)propan-1-
one (182) 
 
Compound 159 (0.596 g, 1.8 mmol) was dissolved in NMP (2.0 mL), then K2CO3 (0.19 g, 
1.4 mmol) and 5-bromo-2-fluoropyridine (0.08 mL, 0.5 mmol) were added. The mixture was 
heated to 120 °C for 4 hours before being diluted with water (10 mL). The product was 
extracted with DCM (4 x 30 mL) and the combined organic phases dried over Na2SO4, then 
purified by flash column chromatography (30-50% EtOAc/40-60 petrol ether) to yield the 
product 182 as a clear, colourless oil (0.325 g, 0.9 mmol, 50%). 
1H NMR (400 MHz, CDCl3)   ppm 2.59-2.68 (m, 2H), 3.13 (t, J = 7.5 Hz, 2H), 3.35-3.51 (m, 6H), 
3.65 (t, J = 5.0 Hz, 2H), 6.47 (d, J = 9.0 Hz, 1H), 6.75 (dd, J = 3.4, 0.9 Hz, 1H), 6.82 (dd, J = 5.1,  
3.4 Hz, 1H), 7.03 (dd, J = 5.1, 0.9 Hz, 1H), 7.47 (dd, J = 9.0, 2.5 Hz, 1H), 8.09 (d, J = 2.5 Hz, 1H); 
13C NMR (100 MHz, CDCl3)   ppm 25.2, 34.9, 40.8, 44.6, 44.7, 44.9, 107.9, 108.3, 123.2, 124.5, 
125.6, 139.6, 143.4, 148.2, 157.2, 170.0; LCMS r.t. 2.69 min, found 382.2 [M+H]+; TLC r.f. 0.27 
(33% EtOAc/40-60 petrol ether). 
1-(4-(5-(Hexylamino)pyridine-2-yl)piperazin-1-yl)-3-(thiophen-2-
yl)propan-1-one (183) 
 
To a mixture of compound 182 (0.108 g, 0.3 mmol) in dry toluene (1.5 mL) under nitrogen was 
added tri-tert-butylphosphine (0.12 mL, 0.5 mmol), sodium tert-butoxide (56 mg, 0.6 mmol), 
hexylamine (0.06 mL, 0.5 mmol) and Pd2(dba)3 (27 mg, 10 mol%). The reaction mixture was 
heated under microwave conditions at 120 °C for 6 hours, then filtered through Celite® and 
evaporated in vacuo. The residue was purified by flash column chromatography (RP-C18, 
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50-60% MeCN/0.1% aqueous formic acid) to yield the product 183 as a purple oil (8 mg, 
0.02 mmol, 7%). 
1H NMR (400 MHz, acetone-d6    ppm     -0.94 (m, 3H), 1.14-1.36 (m, 5H), 1.38-1.47 (m, 2H), 
1.60 (quin, J = 7.2 Hz, 2H), 2.75 (t, J = 7.4 Hz, 2H), 3.06 (t, J = 7.2 Hz, 2H), 3.14 (t, J = 7.4 Hz, 2H), 
3.29 (br. s, 2H), 3.34 (br. s, 2H), 3.61 (t, J = 5.0 Hz, 2H), 6.65 (t, J = 2.1 Hz, 2H), 6.73 (d, J = 8.9 Hz, 
1H), 6.85-6.95 (m, 2H), 7.03 (dd, J = 8.9, 2.9 Hz, 1H), 7.20 (dd, J = 5.0, 1.4 Hz, 1H), 7.67 (d, J = 2.9 
Hz, 1H); 13C NMR (125 MHz, acetone-d6    ppm    4, 23.4, 26.1, 27.7, 32.5, 35.5, 42.1, 45.1, 45.9, 
47.7, 48.0, 109.9, 124.2, 124.3, 125.6, 127.6, 132.8, 139.7, 145.2, 153.4, 170.3; LCMS r.t. 2.88 
min, found 401.4 [M+H]+; HRMS calc C22H33N4OS 401.2375, found [M+H]+ 401.2350; TLC r.f. 
0.22 (RP-C18, 40% water (0.1% ammonia)/MeCN); Purity >98% (LCMS). 
tert-Butyl 4-(5-(methoxycarbonyl)pyridine-2-yl)piperazine-1-
carboxylate (185)124 
 
Methyl-6-bromonicotinate (0.50 g, 2.3 mmol) and N-Boc-piperazine (0.43 g, 2.3 mmol) were 
suspended in acetonitrile (18.0 mL) and heated to reflux under nitrogen atmosphere for 
3 hours. Additional N-Boc-piperazine (0.22 g, 1.2 mmol) was added with K2CO3 (0.69 g, 
5.0 mmol) and DMF (3.0 mL). The mixture was refluxed for a further 2 hours, then evaporated 
under reduced pressure. The residue was diluted with DCM (25 mL) and washed with water  
(3 x 25 mL), dried over MgSO4 and evaporated in vacuo. The resulting material was purified by 
flash column chromatography (20-40% EtOAc/40-60 petrol ether) to yield the product 185 as a 
white solid (0.338 g, 1.1 mmol, 45%). 
1H NMR (400 MHz, CDCl3    ppm       s   H      0-3.60 (m, 4H), 3.64-3.74 (m, 4H), 3.88 (s, 3H), 
6.59 (d, J = 9.0 Hz, 1H), 8.04 (dd, J = 9.0, 2.4 Hz, 1H), 8.80 (d, J = 2.4 Hz, 1H); 13C NMR (125 MHz, 
CDCl3)   ppm 28.4, 44.4, 51.7, 80.1, 105.2, 115.0, 138.6, 151.0, 154.7, 160.5, 168.3; LCMS r.t. 2.13 
min, found 222.0 [M-tBu+2H]+. 
Methyl 6-(piperazin-1-yl)nicotinate hydrochloride (186) 
 
Compound 185 (1.146 g, 3.6 mmol) was dissolved in 1,4-dioxane (20 mL) and HCl (9.0 mL,  
4.0 M in 1,4-dioxane, 36.0 mmol) was added. The reaction mixture was allowed to stir at 
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ambient temperature under nitrogen atmosphere overnight, before the solvent was evaporated 
to yield the product 186 as a white solid which was carried forward without further 
purification. 
Methyl 6-(4-(3-(thiophen-2-yl)propanoyl)piperazin-1-yl)nicotinate 
(187) 
 
Synthesised using the same procedure as compound 145 using acid 157 (0.19 g, 1.2 mmol) and 
compound 186 (0.29 g, 1.1 mmol). 
White solid (0.320 g, 0.89 mmol, 79%); 1H NMR (400 MHz, CDCl3    ppm     -2.78 (m, 2H),  
3.24 (t, J = 7.5 Hz, 2H), 3.51-3.59 (m, 2H), 3.60-3.67 (m, 2H), 3.67-3.73 (m, 2H), 3.74-3.82  
(m, 2H), 3.88 (s, 3H), 6.58 (d, J = 9.0 Hz, 1H), 6.83-6.88 (m, 1H), 6.92 (d, J = 5.1, 3.4 Hz, 1H), 7.13 
(dd, J = 5.1, 1.2 Hz, 1H), 8.05 (dd, J = 9.0, 2.4 Hz, 1H), 8.80 (d, J = 2.4 Hz, 1H); 13C NMR (100 MHz, 
CDCl3    ppm                                                                                     
143.6, 151.0, 160.3, 166.3, 170.4; LCMS r.t. 1.95 min, found 359.9 [M+H]+; HRMS calc 
C18H22N3O3SNa 382.1196, found [M+Na]+ 382.1202; TLC r.f. 0.58 (neat EtOAc);  
IR (cm-1) 3102 (w), 2847 (br. w), 1696 (m), 1638 (m), 1599 (s), 1498 (m), 1410 (s), 1280 (m), 
1229 (s); MP 121-122 °C; Purity >95% (NMR). 
6-(4-(3-(Thiophen-2-yl)propanoyl)piperazin-1-yl)nicotinic acid (188) 
 
Compound 187 (0.22 g, 0.6 mmol) and lithium hydroxide monohydrate (76 mg, 3.5 mmol) were 
suspended in MeOH (5 mL) and water (1.5 mL), and stirred for 3 hours, after which additional 
LiOH.H2O (76 mg, 3.5 mmol) was added and the reaction stirred at ambient temperature 
overnight. The resulting solution was evaporated in vacuo, dissolved in water (15 mL) and 
acidified with HCl (2.5 mL, 3.0 M). The precipitate was collected by filtration and dried in vacuo 
yielding the product 188 as a white solid (0.108 g, 0.3 mmol, 51%). 
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1H NMR      MHz  MeOD    ppm       t  J = 7.3 Hz, 2H), 3.18 (t, J = 7.3 Hz, 2H), 3.63-3.80  
(m, 8H), 6.85-6.93 (m, 2H), 7.00 (d, J = 9.3 Hz, 1H), 7.18 (dd, J = 5.0, 1.1 Hz, 1H), 8.17 (dd, J = 9.3, 
2.1 Hz, 1H), 8.63 (d, J = 2.1 Hz, 1H); 13C NMR (100 MHz, MeOD)   ppm                         45.9, 
46.0, 109.3, 117.1, 124.5, 126.0, 127.9, 141.3, 144.5, 148.2, 159.4, 167.8, 173.2; LCMS r.t. 1.64 
min, found 345.9 [M+H]+; HRMS calc C17H20N3O3S 346.1225, found [M+H]+ 346.1249; IR (cm-1) 
3382 (br. w), 2868 (br. w), 2554 (br. w), 1625 (s), 1604 (s), 1513 (m), 1427 (s)1280 (m), 1229 
(m); MP 171-175 °C; Purity 95% (LCMS). 
6-(4-(3-(Thiophen-2-yl)propanoyl)piperazin-1-yl)nicotinamide (189) 
 
Compound 188 (50 mg, 0.1 mmol), DMAP (1 mg, 10 mol%), and EDC (42 mg, 0.2 mmol) were 
dissolved in DCM (2.0 mL) with DIPEA (0.12 mL, 0.7 mmol) before ammonia (0.35 mL, 2 M in 
MeOH, 0.7 mmol) was added. The reaction was stirred at room temperature overnight. To this 
solution was added HOBt (23 mg, 0.2 mmol) and additional EDC and ammonia, and stirred for a 
further 18 hours. The solution was evaporated under reduced pressure and purified by flash 
column chromatography (10-15% MeOH/DCM) to yield the product 189 as a white solid 
(13 mg, 0.04 mmol, 29%). 
1H NMR (400 MHz, CDCl3    ppm 3.06 (t, J = 7.4 Hz, 2H), 3.50 (t, J = 7.4 Hz, 2H), 3.61-3.66  
(m, 2H), 3.84-3.98 (m, 6H), 3.99-4.08 (m, 2H), 7.00 (d, J = 9.0 Hz, 1H), 7.15 (dd, J = 2.4, 1.0 Hz, 
1H), 7.20 (dd, J = 5.1, 3.5 Hz, 1H), 7.43 (dd, J = 5.1, 1.0 Hz, 1H), 8.29 (dd, J = 9.0, 2.4 Hz, 1H), 8.94 
(d, J = 1.9 Hz, 1H); 13C NMR (100 MHz, CDCl3    ppm 26.1, 35.6, 42.0, 45.0, 45.1, 45.8, 106.6, 
118.9, 124.2, 125.6, 127.5, 135.0, 138.0, 143.7, 149.1, 160.7, 172.1; LCMS r.t. 1.48 min, found 
344.8 [M+H]+; HRMS calc C17H20N4O2S 367.1199, found 367.1200 [M+Na]+ ; IR (cm-1) 3363 (w), 
3167 (br. w), 2919 (w), 2822 (w), 1669 (m), 1627 (s), 1600 (s), 1549 (m), 1503 (m), 1402 (s), 
1357 (s), 1227 (s); MP 199-200 °C; Purity >98% (LCMS).  
   136 
2-(2-(Benzyloxy)ethoxy)ethyl 6-(4-(3-(thiophen-2-yl)propanoyl) 
piperazin-1-yl)nicotinate (190) 
 
A suspension of compound 188 (0.20 g, 0.6 mmol) in anhydrous DCM (2.0 mL) under nitrogen 
atmosphere was cooled to 0 °C. To this was added Et3N (0.12 mL, 0.9 mmol) and 
2,4,6-trichlorobenzyl chloride (0.14 mL, 0.9 mmol) and the solution stirred on ice for 2 hours, 
after which toluene (2.0 mL) was added and the DCM evaporated under reduced pressure, and 
backfilled with nitrogen. DMAP (7 mg, 10 mol%) was added, followed by di(ethylene 
glycol)benzyl ether (0.05 mL, 0.3 mmol) and the reaction stirred at ambient temperature for 
2 hours. The precipitate was removed by filtration and the toluene evaporated under reduced 
pressure to leave a yellow oil. The oil was purified by flash column chromatography (35-50% 
EtOAc/40-60 petrol ether, then 10% MeOH/DCM). The residue was dried under reduced 
pressure, diluted with DCM (15 mL), washed with saturated sodium bicarbonate (15 mL) and 
evaporated under reduced pressure to yield the product 190 as a yellow oil (22 mg, 0.04 mmol, 
14%). 
1H NMR (400 MHz, CDCl3    ppm       dd  J = 8.2, 6.9 Hz, 2H), 3.25 (t, J = 7.4 Hz, 2H), 3.51-3.58 
(m, 2H), 3.60-3.67 (m, 4H), 3.68-3.75 (m, 4H), 3.75-3.80 (m, 2H), 3.81-3.86 (m, 2H), 4.43-4.49 
(m, 2H), 4.58 (s, 2H), 6.55 (dd, J = 9.0, 0.5 Hz, 1H), 6.84-6.87 (m, 1H), 6.92 (dd, J = 5.1, 3.4 Hz, 
1H), 7.13 (dd, J = 5.1, 1.2 Hz, 1H), 7.28-7.37 (m, 5H), 8.06 (dd, J = 9.0, 2.4 Hz, 1H), 8.83  
(dd, J = 2.4, 0.5 Hz, 1H); 13C NMR (100 MHz, CDCl3)   ppm                                           
69.3, 69.4, 70.8, 73.3, 105.1, 115.3, 123.5, 124.8, 126.9, 127.6, 127.7, 128.3, 138.2, 138.8, 143.6, 
151.1, 160.3, 165.7, 170.4; LCMS r.t. 2.42 min, found 524.4 [M+H]+; IR (cm-1) 2855 (br. w),  
1704 (m), 1598 (s), 1503 (m), 1418 (m), 1228 (s); Purity 92% (LCMS).  
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N-(4-Phenylbutyl)-6-(4-(3-(thiophen-2-yl)propanoyl)piperazin-1-
yl)nicotinamide (191) 
 
A solution of compound 188 (0.10 g, 0.3 mmol), DMAP (4 mg, 10 mol%), EDC hydrochloride 
(86 mg, 0.4 mmol) and 4-phenylbutylamine (0.06 mL, 0.4 mmol) in DMF (1.00 mL) was stirred 
under nitrogen overnight. The reaction mixture was evaporated in vacuo, then diluted with DCM 
and water. The organic phase was purified by flash column chromatography (70-100% 
EtOAc/40-60 petrol ether) to yield the product 191 as a white solid (21 mg, 0.04 mmol, 14%). 
1H NMR (400 MHz, CDCl3    ppm     -1.82 (m, 6H), 2.66 (t, J = 6.9 Hz, 2H), 2.73 (t, J = 7.6 Hz, 
2H), 3.24  (t, J = 7.6 Hz, 2H), 3.41-3.49 (m 2H), 3.50-3.56 (m, 2H), 3.62-3.68 (m, 2H), 3.72-3.80  
(m, 2H), 6.05 (t, J = 5.7 Hz, 1H), 6.60 (d, J = 8.9 Hz, 1H), 6.85 (dd, J = 3.4, 0.8 Hz, 1H), 6.92  
(dd, J = 5.1, 3.4 Hz, 1H), 7.13 (dd, J = 5.1, 1.2 Hz, 1H), 7.15-7.22 (m, 4H), 7.28-7.32 (m, 1H), 7.92 
(dd, J = 8.9, 2.5 Hz, 1H), 8.55 (d, J = 2.5 Hz, 1H); 13C NMR (100 MHz, CDCl3    ppm             
29.3, 25.2, 35.5, 39.7, 41.1, 44.3, 44.7, 45.0, 105.7, 119.7, 123.5, 124.8, 125.8, 126.9, 128.3, 128.4, 
136.9, 142.0, 143.6, 147.1, 159.8, 165.8, 170.3; LCMS r.t. 2.36 min, found 477.4 [M+H]+;  
HRMS calc C27H33N4O2S 477.2319, found [M+H]+ 477.2311; TLC r.f. 0.51 (neat EtOAc);  
IR (cm-1) 3320 (w), 2929 (w), 2856 (w), 1620 (s), 1595 (s), 1539 (m), 1491 (m), 1435 (s),  
1329 (m), 1296 (m), 1248 (s), 1229 (s); Purity >98% (LCMS). 
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Jeffamine ED-900 linked molecule (193) 
 
Compound 188 (0.50 g, 1.5 mmol) and COMU (0.62 g, 1.5 mmol) were dissolved in DMF (10 mL) 
with DIPEA (0.51 mL, 2.9 mmol) under inert atmosphere, before Jeffamine ED-900 (0.41 mL, 
0.5 mmol) was added. The reaction was stirred overnight before the solvent was evaporated 
and the residue purified by flash column chromatography (10-30% EtOAc/40-60 petrol ether, 
then 10% MeOH/DCM) to yield the product 193 as an orange oil (0.631 g, 0.4 mmol, 83%). 
1H NMR (400 MHz, CDCl3)   ppm 1.03-1.15 (m, 5H), 1.20-1.34 (m, 12H), 1.99-2.06 (m, 5H),  
2.67-2.75 (m, 4H), 2.79-2.85 (s, 2H), 3.17-3.26 (m, 6H), 3.30-3.83 (m, 98H), 4.10 (q, J = 7.2 Hz, 
3H), 4.22-4.40 (m, 2H), 6.60 (d, J = 9.1 Hz, 2H), 6.83 (dd, J = 3.4, 0.9 Hz, 2H), 6.90 (dd, J = 5.1,  
3.4 Hz, 2H), 7.11 (dd, J = 5.1, 1.1 Hz, 2H), 7.91-8.00 (m, 2H), 8.61 (d, J = 2.4 Hz, 2H);  
13C NMR (125 MHz, CDCl3    ppm 16.1, 18.8, 19.5, 19.6, 19.7, 23.0, 27.4, 37.1, 40.3, 43.1, 46.4, 
46.6, 47.0, 47.2, 47.6, 47.7, 49.2, 62.3, 68.6, 72.1, 72.3, 72.4, 72.5, 74.1, 74.2, 76.3, 76.9, 77.1, 77.4, 
77.9, 107.5, 107.6, 121.6, 121.7, 125.4, 126.8, 128.8, 138.8, 138.9, 145.5, 149.6, 149.8, 161.7, 
167.5, 172.3, 173.1; LCMS r.t. 3.55 min, found mass distribution at m/z 1595 (ESMS-);  
IR (cm-1) 2869 (m), 1636 (m), 1600 (s), 1494 (m), 1444 (m), 1234 (m). 
There was significant overlap in the 13C NMR where not all peaks for the Jeffamine could be 
distinguished.
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